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ABSTRACT 
 
Peripheral arterial disease (PAD), a common manifestation of atherosclerosis, is an important 
healthcare problem with considerable morbidity and mortality. Intermittent claudication (IC) 
is the commonest symptomatic manifestation of this disease. This thesis investigates the 
prevalence of PAD in South Asians (people originating from India, Pakistan and Bangladesh) 
and Blacks (Black African, Black Caribbean) and makes ethnic comparisons of its 
associations with traditional cardiovascular risk factors, inflammatory and haemostatic 
biomarkers and markers of angiogenesis in these ethnic groups. This thesis also makes 
associations between common carotid intima media thickness, a marker of pre-clinical 
atherosclerosis, traditional cardiovascular risk factors and novel biomarkers. Furthermore this 
thesis validates translated versions of the Edinburgh Claudication Questionnaire into Punjabi 
and Urdu. 
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SYNOPSIS 
 
This thesis sets out to examine ethnic differences in the epidemiology and pathophysiology of 
peripheral arterial disease (PAD). Chapter 3 is a sub-study to the Ethnic-Echocardiographic 
Heart of England (E-ECHOES) community based screening study. Chapter 4 is a hospital 
based study.  
 
Chapter 3.1 attempted to validate translated versions of the Edinburgh Claudication 
Questionnaire (ECQ) into languages of the Indian sub-continent (Hindi, Urdu, Bengali, 
Punjabi, Gujurati) and compare their sensitivity and specificity to the original English version 
used in the Edinburgh Artery Study. It also validated the questionnaire in 1
st
 generation Black 
Caribbean UK migrants. This chapter’s findings suggest that the ECQ is not as sensitive or 
specific a diagnostic tool in 1
st
 generation Black Caribbean and South Asian UK migrants 
than in the indigenous White European population participating in the Edinburgh Artery 
Study, reflecting the findings of other diagnostic questionnaires in these minority ethnic 
groups. 
 
Chapter 3.2 investigated ethnic differences in the prevalence of PAD in South Asians and 
Blacks and made associations with traditional cardiovascular risk factors. In this cross-
sectional study this chapter found the prevalence of PAD was similar overall but South Asian 
females had significantly higher prevalence of disease, not explained but traditional 
cardiovascular risk factors. 
 
Chapter 3.3 investigated ethnic differences in mean and maximum common carotid intima 
medial thickness (CCIMT) and made associations with traditional cardiovascular risk factors 
and PAD. This chapter found that Black ethnicity was related to greater mean and maximum 
CCIMT when compared to South Asians, even after adjusting for traditional cardiovascular 
risk factors. The presence of PAD independently predicted mean and maximum CCIMT 
adjusting for ethnicity, age and cardiovascular risk factors. 
 
Chapter 3.4 investigated ethnic differences in circulating haemostatic and inflammatory 
biomarkers and their association with ankle brachial pressure index (ABPI) and mean and 
maximum CCIMT. This chapter found that amongst South Asians, Von Willebrand Factor 
(VWF) correlated with ABPI and mean and maximum CCIMT. In Blacks, D-dimer was 
higher in PAD than in normal ABPI participants. This chapter’s findings may reflect different 
pathophysiological processes predominating in different ethnic groups. 
 
Chapter 4.1 looked at ethnic differences in plasma expression of circulating markers of 
angiogenesis amongst South Asians, Blacks and Whites and also between healthy volunteers, 
risk factor controls and participants with traditional cardiovascular risk factors and 
cardiovascular disease. In healthy controls, angiogenin was higher in South Asians and Blacks 
compared to Whites. The differences were not influenced by the presence of other risk factors 
or the presence of stable cardiovascular disease. 
 
TABLE OF CONTENTS 
Title Page 
Abstract 
Declaration 
Acknowledgements 
Glossary of Terms 
Synopsis 
Table of Contents 
List of Tables 
List of Figures 
           Page 
Chapter 1  INTRODUCTION              1 
1.1 Background of Peripheral Arterial Disease    1 
1.1.1 Introduction         1 
1.1.2 Defining peripheral arterial disease and its complications   3 
1.1.3 Epidemiology of peripheral arterial disease     5 
1.2 Ethnic Differences in Peripheral Arterial Disease    8 
1.2.1 Ethnic differences in vascular disease     8 
1.2.2 Ethnic differences in traditional cardiovascular risk factors and  10 
 Their  association with peripheral arterial disease  
1.2.3 The metabolic syndrome       21 
1.2.4 Ethnic differences in peripheral arterial disease distribution   22 
1.2.5 Summary of ethnicity and peripheral arterial disease   25 
1.3 Peripheral Arterial Disease and Virchow’s Triad    27 
1.3.1  Introduction         27 
1.3.2 Defining Virchow’s Triad       28 
1.3.3 Abnormal blood vessel wall and peripheral arterial disease   30 
1.3.4 Circulating markers of endothelial damage/ dysfunction associated with 38 
peripheral arterial disease 
1.3.5 Abnormalities of blood constituents and peripheral arterial disease  50 
1.3.6 Abnormal blood flow and peripheral arterial disease    61 
1.3.7 Summary of Virchow’s triad and peripheral arterial disease   64 
1.4 Angiogenesis and Peripheral Arterial Disease    65 
1.4.1 Introduction         65 
1.4.2 Vascular Endothelial Growth Factor      66 
1.4.3 Angiopoietins         68 
1.4.4 Angiogenin         70 
1.4.5 Angiogenesis and thrombogenesis      71 
1.4.6 Angiogenesis and atherogenesis      72 
1.4.7 The Endothelium: A link between angiogenesis,     74 
atherogenesis and thrombogenesis 
1.4.8 Summary of angiogenesis in peripheral arterial disease   76 
Chapter 2 THE PROJECT RATIONALE AND HYPOTHESIS  78 
2.1 Project Rationale        78 
2.2 Primary Aim of Research       79 
2.3 Hypotheses         80 
2.4 Study Designs        82 
2.4.1 Sub-study to Ethnic-Echocardiographic Heart of England    82 
Screening (E-ECHOES) Study 
2.4.2 Hospital based study        100 
Chapter 3 SUB-STUDY TO ETHNIC-ECHOCARDIOGRAPHIC   106 
HEART OF ENGLAND SCREENING (E-ECHOES) STUDY 
3.1 Validation of the Edinburgh Claudication Questionnaire   106 
in 1
st
 generation Black Caribbean and South Asian UK migrants 
3.1.1 Abstract         106 
3.1.2 Introduction         108 
3.1.3 Hypothesis to be tested       109 
3.1.4 Patients and Methods        110 
3.1.5 Results         121 
3.1.6 Discussion         131 
3.1.7 Conclusion         136 
3.2 The Contribution of Cardiovascular Risk Factors to    137 
Peripheral Arterial Disease in South Asians and Blacks 
3.2.1 Abstract         137  
3.2.2 Introduction         139 
3.2.3 Hypotheses to be tested       140 
3.2.4 Patients and Methods        141 
3.2.5 Results         143 
3.2.6 Discussion         158 
3.2.7 Conclusion         166 
3.3 Ethnic differences in Common Carotid Intima Media Thickness,  167 
and the Relationship to Cardiovascular Risk Factors and  
Peripheral Arterial Disease 
3.3.1 Abstract         167 
3.3.2 Introduction         169 
3.3.3 Hypotheses to be tested       171 
3.3.4 Patients and Methods        172 
3.3.5 Results         174 
3.3.6 Discussion         200 
3.3.7 Conclusion         206 
3.4 Haemostatic Cardiovascular Risk Factors, Common Carotid Intima 207  
Medial Thickness and Peripheral Arterial Disease in South Asians  
and Blacks 
3.4.1 Abstract         207  
3.4.2 Introduction         209 
3.4.3 Hypothesis to be tested       211 
3.4.4 Patients and Methods        212 
3.4.5 Results         215 
3.4.6 Discussion         224 
3.4.7 Conclusion         229 
Chapter 4 HOSPITAL BASED STUDY      230 
4.1 Ethnic differences in Circulating Markers of Angiogenesis and  230 
their association with Cardiovascular Risk Factors and 
 Cardiovascular Disease 
4.1.1 Abstract         230 
4.1.2 Introduction         232 
4.1.3 Hypotheses to be tested       234 
4.1.4 Patients and Methods        235 
4.1.5 Results         237 
4.1.6 Discussion         244 
4.1.7 Conclusion         247 
Chapter 5 SUMMARY AND CONCLUSIONS    248 
5.1 Summary of Results        248 
5.2 Recommendations for Future Study      254 
5.3 Conclusions          259 
LIST OF PUBLICATIONS ARISING FROM THIS THESIS   261 
LIST OF PRESENTATIONS ARISING FROM THIS THESIS  262 
Appendix I. Consent form for hospital based study 
Appendix II. Participant information sheet 
Appendix III. Letter to GP 
REFERENCES 
PAPERS FROM PEER REVIEWED PUBLICATIONS ARISING 
FROM THIS THESIS 
LIST OF TABLES 
Table                    Page 
1.1: Population based studies investigating Peripheral Arterial Disease  6 
1.2: Examples of studies demonstrating ethnic differences in disease   24 
 distribution of PAD 
1.3: Examples of recent studies reporting positive associations between  32  
 components of Virchow’s Triad and peripheral arterial disease 
3.1: Characteristics of subjects eligible for participation in validation study  123 
3.2: Demographic details of subjects by language of Edinburgh    125 
Claudication Questionnaire 
3.3: 2x2 Tables illustrating the Edinburgh Claudication Questionnaire Results 128 
  and ABPI measurements  
3.4: Sensitivity, Specificity, Positive and Negative predictive values   129 
of the Edinburgh Claudication Questionnaire 
3.5: Sensitivity, Specificity, Positive and Negative predictive values  130 
 of each question of the Edinburgh Claudication Questionnaire 
3.6: Characteristics of study subjects by Ethnic Group    144 
3.7: Univariate comparisons between male and female South Asian subjects 146 
3.8: Univariate comparisons between PAD and non-PAD groups in  147 
 South Asian subjects 
3.9: Possible predictors of PAD on multivariate analysis in South Asian  148 
 subjects 
3.10: Possible predictors of ABPI on linear regression in South Asian subjects 149 
3.11: Univariate comparisons between male and female Black subjects  151 
3.12: Univariate comparisons between PAD and non-PAD groups in   152 
 Black subjects 
3.13: Possible predictors of PAD on multivariate analysis in Blacks  153 
3.14: Possible predictors of ABPI in Black subjects on linear regression  154 
3.15: Clinical, demographic and CCIMT characteristics by Ethnic group  175 
3.16: Characteristics of the South Asian group by sex    178 
3.17: Categorical variables associated with mean and maximum    179 
CCIMT in South Asians on univariate analysis 
3.18: Correlations between continuous variables and CCIMT in South   180 
Asians on univariate analysis 
3.19: Variables entered into multivariate analysis as possible independent 181 
predictors of mean and maximum CCIMT in South Asians  
3.20: Characteristics of Black subjects by sex     188 
3.21: Categorical variables and CCIMT in Blacks     189 
3.22: Correlations between continuous variables and mean and   190 
 maximum CCIMT in Blacks on univariate analysis 
3.23: Variables entered into multivariate analysis as possible independent 196 
 predictors of mean and maximum CCIMT in Blacks 
3.24: Clinical and demographic characteristics of South Asian and Black  216 
subjects 
3.25: Ethnic differences in expression of indices of Haemostasis and   219 
Inflammation by sex 
3.26: Univariate correlations between novel cardiovascular risk factors,   222 
ABPI and mean and maximum CCIMT 
4.1: Clinical and demographic details of hospital study participants  238 
4.2: Univariate comparisons of angiogenic markers    241 
LIST OF FIGURES 
Figure                   Page 
1.1:  Fontaine & Rutherford Classification Systems for Peripheral Arterial  4 
Disease 
1.2:  Stages of atherogenesis       29 
1.3:  Thrombogenesis, atherogenesis and angiogenesis in vascular disease: 77 
The Birmingham ‘Vascular Triad’ 
2.1:  Flow of participants through E-ECHOES Study    84 
2.2: Bland-Altman plot of mean CCIMT between PB and AL   90 
2.3: Bland-Altman plot of maximum CCIMY between PB and AL  91 
2.4: Edinburgh Claudication Questionnaire     95 
3.1: Schematic illustrating ECQ translation process    110 
3.2: The Edinburgh Claudication Questionnaire and translations  112 
3.3: Diagrammatic representation of recruitment process    121 
3.4: ABPI comparisons by sex and Ethnic group     157 
3.5:  Correlation between mean CCIMT vs. Age in South Asians   182 
3.6:  Correlation between mean CCIMT vs. mean Systolic Blood Pressure 183 
in South Asians 
3.7:  Correlation between mean CCIMT vs. Pulse Pressure in South Asians 183 
 in South Asians 
3.8: Correlation between maximum CCIMT vs. Age in South Asians  184 
3.9:  Correlation between maximum CCIMT vs. mean Systolic    185 
 Blood Pressure in South Asians 
3.10:  Correlation between maximum CCIMT vs. Pulse Pressure in   185 
 South Asians 
3.11: Correlation between Systolic Blood Pressure and Pulse Pressure in  186 
 South Asians 
3.12: Correlation between mean CCIMT vs. Age in Blacks   191 
3.13:  Correlation between mean CCIMT vs. mean Systolic Blood Pressure 192 
  in Blacks 
3.14:  Correlation between mean CCIMT vs. Pulse Pressure in Blacks  192 
3.15: Correlation between maximum CCIMT vs. Age in Blacks   193 
3.16: Correlation between maximum CCIMT vs. mean Systolic Blood Pressure 194 
in Blacks 
3.17: Correlation between maximum CCIMT vs. Pulse Pressure in Blacks 194   
3.18: Correlation between Systolic Blood Pressure and Pulse Pressure   195 
 in Blacks 
3.19: Interval Plot illustrating mean CCIMT by sex and ethnicity   198 
3.20: Interval Plot illustrating maximum CCIMT by sex and ethnicity  198 
3.21: Interval plot illustrating CCIMT in South Asians and Blacks with and 199 
 without PAD 
4.1: Correlation between sTie2 and angiogenin in healthy controls  242 
 
1 
 
CHAPTER 1 
 
 INTRODUCTION 
 
1.1 Background into Peripheral Arterial Disease 
 
1.1.1 Introduction 
 
Peripheral arterial disease (PAD) is an important healthcare problem in developed nations 
and is associated with considerable morbidity and mortality [Norgren et al. 2007]. PAD is 
the disease process resulting from stenosis of large peripheral arteries, exclusive of the 
coronary and intracranial cerebrovascular system, most commonly due to atherosclerosis. 
Most typically, it is referred to in relation to the lower limbs.  PAD is an indicator of 
widespread atherosclerosis in other vascular territories, such as the cerebral and coronary 
circulations [Norgren et al. 2007]. There is also considerable overlap between PAD, 
cerebrovascular disease (CBVD) and coronary artery disease (CAD) [CAPRIE steering 
committee 1996; Pasternak et al. 2004], with the presence of PAD being associated with an 
increased risk of CBVD and CAD and their consequences [Golomb et al. 2006; Criqui et al. 
1998, Dormandy et al. 1999]. People with PAD have 4-5 times greater risk of dying from a 
cardiovascular disease event compared to those without, and a 2-3 times greater all-cause 
mortality [Newman et al. 1993b; Criqui et al. 1992].  
 
In patients with both asymptomatic and symptomatic PAD, repeated skeletal muscle 
ischaemia and subsequent reperfusion are associated with an increase in oxidative stress and 
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its subsequent production of reactive oxygen species (ROS) along with elevation of 
neutrophil counts and platelet activation. Whilst hypoxia is the main driver of angiogenesis, 
oxidative stress acts as a stimulus for angiogenesis and potentiates the atherogenic and 
thrombogenic profile seen in PAD. 
 
Risk factors for the development of PAD are very similar to those of CAD and CBVD. 
Traditional risk factors include tobacco smoking, diabetes mellitus, dyslipidaemias, 
hypertension, advancing age and male gender [Makin et al. 2002; McDermott et al 2001; 
Hankey et al, 2006; Caro et al. 2005, Price et al. 1999; Norgren et al. 2007]. Diabetes 
mellitus and smoking are the strongest modifiable risk factors for PAD in predominantly 
White populations [American Diabetes Association 2003; Garcia 2006]. Age and sex are the 
most important non-modifiable risk factors in all ethnic groups [Dormandy et al. 1999].  
Risk factors that reduce the risk of getting PAD include regular physical activity and 
moderate alcohol intake [Dieter et al. 2002]. 
 
In recent years, several new plausible risk factors for atherosclerosis have been proposed 
including homocysteine [Smith et al. 2004; Khawaja et al. 2007], C reactive protein (CRP) 
[Selvin et al. 2004; Khawaja et al. 2007], fibrinogen [Selvin et al 2004; Khawaja et al. 2007], 
lipoprotein (a) [Smith et al. 2004; Cheng et al. 1997; Tseng et al. 2004], increased platelet 
activity [Dieter et al. 2002] and hypercoagulability [Dieter et al. 2004].  The relationship 
between PAD and these cardiovascular risk factors have not been fully elucidated, although 
some may explain the ethnic variations in susceptibility to PAD [Khawaja et al. 2007]. 
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1.1.2 Defining Peripheral Arterial Disease and its complications 
 
The most widely used definition of PAD is a diminution in the ankle brachial pressure index 
(ABPI). The ABPI is calculated by dividing the systolic blood pressure at the ankle by the 
systolic blood pressure in the arm. The ABPI <0.9 has been found to be up to 95% sensitive 
[Dormandy et al. 2000; Hummel et al. 1978] and 95% specific [Hummel et al. 1978] in 
detecting angiogram positive disease, with little inter-observer variability after relatively 
little training [Matzke et al. 2003].  
 
PAD can be classified clinically using either the Fontaine or Rutherford classifications 
[Figure 1.1] [Norgren et al. 2007]. While the majority of patients are asymptomatic, the most 
common clinical manifestation of PAD is intermittent claudication (IC) [McDermott et al. 
2001], affecting a quarter of this population. Of the asymptomatic patients 5 to 10% develop 
symptoms of PAD over 5 years [Hooi et al. 1999].  Only a minority of patients with IC 
develop symptoms of critical leg ischaemia. The development of symptomatic disease is 
typically preceded by and dependent upon the development of multiple collateral blood 
vessel formation. It is thought that the extent of this collateral formation affects the clinical 
manifestation of PAD; thus insufficient angiogenesis, and a failure to develop collateral 
blood vessels, may be responsible for the different symptomatic presentations of IC and CLI 
[Findley 2008]. 
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Figure 1.1: Fontaine [Fontaine et al. 1954] & Rutherford [Rutherford et al. 1997] 
Classification Systems for Peripheral Arterial Disease 
 
Fontaine Rutherford 
Stage Clinical Grade Category Clinical 
I Asymptomatic 0 0 Asymptomatic 
IIa Mild 
claudication 
I 1 Mild 
claudication 
IIb Moderate-
severe 
claudication 
I 2 Moderate 
claudication 
  I 3 Severe 
claudication 
III Ischaemic rest 
pain 
II 4 Ischaemic rest 
pain 
IV Ulceration or 
gangrene 
III 5 Minor tissue 
loss 
  IV 6 Ulceration or 
gangrene 
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1.1.3 Epidemiology of Peripheral Arterial Disease 
 
Several population based studies [Fowkes et al. 1991; Meijer et al. 1998; Diehm et al. 2004] 
based on predominantly White European populations have found the prevalence of PAD to 
be between 6 to 18% over the age of 55. The prevalence rises with age and has been found to 
be approximately 20% in people over 70 years of age [Regensteiner et al. 2002] and up to 
60% in the over 85 age group [Meijer et al. 1998]. There has however, been very little 
research into the prevalence of PAD in non-White populations although previous population 
based studies have shown variations in the prevalence of this disease amongst different 
ethnic groups [Table 1.1] [Premalatha et al. 2000, Criqui et al. 2005; UK Prospective 
Diabetes Study Group 1994; Mohan et al. 1995, Chaturvedi et al. 2007; Collins et al. 2005; 
McDermott et al.2005]. 
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Table 1.1 Populations based studies investigating Peripheral Arterial Disease 
Study Country  
Race/Ethnic 
Group Studied 
Sample 
Size Age 
PAD 
Prevalence (%) 
Fowkes et al. 
1991
 
UK European 1592  55-74 18.3 
Meijer et al. 
1998
 
Netherlands European 6450  >55 19.1 
Fabsitz et al. 
1999 US 
Native American 
Indians 4549 45-74 5.3 
Premalatha et 
al. 2000
 
South India Indian 631 >20 3.2 
Diehm et al. 
2004 Germany European 6821 ≥65 18 
Selvin et al. 
2004
 
US 
African 
American 
Non-Hispanic 
White 
Hispanic 2174 >40 
4.3 
 
 (AA:7.9; 
NHW:4.4; 
H:3.0) 
Collins et al. 
2005
 
US 
African 
American 
Non-Hispanic 
White 
Hispanic 403 >55 
16.6 
 
 (AA:22.8; 
NHW:13.2;H:13.7) 
McDermott et 
al. 2005
 
US 
African 
American 
Non-Hispanic 
White 
Hispanic 
Chinese 6560  45-84 
3.7 
 
 M(NHW:2.7; 
Ch:1.1;AA:7.1;H:3) 
 
F(NHW:3.5;Ch:2.2; 
AA:6.1;H:1.7) 
Criqui et al. 
2005
 
US 
African 
American 
Non-Hispanic 
White 
Hispanic  
Asian 2343 29-91 
4.4 
 
 (AA:7.8; NHW:4.9 
H:1.8;As:1.4) 
Allison et al. 
2006
 
US 
African 
American 
Non-Hispanic 
White 
Hispanic 
Chinese 6653 45-85 
4.3 
 
(AA:7.2; NHW:3.6; 
H:2.4; Ch: 2) 
He et al. 2006 China Chinese 2334 ≥60 19.8 
Al-Sheikh et al. 
2007 Saudi Arabia Arabic 471 ≥45 11.7 
Garofolo et al. 
2007 Brazil Japanese 1008 ≥30 20.4 
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AA: African American; As: Asian; Ch: Chinese; F: Female; H: Hispanic; M: Male;  NHW: Non-Hispanic 
White; PAD: peripheral arterial disease; UK: United Kingdom; US: United States of America. 
Sritara et al. 
2007 Thailand Thai 2305 52-73 5.2 
Carbayo et al. 
2007 Spain European 784 ≥40 10.5 
Sigvant et al. 
2007 Sweden European 5080 60-90 18 
Kumar et al. 
2007 South Africa Black African 542 >50 29.3 
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1.2 Ethnic differences in Peripheral Arterial Disease 
 
1.2.1 Ethnic Differences in Vascular Disease 
Ethnic minority groups make up 7.9% of the general population of the UK [Gill et al. 2007]. 
The largest of these being Asian/Asian British (50.2%) and Black/Black British (24.8%) 
[National Statistics online]. The remainder of this thesis will focus on these 2 largest 
minority ethnic groups within the UK.  
 
There are well recognised differences in vascular disease in different ethnic groups. South 
Asians (People originating from India, Pakistan and Bangladesh) living in the UK have a 
higher mortality for ischaemic heart disease (IHD) then Europeans [Balarajan 1991] and 
Blacks (Black Caribbean and Black African) have a higher CBVD mortality in both sexes 
[Balarajan 1991]. However studies both in the UK and India suggest PAD prevalence is 
lower in South Asians than in White Europeans in general population, diabetic and CAD 
cohorts [Premalatha et al. 2000; UK Prospective Diabetes Study 1994; Mohan et al. 1995; 
Chaturvedi et al. 2007]. Traditional risk factors could not account for the observed difference 
in PAD in a recent UK study [Chaturvedi et al. 2007] as Indians are exposed to a number of 
risk factors which should increase their risk of PAD, such as dyslipidaemia and diabetes 
[Bhopal et al. 1999]. 
 
Several US studies [Table 1.1] found the prevalence of PAD in African Americans (AA) to 
be higher than in Non-Hispanic Whites (NHW). Compared to NHW, AA also had a 
significantly worse risk factor profile, with the exception of dyslipidaemia [Allison et al. 
9 
 
2006]. However differences in prevalence were only partially attributable to higher rates of 
diabetes mellitus (DM) and hypertension in this ethnic group [Criqui et al. 2005]. In the 
National Health And Nutrition Examination Survey (NHANES), when adjusting for all 
traditional risk factors the odds ratio (OR) for PAD in AA over NHW was 1.67. This OR 
reduced when further adjusting for novel risk factors suggesting that novel risk factors play 
some role at least in their susceptibility to PAD [Allison et al. 2006]. 
 
Whilst the prevalence of risk factors is variable amongst different ethnic groups it is thought 
that the underlying pathophysiology of arterial disease is affected by ethnicity and race and 
that some ethnic variations in risk factors may be genetically based.  
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1.2.2 Ethnic Differences in Traditional Cardiovascular Risk Factors and their 
association with Peripheral Arterial Disease 
 
1.2.2.1 Tobacco Smoking 
 
Smoking tobacco is a major risk factor in the development of PAD [McDermott et al. 2001; 
Caro et al. 2005] as a sequel of atherosclerosis [Fowkes et al.1992]. It can result in a 7 fold 
increase in PAD [Heliovaara et al. 1978] and its impact persists with advanced age [Kannel 
et al. 1994].  Smoking has been related to elevated CRP, fibrinogen and homocysteine, novel 
risk factors, in both white and non-white ethnic groups [Bazzano et al. 2003]. 
 
The Edinburgh Artery Study reported a dose dependent relationship between smoking and 
PAD [Price et al.1999]; a finding supported by other, more recent studies [Willigendael et al. 
2004; Fowler et al. 2002]. NHANES found PAD prevalence increased sequentially from 
never smokers to ex-smokers to current smokers across all ethnic groups [Allison et 
al.2006]. In patients with PAD, smoking is associated with increased progression of disease 
and increased risk of amputation [Lassila et al. 1988]. It also reduces the effectiveness of 
antiplatelet medication in such patients [Lepantalo et al. 1991]. Cessation is associated with 
reduced disease progression and increased survival [Jonason et al. 1987]. 
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The Prevalence of smoking varies among ethnic groups and gender. Even within the South 
Asian group there is considerable variation; for example Bangladeshi and Pakistani men 
having the highest and Indians the lowest of the male smokers and low rates of smoking 
amongst all of the female South Asians [Bhopal et al. 1999]. In the US, Asian Indians were 
much less likely to be current smokers than NHW [Mohanty et al. 2005]. 
 
There is limited evidence investigating smoking and PAD in ethnic groups. A population 
based study in South India [Premalatha et al. 2000] found that smokers had a 2.7 times 
higher risk for PAD, although the result did not reach statistical significance. A recent UK 
study on Indian Asians and Europeans with equivalent rates of CAD found the prevalence of 
PAD to be much lower in the former group [Chaturvedi et al. 2007], with smoking rates also 
lower in Indians. Adjustment for pack years reduced the significance of ethnicity 
considerably but could not account for the ethnic differences in PAD observed [Chaturvedi 
et al. 2007]. 
 
South Asian smokers were found to have a four times greater prevalence of CAD than non-
smokers in a previous cross-sectional study [Bhopal et al. 1999], a similar elevation in risk to 
Europeans. However as a cross-sectional study causal associations between risk factors and 
PAD cannot be made and results should be interpreted with caution. Indeed only 1 to 5% of 
Asian females smoke yet they have double the risk of suffering CAD than White European 
females [Bhopal et al. 1999]. It could be perceived that with the overlap that exists with 
chronic vascular disease at different sites in predominantly White populations, there would 
be a similar relationship in ethnic minority groups. Whereas South Asians are at increased 
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risk of premature death from CAD [Chaturvedi et al. 2003; Lane et al. 2005] as compared to 
White European populations, limited data suggests that the prevalence of PAD in this group 
is much lower than in Europeans [Premalatha et al. 2000]. Another hypothesis suggests that 
either South Asians are not living long enough to develop symptomatic PAD or other - as yet 
undetermined - factors are responsible for the development of atherosclerosis in different 
vascular territories. 
 
Evidence investigating the relationship between Black ethnicity, smoking and PAD is 
conflicting and comes only from cross-sectional studies. The United Kingdom Prospective 
Diabetes Study (UKPDS) [UKPDS 1994] found that PAD was less frequent in Blacks than 
in White Europeans and that the proportion of never smokers was greater in the former 
group. AAs on the other hand, were found to have a higher prevalence of PAD compared to 
NHW yet had a lower prevalence of smoking in another study [Collins et al. 2003] yet in 
another [Kuller et al. 1998] the percentage of current smokers was higher in AA with sub 
clinical vascular disease than in NHW. With methodological differences between these 
studies it is difficult to elucidate whether smoking confers a greater risk for PAD in Blacks 
than in Whites; especially as these studies are all cross-sectional studies and as such one 
must be very cautious when interpreting the data as causal associations shouldn’t be made in 
such studies between socio-demographic factors and PAD. 
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1.2.2.2 Diabetes mellitus and impaired glucose tolerance (IGT) 
 
Diabetes mellitus (DM) is a major cardiovascular risk factor, and the incidence of type 2 
diabetes is rising in developed nations as a consequence of lifestyle changes resulting in 
increased obesity.  
 
DM is associated with an increased risk of stroke and with a two- to four-fold increased risk 
of developing CAD [Luscher et al. 2003] and PAD [Newman et al.1993a]. DM and smoking 
are together the most important risk factors for the development and progression of PAD 
[Smith et al. 2004]. In diabetic patients, the risk of PAD is increased by age, duration of DM, 
blood glucose control and peripheral neuropathy.  Approximately 5 to 10% of PAD patients 
have type 1 and 90 to 95% have type 2 DM [Creager et al. 2003]. Blood glucose control 
seems to be an important factor for PAD [Selvin et al. 2006] and it has been estimated that 
with each 1% increase in glycosylated haemoglobin (HbA1c) level comes a 28% increased 
risk of incident PAD [UKPDS 1998]. In the Framingham Heart Study, 20% of symptomatic 
PAD patients had DM [Murabito et al. 1997]. Other studies have found the prevalence of 
PAD in diabetics to be 20% in people over 40 years old [Elhadd et al. 1999]
 
and 29% in 
people aged over 50 [Hirsch et al 2001]. IC and Critical leg ischaemia are also more 
common in patients with DM [American Diabetes Association 2003]; the risk of IC being 
two-fold higher [Norgren et al. 2007]. 
 
The prevalence of type 2 DM in the UK is much higher in African Caribbean and South 
Asian groups compared to the general population [Health Survey for England 2004]. Various 
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studies have shown that 16 to 17% African Caribbeans and 20% of South Asians aged 
between 40 and 64 years have type 2 DM compared to 3 to 5% of Europeans [Chaturvedi et 
al. 1994; Diabetes in the UK 2004]. After standardising for age, South Asians have a 3 to 6 
fold and African Caribbeans a 2.5-fold greater risk of DM than the general population [HSE 
2004].   By contrast, the prevalence of DM in rural India is 2 to 3% and approximately 8% in 
urban areas [Ramachandran et al. 1992].  
 
Interestingly, a migration study found fasting glucose to be much higher in South Asians 
living in West London, UK than their siblings living in the state of Punjab, India [Bhatnagar 
et al. 1995]. This difference infers that there could be a genetic susceptibility to the 
development of DM, which is exacerbated by lifestyle differences and environmental factors 
which arise from living in developed countries. However, this was not supported by another 
migration study comparing Gujuratis living in Birmingham, UK and age, gender and caste-
matched non-migrant Gujuratis remaining in their villages of origin in Navsari, India, which 
found the diabetes prevalence to be similarly high in both native Indians and UK migrants 
[Patel et al. 2006]. Both studies were matched on age and gender and compared migrants 
living in urban areas of the UK with rural areas in India. Both studies found UK migrants to 
have higher BMI, higher systolic blood pressure and higher fasting cholesterol. Whilst Patel 
et al. 2006 found no difference in impaired glucose tolerance between migrants and those in 
rural India, they reported that diabetes and impaired glucose tolerance were less frequently 
associated with excess metabolic cardiovascular risk factors in India [Patel et al. 2006]. 
 
A cross-sectional study, in subjects with a mean age of 46 years, in South India reported a 
prevalence of PAD of 6.3% amongst diabetics compared to 3.2% in the whole population 
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[Premalatha et al. 2000] This contrasts with a cohort study from the US, with subjects 
between 50 and 70 years of age, which reported the PAD prevalence to be 22% in its 
diabetic cohort as compared to 3% in people with normal glucose tolerance [Beach et al. 
1998].  This discrepancy in PAD prevalence in diabetics may be due to differences in the age 
of subjects between the 2 studies. 
 
When compared to diabetic Whites in other studies, the prevalence of PAD in diabetic South 
Asians was found to be much lower [Abbot et al. 2005; Chaturvedi et al 2001]. Chaturvedi et 
al. 2007 found Indian Asians to have a lower prevalence of PAD than White  Europeans with 
equivalent CAD levels despite Indians having a higher prevalence of insulin resistance and a 
higher HbA1c [Chaturvedi et al 2007]. 
 
AAs with diabetes were found to have a higher prevalence of PAD than NHW in the US 
[American Diabetes Association 2003] but no difference in prevalence between Blacks and 
Whites were apparent in a UK study [Abbot et al. 2005]. Interestingly amongst patients with 
PAD in the US a similar prevalence of DM was found between AA and NHW [Collins et al. 
2003]. As with smoking, these studies have all been cross-sectional in design and as such it 
is difficult to establish a link between diabetes and PAD which accounts for the apparent 
increase in prevalence of this disease in Blacks. 
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1.2.2.3 Dyslipidaemia 
 
Abnormalities in the components of the lipid profile are associated with PAD. These do not 
appear to carry the same importance as smoking and DM in its development [Faxon et al. 
2004].  The ratio of Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) 
is the strongest lipid predictor of PAD risk [Norgren et al. 2007; Ridker et al. 2001]. The 
most frequent dyslipidaemia associated with PAD is elevated triglycerides and low HDL-C 
[Smith et al. 2004]. The association between Low Density Lipoprotein Cholesterol (LDL-C) 
and PAD appears to be weaker [Pasternak et al. 2004] than for HDL-C and triglycerides 
(TG), and furthermore weaker than its association with the development of CAD. 
 
In the UK no statistically significant differences in TC were found between ethnic groups, 
with the exception of African Caribbean females [Health Survey for England 1999]. In the 
US, the TC: HDL-C ratio has also been found to be quite similar in NHW, African 
Americans and Asians [Criqui et al.2005]. South Asians appear to have a less favourable 
lipid profile than other ethnic groups with a lower HDL-C and higher TG than White 
[Chaturvedi et al. 1994; HSE 1999; Miller et al. 1984; Li et al. 2006; Zoratti et al. 1998]. 
This finding is apparent even in children [Whincup et al. 2002]. These abnormalities in 
HDL-C and TG become more pronounced on migration from the Indian subcontinent 
[Bhatnagar et al. 1995; Patel et al. 2006], suggesting both environmental and genetic factors 
are at play. On the other hand Blacks have a more favourable lipid profile than White 
[Allison et al. 2006; Whincup et al. 2002; Lip et al 2007] with higher HDL-C levels [Kuller 
et al. 1998; HSE 1999]. Interestingly statistically significant disease/race interactions for 
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LDL-C levels have been found, showing a stronger association in Blacks (especially in 
women) [Kuller et al. 1998]. 
 
There are limited data linking PAD to dyslipidaemia in ethnic groups. A population based 
study in India linked hypercholesterolaemia and LDL-C to the development of PAD (ORs 
1.4 and 1.5 respectively) [Premalatha et al. 2000], although the findings were not statistically 
significant. A South African study found Blacks with PAD had lower TC, TG and HDL 
levels than White with PAD [Keenen et al. 1985]. The discordance between lipid profile and 
PAD risk in South Asians and Blacks suggests that dyslipidaemia does not play as important 
a role in its development as in the pathogenesis of CAD. 
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1.2.2.4 Hypertension 
 
Hypertension is a major risk factor for all vascular disorders and is associated with a 2 to 3 
fold risk for PAD [Norgren et al. 2007]. Several components of blood pressure, including 
pulse pressure (PP), systolic blood pressure (SBP) and diastolic blood pressure (DBP) have 
been shown to be independent cardiovascular risk factors [Safar et al. 2003]. SBP in 
particular is a major risk factor for CAD and stroke.  In PAD hypertension is a risk factor for 
both symptomatic and asymptomatic disease [Dieter et al. 2002; Murabito et al. 1997] and 
the degree of hypertension is also closely linked to the development of PAD [Murabito et al. 
1997]. 
 
PAD and hypertension are associated diseases with 35-55% of patients with PAD also 
having hypertension at presentation [Cheng et al. 1999; Vidi et al. 1996; Makin et al. 2001]. 
The prevalence of PAD in patients with DM increases with the presence of systolic 
hypertension in all racial groups. If hypertension in these patients is controlled, the 
progression of PAD can be slowed [Palumbo et al.1991]. 
 
The prevalence of hypertension has previously been reported as being higher in Blacks 
compared to Whites in the UK [Agyemang et al. 2003]. Black people have been found to 
develop hypertension at an earlier age [Brown 2006], have more severe disease [Cooper et 
al. 1997], have worse BP control, have a different distribution of target organ damage 
[Brown 2006] and a raised mortality from hypertension; perhaps 1.5 times higher than 
national average [Agyemang et al. 2003]. Interestingly, when comparing the prevalence of 
hypertension internationally between White European populations and Blacks, a wide 
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variation was found in hypertension prevalence [Cooper et al. 2005]. In fact Black ethnicity 
did not have unusually higher prevalence of hypertension than Whites [Cooper et al. 2005]. 
In some studies, the prevalence of hypertension in the South Asian immigrant population in 
the UK is also significantly higher [Cappuccio et al. 1997; Primatesta et al. 2000]. However, 
the mean population blood pressure in these ethnic groups is similar to that of White 
European populations [HSE 2004], possibly due to heterogeneity of the South Asian and 
White populations. 
 
A meta-analysis of hypertension in South Asians in UK found that they had lower mean 
systolic but higher diastolic blood pressures in both males and females compared to whites 
[Agyemang et al. 2002]. The prevalence of hypertension was higher in South Asian males 
but results were inconclusive in females [Agyemang et al. 2002]. The researchers 
commented that mean BP and prevalence were different amongst South Asian subgroups but 
they were usually combined into one homogenous group [Agyemang et al.2002].  This is an 
important finding given that the classic risk factor profile of these subgroups differs, which 
may affect any analyses associating them with PAD. A meta-analysis in India found that 
hypertension is rising in general, and significantly more so in urban than rural populations 
[Gupta et al. 1996], suggesting that changes in lifestyle and environmental factors play an 
important role. This is supported by a recent UK migrant study, which found a higher 
prevalence of hypertension in migrants than in indigenous Indians [Patel et al. 2006]. 
 
While being a risk factor for PAD, hypertension appears to have a stronger association with 
CAD and both haemorrhagic and ischaemic stroke. The association appears to be greater for 
ischaemic stroke [Perry et al. 2000]. Treating hypertension reduces the incidence of both 
haemorrhagic and ischaemic stroke [Perry et al. 2000]. This finding may explain why 
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cerebrovascular disease is more common in Blacks [Dieplinger et al. 1999; Raleigh et al. 
1996]. It may also explain the higher risk of and mortality from stroke in South Asians 
compared to White in the UK [Wild et al. 1997]. 
 
There is a paucity of data regarding the association between hypertension and PAD in 
different ethnic groups. US Studies have shown that among patients with PAD, the 
prevalence of hypertension was higher in AA than NHW [Criqui et al.2005; Collins et al. 
2003] and lower in Asians [Criqui et al. 2005]. A population based study in India found that 
PAD patients had a significantly higher mean SBP than those without PAD [Premalatha et 
al. 2000] and the OR for hypertension and PAD was 2.7 [Premalatha et al. 2000].  However, 
more research needs to be undertaken to explain the variation in PAD with hypertension in 
different ethnic minority groups. 
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1.2.3 The metabolic syndrome 
 
Many studies have identified a pattern of inter-related metabolic disturbances that are 
associated with cardiovascular risk, which are referred to as the so-called ‘metabolic 
syndrome’. The current definition of metabolic syndrome requires the presence of 3 or more 
of the following: Increased waist circumference, Reduced HDL cholesterol, Increased 
Triglycerides, Hypertension, Impaired fasting glucose or DM [International Diabetes 
Federation 2008]. Metabolic syndrome varies by ethnic group and is especially prevalent 
amongst South Asians [Ridker et al. 2001]. Even though African Caribbeans have a 
tendency for insulin resistance and an increased risk of DM, they appear to have a more 
favourable lipid profile than South Asian [Lip et al. 2007] and thus do not fit the typical 
definition of metabolic syndrome [Whitty et al. 1999]. 
 
Metabolic syndrome has been associated with the development and progression of and more 
advanced PAD [Wild et al. 2006; Olijhoek et al. 2004; Lahoz et al. 2006]. However, with the 
components of metabolic syndrome being associated with low ABPI, defining the syndrome 
does not add any more per se to the patient’s classical risk factor status when assessing the 
risk of suffering from asymptomatic PAD [Lahoz et al. 2006]. While this syndrome has been 
associated with PAD, it seems clear that ethnicity/ race play a greater role in conferring 
susceptibility to this disease. 
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1.2.4 Ethnic Differences in Peripheral Arterial Disease Distribution   
 
As well as the variations that exist in vascular risk factors, the anatomical distribution of 
vascular disease appears to differ between ethnic groups. Black people have an increased 
incidence of cerebrovascular disease and end stage renal disease than White and a lower 
incidence of CAD, whereas South Asians appear to have a higher incidence of CAD 
[Chaturvedi et al. 2003]. Whites, on the other hand, appear to have a higher rate of 
abdominal aortic aneurysm (AAA) [Kent et al. 2010; Salem et al. 2009; Hobbs et al. 2003]. 
Interestingly when AAAs are found in Blacks, they present at a significantly younger age 
than White and atherosclerosis is less likely to be the causative factor [Robbs et al. 1985; 
Dardik et al. 1999]. In people with strokes, Black people appear to have more cerebral small 
vessel and less large vessel atherosclerotic disease than White [Markus et al. 2007]. They 
also have a greater mortality from this disease than White [Balarajan et al. 1991]. 
 
Previous studies have indicated that African Caribbeans and South Asians seemed to report 
more distal PAD than the general population [Collins et al. 2005; Lip et al. 2007; Hobbs et 
al. 2003; Robbs et al. 1985; Deneuville et al. 2008]. Examples of these studies are illustrated 
in table 1.2. In Indians, thromboangiitis obliterans appears to contribute to this increase 
[Shead et al. 1978]. In a previous hospital based study in India, this disease reflects the 
younger age of presentation of patients with distal PAD [Shead et al. 1978].  The study by 
Chaturvedi et al. found that Indian Asians had less lower limb atherosclerosis than 
Europeans, while common carotid intima-medial thickness (CIMT) did not differ 
[Chaturvedi 2007] and disease distribution was similar. This finding is consistent with other 
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studies reporting lower rates if limb amputation in Indian Asians compared to White 
Europeans [Premalatha et al. 2000; Mohan et al. 1995; Chaturvedi et al. 2001]. 
 
It is not known whether distal PAD is due to genetic differences in disease distribution or the 
fact that the incidence of DM is higher in South Asians and Blacks than in White and DM 
has been shown to be associated with distal PAD. There is evidence to suggest that there are 
regional differences in atherosclerosis risk susceptibility to specific risk factors [Chaturvedi 
et al. 2007]. DM usually affects smaller arteries and therefore is associated with femoro-
popliteal and tibial PAD [American Diabetes Association 2003; Jude et al. 2001]. This 
pattern differs from other risk factors such as smoking and hypertension which are 
associated with more proximal disease in the aorto-iliac vessels [American Diabetes 
Association 2003]. However, the finding of distal PAD in South Asians and Blacks is 
apparent even after adjusting for the increased prevalence of DM [Leggeter et al. 2002]. 
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Table 1.2 Examples of studies demonstrating ethnic differences in disease distribution 
of peripheral arterial disease 
Study Country Race/ 
Ethnic 
Group 
Studied 
Sample 
Size and 
Sex 
Age 
(years) 
Summary of Findings 
Kent et al. 
2010 
US NHW, 
Hispanic, 
AA, Asian, 
Native 
American 
3.1 million 
male & 
female 
>50 Prevalence of AAA: 
NHW:0.8%, H:0.28%, 
AA:0.39%, As:0.29%, 
NA: 0.95% 
Salem et al. 
2009 
UK White 
Asian 
19014 male >65 Prevalence of AAA: 
White: 4.69%, 
As: 0.45% 
Wilson et al. 
2008 
US NHW, AA 606000 
male 
>65 Prevalence of AAA: 
NHW: 1.41%, 
AA: 0.55% 
Deneuville et 
al. 2008 
West 
Indies 
African 
Caribbean 
754 male & 
female 
Mean 
age 73+/-
10 
Vascular disease 
distribution: 
Infra-genicular: 86%, 
Femoro-popliteal: 51% 
Aorto-iliac: 7% 
Robbs et al. 
1985 
South 
Africa 
White, 
Black, 
Indian 
1342 male 
& female 
Mean 
age 
White: 
59 
Black: 
54.8 
Indian: 
54.6 
Vascular disease 
distribution: 
White: Extra-cranial 
cerebrovascular 10.1%, 
Aorto-iliac: 30.5%  
Femoro-popliteal: 22%, 
Tibio-peroneal: 9.4%, 
AAA: 25%, 
Indian: Extra-cranial 
cerebrovascular: 12.7%, 
Aorto-iliac: 33.3%, 
Femoro-popliteal: 33% 
Tibio-peroneal: 14.6% 
AAA: 3.9%, 
Black: Extra-cranial 
cerebrovascular: 2.7%, 
Aorto-iliac: 34.1% 
Femoro-popliteal: 36.8% 
Tibio-peroneal: 10.2% 
AAA: 5.6% 
AA: African American; AAA: Abdominal aortic aneurysm; As: Asian; H: Hispanic; NA: 
Native American; NHW: Non-Hispanic White 
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1.2.5 Summary of Ethnicity and PAD 
 
PAD is an important healthcare problem worldwide due to morbidity and mortality 
associated with this condition. Most population based studies investigating PAD prevalence 
and risk factors for its development and progression have been based on predominantly 
White European groups. Much less is known about the characteristics of this disease in 
minority ethnic groups. As a consequence, decisions regarding management of PAD, 
including risk factor modification, have been made on the basis of majority White European 
populations.  Understanding the epidemiology of PAD amongst ethnic groups is relevant, 
given that the proportion of minority ethnic groups in the UK rose by 53% between 1991 
and 2001 [National Statistics Online 2008] and it is likely to rise further in the next census of 
2011.  It is also evident that there is considerable heterogeneity in risk factors within the 
South Asian ethnic group, which may affect any conclusions made linking PAD and 
ethnicity to traditional vascular risk factors. 
 
Although South Asians have an apparently worse risk factor profile than the general 
population and a greater risk of CAD, they appear to have a lower prevalence of PAD. This 
could be a reflection of the higher premature death rate from CAD in South Asians 
compared to the general population [Balarajan et al. 1991]. Susceptible South Asians may 
not live long enough to develop symptoms of PAD. Given that PAD prevalence risk 
increases with age the apparent finding of lower prevalence in South Asians may be genuine; 
however, communication difficulties in describing symptoms of PAD which may result in its 
under diagnosis in this group. Amongst people of Black ethnicity, there is a discrepancy as 
to whether or not they have a higher prevalence of PAD.    
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Given the lack of concordance between risk of CAD, cerebrovascular disease and PAD in 
South Asian and Black ethnic groups it would appear likely that the development and 
distribution of chronic vascular diseases has some genetic basis.  With little data it is hard to 
make firm conclusions regarding the importance of risk factors in the development of PAD 
in different minority ethnic groups 
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1.3 Peripheral Arterial Disease and Virchow’s Triad 
 
1.3.1 Introduction 
 
Over 150 years ago, Virchow described a triad of abnormalities (abnormal blood flow, 
abnormal vessel wall and abnormal blood constituents) associated with thrombus formation 
(thrombogenesis). Given that the underlying pathophysiological mechanisms involved in the 
development, progression and complications of PAD are atherogenesis and thrombogenesis, 
abnormalities in Virchow’s triad, initially used with reference to venous thrombosis 
[Virchow et al. 1856], has been discussed in relation to this disease [Makin et al. 2002; 
Chung et al. 2003/2004; Lowe et al. 2003/2004]. Indeed there has been increasing interest in 
the components of Virchow’s triad in understanding the development and progression of 
PAD, as well as its symptomatic complications. 
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1.3.2 Defining Virchow’s triad 
 
The original components of the triad have been updated for the 21
st
 century- for example, 
abnormal vessel wall now relates to endothelial damage/ dysfunction and structural changes 
within the vessel wall, whilst abnormal blood constituents refers to abnormalities in 
platelets, as well as coagulation and fibrinolytic pathways; and abnormal flow refers to 
abnormalities in haemorrheology and turbulence at bifurcations and stenotic regions [Lip et 
al. 2004]. Improvements in biochemical techniques, notably doppler flow analysis, enzyme-
linked immunosorbant assay (ELISA) and coagulation bioassays, have allowed components 
of Virchow’s triad to be quantified and studied in relation to their role in arterial thrombosis. 
 
It should not be forgotten that traditional cardiovascular risk factors, including smoking, 
hypertension, hyperlipoproteinaemia and hyperglycaemia, play an important role in initiating 
and accelerating atherogenesis [Figure 1.2], also by altering components of Virchow’s triad. 
Studies have reported that abnormalities in markers of thrombogenesis appear to be related 
to – and even additive to - conventional risk factors. For example, subjects in the highest 
tertiles of both fibrinogen and total or low-density lipoprotein (LDL) cholesterol are at 
greatest cardiovascular risk compared to subjects with high cholesterol but modest 
fibrinogen [Ridker1997]. There is also mounting evidence of the prognostic value of various 
markers of thrombogenesis, which suggests that they are not merely consequences of 
atherothrombotic diseases, but may actively contribute to the pathogenesis of vascular 
disease and its complications [Lip et al. 2004]. 
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Figure 1.2: Stages of atherogenesis (based on Ross et al. 1999 and American Heart 
Association Classification of Atherosclerotic lesions [Stary et al. 1995]) 
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1.3.3 “Abnormal Vessel Wall” and Peripheral Arterial Disease 
 
Endothelial dysfunction is the earliest pathological process in atherogenesis [Ross 1999] 
[Figure 1.2]. Atheroma, typically occurring at branches, bifurcations and curvatures, disrupts 
normal laminar blood flow, leading to turbulence and altered wall shear stress (WSS). The 
latter causes platelet activation and aggregation, which enhances thrombus formation at these 
sites. Rupture of an atherosclerotic plaque, leads to exposure of its thrombogenic lipid core, 
which precipitates thrombus formation, causing occlusion with resulting ischaemia [Hiatt et 
al. 2002]. 
 
With endothelial damage or dysfunction there is a reduction in the bioavailability of 
vasodilators, such as nitric oxide (NO) leading to decreased endothelium-dependent 
vasodilatation and disruption of normal vascular homeostasis. This is characterised by a state 
of endothelial activation, which predisposes the endothelial micro-environment to a pro-
inflammatory, hypercoagulable or pro-thrombotic state, which promotes all stages of 
atherogenesis. Many of the traditional risk factors are associated with the over-production of 
reactive oxygen species (ROS) or increased oxidative stress [Cai et al. 2000]. By reacting 
with NO, ROS may decrease the bioavailability of NO, impairing flow-mediated 
vasodilatation (FMD). Whilst PAD has previously been associated with a reduction in FMD 
[Brevetti et al. 2003] protocols for assessing FMD still vary among different laboratories and 
can be operator dependent [Anderson 1999; Coretti et al. 2002]. This decreases the 
feasibility of this measurement technique as a screening tool for endothelial dysfunction in 
large-scale multinational epidemiological studies [Bonetti et al. 2003]. 
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The abnormal blood vessel wall in PAD can also be demonstrated by abnormalities of levels 
of specific plasma markers of endothelial damage/dysfunction as well as by abnormalities in 
vessel structure, for example, intima- medial thickness and arterial stiffness, as described 
below.  Examples of studies reporting positive associations between markers of endothelial 
dysfunction and PAD are shown in Table 1.3. 
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Table 1.3: Examples of studies reporting positive associations between components of 
Virchow’s Triad and peripheral arterial disease 
 
Components of Virchow’s Triad: 
A: Abnormal blood vessel wall 
B: Abnormal blood constituents 
C: Abnormal blood flow 
 
ABPI: ankle brachial pressure index; PAD: peripheral arterial disease; IC: intermittent claudication; CLI: 
critical limb ischaemia; MI: myocardial infarction; TIA: transient ischaemic attack; CAD: coronary artery 
disease; AAA: abdominal aortic aneurysm; BMI: body mass index; PTA: percutaneous transluminal 
angioplasty; TF: tissue factor; TFPI: tissue factor pathway inhibitor; CRP: C-reactive protein; IL: interleukin; 
VCAM-1: vascular adhesion molecule-1; ICAM-1: intercellular adhesion molecule-1; Hcy: homocysteine; 
PAI-1: plasminogen activator inhibitor-1; tPA: tissue plasminogen activator; TM: thrombomodulin;  SAA: 
serum amyloid A; IMT: intima medial thickness; AIx: aortic index; P-sel: p-selectin;  VWF: von Willebrand 
factor; Lp(a): lipoprotein (a); TAT: thrombin antithrombin three; PMA; platelet microaggregates, MCP-1: 
monocyte chemoattractant protein-1; PMP: platelet microparticles; WSS: wall shear stress, CEC: circulating 
endothelial cells; Hct: haematocrit. 
 
 
Study & 
Population 
Markers Studied Summary of significant (P<0.5) 
associations 
Components of 
Virchow’s Triad 
Khaleghi et al. 
2009 
 
1051 African 
Americans, 894 
Non-Hispanic 
Whites 
Fibrinogen, D-
dimer, Factors V, 
VII, VIII, VWF, 
Antithrombin III 
Elevated fibrinogen and D-dimer 
were the only markers 
independently associated with 
lower ABPI in African Americans 
and Non-Hispanic Whites 
A, B 
Bartlett et al. 2009 
 
785 men with PAD 
Fibrinogen Baseline fibrinogen was an 
independent predictor of 3 and 6 
month risk of death adjusting for 
baseline risk factors including age, 
total and HDL cholesterol, 
triglycerides, SBP, DBP, smoking, 
previous MI, stroke, stable angina 
and use of antiplatelets. Individual 
led predictions may not be 
improved materially by 
measurement of fibrinogen. 
B 
Gosk-Bierska et 
al. 2008 
62 patients with IC, 
20 controls 
TF, TFPI Patients with PAD had higher TF, 
total TFPI and truncated TFPI than 
controls. Full-length TFPI was 
lower in patients with PAD than in 
controls 
A 
McDermott et al. 
2008 
 
423 patients with 
D-dimer, CRP, IL-
6, VCAM-1, 
ICAM-1, Hcy 
Elevated levels of all of these 
factors were associated with 
poorer 6 minute walking 
performance. Increased D-dimer, 
A, B 
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PAD IL-6, VCAM-1 and Hcy were 
associated with slower usual paced 
4 metre walking speed 
Mota et al. 2008 
 
36 patients with 
PAD, 30 Controls 
D-dimer, 
plasminogen, 
prothrombin 
fragment 1 & 2, 
PAI-1, TM 
Patients had higher levels than 
controls. Inverse correlations 
between plasminogen and PAI-1 
A, B 
Heneghan et al. 
2008 
 
225  patients with 
CLI undergoing 
revascularisation 
procedures 
Hcy Patients with raised Hcy had 
significantly lower primary, 
assisted primary and secondary 
patency rates at all intervals to 36 
months. Mean amputation survival 
was lower in patients with raised 
Hcy 
B 
Hogh et al. 2008 
 
452 patients with 
symptomatic PAD 
 
CRP CRP levels were higher overall 
among patients developing 
primary endpoints (death, lower 
limb amputation, peripheral 
revascularisation) or secondary 
endpoint (thrombosis of lower 
limbs, MI, stroke, TIA) 
B 
Vidula et al. 2008 
 
377 patients with 
PAD 
D-dimer, CRP, 
SAA 
Higher levels of these factors was 
associated with higher all cause 
and higher cardiovascular 
mortality among patients who died 
within 1
st
 2 years of measurement 
in people with PAD 
B 
Sodhi et al. 2007 
 
195 patients >40 
years free from 
cardiovascular 
disease and 
symptomatic PAD 
IMT There was a significant correlation 
between ABPI and common 
carotid IMT 
A 
Khaleghi et al. 
2007 
 
475 Patients with 
PAD 
AIx. AIx. Was independently 
associated with lower ABPI; 
association modified by age  
 
A 
Brewer et al. 2007 
 
106 Patients with 
PAD 
AIx. High AIx associated with lower 
walking distance in people with 
PAD 
A 
Rajagapolan et al. 
2007 
 
182 patients with 
P-Sel 
Fibrinogen 
Patients with sub-critical limb 
ischaemia had significantly 
enhanced ADP stimulation, P-Sel 
expression and bound fibrinogen. 
B 
34 
 
symptomatic PAD 
 
Also had higher TRAP platelet 
aggregation 
Cleanthis et al. 
2007 
 
19 patients with IC 
and 10 patinets 
with CLI taking 
aspirin 
12 controls not on 
aspirin 
PMA, P-Sel, MCP-
1 
P-Sel, PMA and MCP-1 were all 
higher in CLI compared to IC and 
controls despite aspirin 
B 
Tzoulaki et al. 
2007 
 
1519 men & 
women 
CRP, fibrinogen, 
Lp(a), Hct, IL-6, 
ICAM-1, VCAM-
1, blood viscosity. 
plasma viscosity, 
tPA 
CRP, fibrinogen, Lp(a) and Hct 
were significantly associated with 
PAD after 17 years follow up. 
Significant trend between higher 
levels of ICAM-1, D-dimer, tPA 
and Hct and worsening disease 
from no disease to moderate (IC) 
and severe (CLI or surgical 
intervention). IL-6, ICAM-1, 
Lp(a), fibrinogen, tPA and D-
dimer and al rheological markers 
were significantly elevated at 
baseline in patients who 
experienced symptomatic PAD 
during 17 year follow up. 
A, B, C 
Iwashima et al. 
2006 
 
40 patients with 
PAD 
48 controls 
ICAM-1, VCAM-
1, Adiponectin, 
CRP 
Adiponectin was lower in PAD 
than without. Adiponectin, 
sICAM-1, sVCAM-1, CRP were 
independently associated with 
ABPI 
A 
Allison et al. 2006 
 
6814 men and 
women free from 
clinically apparent 
cardiovascular 
disease from AA, 
NHW, Hispanic 
and Chinese ethnic 
groups 
 
IL-6, fibrinogen, 
D-dimer, Hcy, 
VWF 
IL-6, fibrinogen, D-dimer and Hcy 
were all significantly associated 
with PAD after adjustment for 
traditional cardiovascular risk 
factors in this large cross-sectional 
study. These novel risk factors do 
not entirely explain the difference 
in ethnic-specific odds for PAD.  
A, B 
Kals et al. 2006 
 
38 Patients with 
PAD 
28 Controls 
Arterial elasticity, 
oxidative stress 
Patients with PAD had decreased 
large and small artery elasticity. 
Decreased arterial elasticity and 
high grade oxidative stress was 
found in patients with 
A, C 
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 atherosclerosis. 
Spring et al. 2006 
 
31 Patients with 
PAD 
31 patients with 
AAA 
37 Controls 
WSS, erythrocyte 
aggregation, 
leucocyte count, 
fibrinogen, plasma 
viscosity, IMT 
WSS was lower in patients with 
PAD and AAA than in controls. 
WSS was inversely related to 
erythrocyte aggregation, 
fibrinogen, leucocyte count, 
plasma viscosity and IMT. 
A, B, C 
Brevetti et al. 
2006 
 
154 patients with 
PAD 
CRP, metabolic 
syndrome 
Metabolic syndrome was present 
in 51.9% of PAD patients. Patients 
with an ABPI <0.64 were more 
likely to have metabolic syndrome 
than those with less severe PAD. 
PAD patients with metabolic 
syndrome had higher BMI & CRP 
than those without. 
B 
Unlu et al. 2006 
 
45 patients with 
PAD 
44 controls 
D-dimer, CRP, 
fibrinogen, SAA 
D-dimer, CRP, SAA were higher 
in PAD group than control group. 
PAD associated with moderately 
higher fibrinogen. CRP & serum 
amyloid A had an inverse 
relationship with ABPI. D-dimer 
& fibrinogen were related to lower 
ABPI 
B 
Kudoh et al. 2006 
 
42 patients with 
CAD and PAD 
56 CAD only 
32 controls 
 
Platelet aggregation The level of small platelet 
aggregates was increased 
significantly in the PAD group 
compared with both CAD and 
control groups. Platelet 
aggregability was increased in 
patients with PAD with the degree 
of platelet aggregation being 
closely related to ABPI 
B 
Laxdal et al. 2006 
 
139 vascular 
interventions on 
103 patients with 
common iliac 
occlusive disease 
Hcy, fibrinogen, d-
dimer, activated 
protein C resistance  
There was a significant association 
between patency rate and levels of 
fibrinogen, Hcy.  The highest 
values of Hcy and fibrinogen were 
independent predictors of failure 
B 
McDermott et al. 
2005 
 
6570 men and 
women free from 
clinically evident 
disease 
CIMT Men and women with definite 
PAD, borderline ABPI or low-
normal ABPI had significantly 
higher internal CIMT than those 
with normal ABPI. In men the 
association between ABPI and 
internal CIMT were significantly 
less inverse in White than in 
A 
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African Americans 
 
Cassar et al. 2005 
 
132 patients with 
IC 
30 CLI 
40 controls 
 
CRP, VWF, D-
dimer, TAT 
CRP, vWF, D-dimer and TAT 
were significantly raised in 
patients with IC compared to 
controls. Patients with CLI had 
significantly higher levels of CRP, 
VWF, and TAT than claudicants 
A, B 
 
 
Sofi et al. 2005 
 
280 patients with 
symptomatic PAD 
280 controls 
 
PAI-1, Lp(a), Hcy, 
factor V leiden 
mutation, 
prothrombin 
variant 
There was an association between 
PAD symptoms and prothrombin 
variant, altered levels of 
homocysteine, Lp(a), PAI-1 and 
APA. The presence of Lp(a) and 
another metabolic antibody 
increased the risk of PAD 
symptoms. There was a correlation 
between the number of altered 
thrombophilic factors and 
Fontaine stage of PAD. 
B 
Tan et al. 2005 
 
23 patients with 
CLI 
36 with IC 
30 controls 
 
Platelets, P-sel, 
PMP 
PMPs were increased relatively to 
healthy controls in patients with 
IC and further increased in critical 
limb ischaemia. Platelets and sP-
Sel independently predict PAD 
severity on multivariate analysis 
B 
Wildman et al. 
2005 
 
4787 men and 
women 
 
CRP, fibrinogen, 
leucocyte count 
On multivariate analysis there 
were significantly higher odds of 
developing PAD in the highest 
compared to the lowest quartiles 
of CRP, fibrinogen and leucocyte 
count levels 
B 
Urge et al. 2005 
 
37 Diabetic 
patients with PAD 
Hct Increase in claudication distance 
correlated with haematocrit 
decrease in diabetic patients with 
peripheral vascular disease. 
C 
Makin et al. 2004 
 
20 patients in each 
group of ischaemic 
rest pain, acute MI, 
stable IC, healthy 
controls 
CEC, TF, VWF Increased number of CECs and 
elevated TF and VWF in patients 
with ischaemic rest pain compared 
to those with IC and healthy 
controls. 
 
A 
Lee et al. 2004 
 
33  PAD patients 
admitted for 
VCAM-1, ICAM-
1, P-sel, CRP 
VCAM-1, ICAM-1 and CRP were 
all higher and P-sel significantly 
lower in patients with systemic 
arterial disease. P-Sel, VCAM-1, 
A, B 
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elective PTA 
 
hsCRP were elevated significantly 
for at least 2 weeks post 
PTA/stenting 
 
Tseng et al. 2004 
 
557 patients with 
type II diabetes 
Lp(a) ABPI was associated with log 
Lp(a) especially in men or in 
patients with PAD. Lp(a) levels 
increased from no PAD to mild 
and severe PAD. 
B 
Parsson et al. 2004 
 
40 patients with 
CLI undergoing 
either femoro-
popliteal or 
femoro-distal 
reconstruction 
tPA, PAI-1, D-
dimer, IL-6, IL-2 
rec, MCP-1, IL-10, 
TAT 
Patients with CLI had increased 
IL-6, IL-2 receptor, TAT, tPA, D-
dimer and fibrinogen prior to 
revascularisation. Elevated tPA 
and D-dimer were found after 30 
days posoperatively. Increased IL-
6, IL-10, MCP-1 was observed 
after reperfusion but normalised 
after 30 days. 
B 
Riba et al. 2004 
 
39 patients with IC 
14 controls 
 
Hcy 63% of patients with PAD were 
found to be mildly 
hyperhomocysteinaemic. 
Claudicants with elevated 
homocysteine had altered platelet 
function compared to controls 
B 
Koscielney et al. 
2004 
 
2821 men and 
women 
 
Hct, plasma 
viscosity, 
fibrinogen, 
erythrocyte 
aggregation 
In males with PAD, Hct, plasma 
viscosity, fibrinogen and 
erythrocyte aggregation were 
significantly higher than controls. 
 
B, C 
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1.3.4 Circulating markers of endothelial damage/ dysfunction associated with PAD 
 
1.3.4.1 Von Willebrand Factor (VWF) 
 
Von Willebrand Factor is produced in the Wiebel-Palade bodies of endothelial cells, α-
granules of platelets and in sub-endothelial connective tissue. VWF is considered as a well-
validated plasma marker for the measurement of endothelial damage [Lip et al. 1997] in 
atherosclerosis and its levels may be regulated by several factors, including blood flow, 
platelet number, thrombin, angiogenic markers and pro-inflammatory cytokines [Zanetta et 
al. 2000]. VWF is also associated with the major established cardiovascular risk factors, and 
modification of these risk factors has been shown to reduce its levels [Blann et al.  1993a; 
Blann et al. 1993b; Spencer et al. 2002]. VWF is also a carrier for the coagulation factor VIII 
and VWF promotes thrombus formation by mediating the adhesion of platelets to the sub-
endothelium and to each other during haemostasis [Ruggeri 1997]. 
 
In the context of PAD, VWF appears to be related to the degree of endothelial damage in 
diseased lower extremity arteries [Blann et al. 2000]. In PAD, VWF concentration was 
correlated with transcutaneous oxygen pressure (a marker of severity of limb ischaemia 
[Seigneur et al. 1995]. VWF has been associated with both progression and severity of 
disease [ Seigneur et al. 1995; Lee et al 1995; Cassar et al. 2005; Cassar et al. 2003] and its 
elevated levels in patients with critical limb ischaemia have been reported to partially resolve 
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with resolution of ischaemia [Woodburn et al. 1995], implying some improvement in 
endothelial function in these patients. 
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1.3.4.2 Soluble Thrombomodulin (sTM) 
 
Thrombomodulin (TM) is an anticoagulant protein that is specifically expressed on the 
surface of endothelial cells [Peterson et al. 1999] and is released by these cells in a soluble 
form (sTM) following endothelial injury. sTM has been shown to be a specific marker of 
endothelial cell damage [Ishii et al. 1991; Boffa et al. 1991]. Bound TM normally enhances 
the thrombin-dependent activation of anticoagulant protein C as well as inhibits the pro-
coagulant effects of thrombin [Esmon 1995]. The loss of this anticoagulant from the 
endothelial surface results in a change towards a pro-coagulant state [Blann et al. 1997].  
 
 Correlations between TM and Fontaine stage of PAD have been previously reported 
[Seigneur et al. 1995; Blann et al. 1997] illustrating the progressive release of TM following 
increasing endothelial injury that occurs as PAD progresses. sTM also rises after exercise in 
PAD patients and correlates with transcutaneous oxygen pressure [Constans et al. 2000]. The 
prognostic value of sTM was initially suggested by sTM being the only endothelial marker 
associated with a significant relative risk for re-stenosis after percutaneous transluminal 
angioplasty (PTA) in symptomatic PAD patients [Tsakiris et al. 1999]. However, sTM has 
not been conclusively associated with PAD in all studies. The most notable is the 
Atherosclerosis Risk in Communities (ARIC) study, which found no association between 
sTM and PAD in asymptomatic patients [Salomaa et al. 2001]. These conclusions are also 
supported by other studies [Blann et al. 2000a; Sernau et al. 1995; Peter et al. 1997].  
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1.3.4.3 Circulating endothelial cells (CECs) 
 
Circulating endothelial cells in the blood are thought to be the product of a disease process 
irreversibly damaging the endothelium causing endothelial cells to slough off [Blann et 
al.2005]. This may leave a denuded sub-endothelium exposed to pro-coagulant factors in the 
blood and thus, may potentiate thrombosis [Lee et al. 2006].  In healthy volunteers CEC 
numbers have been correlated with thrombomodulin levels [Strijbos et al. 2008]. In disease 
states, CECs have been correlated with VWF levels and inversely correlated with flow 
mediated vasodilatation (FMD) suggesting they reflect endothelial cell dysfunction and 
damage [Rajagopalan et al. 2004]. CECs have also been correlated with tissue factor in 
pathological disease states linking endothelial damage to on-going thrombogenesis 
[Rajagopalan et al. 2004]. Elevated CECs may also result in reduced NO release, further 
amplification of platelet thrombosis and potentiation of atherogenesis [Loscalzo 2001; 
Freedman et al. 1998].  
 
CEC levels have been reported to be higher in PAD patients with ischaemic rest pain 
compared to patients with stable claudication, reflecting the irreversible endothelial damage 
in the more severe manifestations of PAD [Makin et al. 2004]. The prognostic implications 
of CECs in PAD have yet to be established. 
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1.3.4.4 Tissue Factor (TF) 
 
Tissue factor (TF) is a cell-surface receptor for coagulation factor VIIa which is expressed 
on sub-endothelial tissue, platelets and leucocytes, and is a major initiator of thrombogenesis 
as part of the extrinsic pathway. TF expression is regulated by various cytokines, including 
tumour necrosis factor (TNF)-α and interleukin (IL)-6. Exposure of the sub-endothelium, 
either by endothelial injury or by rupture of an atherosclerotic plaque, allows TF to complex 
with circulating factor VIIa, which via activation of factor X leads to the formation of 
thrombin and ultimately, formation of a fibrin clot.  TF is elevated in prevalent PAD [Makin 
et al. 2003; Blann et al. 2000b] and associated with disease severity [Makin et al.2004]. TF is 
yet to be established conclusively as a marker of endothelial damage/ dysfunction and 
further research is required into its prognostic value in patients with PAD. 
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1.3.4.5 Cellular adhesion molecules (CAM) 
 
Cellular adhesion molecules (Intracellular adhesion molecule-1 (ICAM-1) and vascular 
adhesion molecule-1 (VCAM-1)) are endothelial ligands for integrins expressed on 
leucocytes and platelets [Constans et al. 2006]. These molecules facilitate platelet and 
leucocyte adhesion to the endothelium. Their over-expression causes increased endothelial 
adhesion of leucocytes and their accumulation in sub-endothelial regions of atheroma 
[Davies et al. 1993]. Although considered a measurement of endothelial 
damage/dysfunction, CAMs are not specific to the endothelium and are expressed on a 
variety of other cell types. CAM expression is up-regulated by atherogenic stimuli and their 
soluble levels increase in response to inflammatory cytokines and oxidised LDL-C 
[Constans et al. 2006]. 
 
The prognostic value of sICAM-1 and sVCAM-1 in PAD has not been established and there 
is a suggestion that their association with PAD may be race related [Khalegi et al. 2008]. 
Nonetheless, elevated sVCAM-1 and sICAM-1 have both been correlated with ankle 
brachial pressure index, an index of PAD severity [Iwashima et al 2006]. In the Edinburgh 
Artery Study, sICAM-1 (but not sVCAM-1) was an independent predictor for the 
development of PAD [Pradhan et al. 2002; Tzoulaki et al. 2007] and symptomatic PAD 
[Tzoulaki et al. 2007]. There was also a significant trend between higher sICAM-1 levels 
and the progression of PAD over 17years, from no disease at baseline, to moderate severity 
(intermittent claudication) and severe disease (i.e. critical limb ischaemia (CLI) or surgical 
intervention) [Tzoulaki et al. 2007]. Other studies have reported raised sVCAM-1 but not 
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sICAM-1 that correlated with the extent of peripheral atherosclerosis [Peter et al. 1997] and 
a higher cardiovascular event rate in symptomatic PAD subjects [Silvestro et al. 2005]. In 
one study on Fontaine II-IV PAD patients, higher sVCAM-1 but not sICAM-1 levels were 
also seen at two weeks post percutaneous transluminal angioplasty (PTA) [Lee et al. 2004] 
and correlated with re-stenosis following PTA [Taskiris et al. 1999].  
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1.3.4.6 Abnormal structural indices 
 
Various structural indices can be easily quantified in individuals using ultrasound imaging 
techniques, whereby abnormal measures such as carotid intima medial thickness (IMT and 
arterial stiffness reflect blood vessel abnormalities. 
 
1.3.4.6.1 Carotid artery intima media thickness 
 
Intima-media thickness (IMT) measurement by ultrasonic evaluation is a well-recognised 
index of pre-clinical atherosclerosis [Allan et al. 1997] and a predictor of future 
cardiovascular events [O’Leary et al. 1999].  IMT can be measured at a single site or several 
sites in the common carotid, carotid bifurcation and internal carotid arteries, but it is unclear 
whether generalised IMT or focal plaque formation is of more importance in determining 
cardiovascular risk. 
 
Common carotid IMT has been significantly correlated with the conventional cardiovascular 
risk factors, such as smoking, diabetes mellitus and LDL-C [Markus et al. 2001; Mohan et 
al. 2000]. Only C-reactive protein (CRP) and fibrinogen seem to be unequivocally related to 
IMT [Baldassarre et al. 2008].  
 
Studies in dyslipidaemic and diabetic patients have reported that a combination of carotid 
IMT and Framingham Risk Score improved the prediction of subsequent cardiovascular 
46 
 
events, better than using the Framingham Risk Score alone [Baldassarre et al. 2007; Bernard 
et al. 2005]. CCIMT is thought to be an independent risk factor for cardiovascular events in 
European high risk individuals over and above Framingham risk factors [Baldessarre et al. 
2012]. Baldessarre et al. 2007 reported that elevated maximum CCIMT significantly 
improved the predictive value of Framingham risk score in subjects having a high 
Framingham risk score (20-30%) (χ2 =8.13; p=0.04). Bernard et al. 2005 reported an 
improvement in risk prediction by addition of CCIMT to Framingham risk score in a Cox 
model (global χ2 increased from 14.1 to 18.1, P = 0.035).  A recently published multi-centre 
study on 3703 subjects followed up over a median of 36.2 months investigating whether 
IMT adds to the predictive accuracy of Framingham risk factors [Baldassarre et al. 2012] has 
shown that maximum CCIMT measurement has a net reclassification improvement of 11.9% 
over Framingham risk factors alone (p<0.01). When this measurement combined with inter-
adventitia common carotid artery diameter had a net reclassification improvement of 19.9% 
(p<0.01). Compared to classification based upon Framingham risk factors alone, a 
combination of CCIMT (mean and maximum) and inter-adventitia common carotid artery 
diameter had a net reclassification improvement of 12.1% (p<0.01) [Baldassarre et al. 2012]. 
This remained significant even after adjustment for pharmacological treatment [Baldassarre 
et al. 2012]. 
 
IMT is associated with both asymptomatic and symptomatic PAD [Allan et al 1997; 
McDermott et al. 2005; Price et al. 2007].  In PAD subjects, high common carotid IMT is 
significantly associated with a risk of subsequent cardiovascular events, independent of 
traditional risk factors [Price et al. 2007]. However, it is not evident from the published 
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literature whether carotid IMT alone contributes to risk prediction above what is provided by 
neither traditional cardiovascular risk factors nor the effect of routine IMT measurements on 
patient outcomes.  
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1.3.4.6.2 Arterial Stiffness 
 
The elastic property of arteries varies along the arterial tree; proximal arteries being more 
elastic than the stiffer distal arteries. Normally the systolic pressure wave is transmitted 
forwards along the more elastic proximal arteries, with the stiffer distal vessels causing 
resistance to flow and wave reflections [Laurent et al. 2006]. Branches and bifurcations 
along the vessel also contribute to reflected pressure waves. With age, and atherosclerosis-
associated accumulation of arterial calcium and elastin, there is decreased elasticity and 
compliance of proximal arteries [Chobnanian 2007], although arterial stiffening with age 
does not appear to depend on the presence of atherosclerotic diseases [Avolio et al. 1985]. 
Arterial stiffness may therefore be considered both an index of endothelial dysfunction and 
an index of abnormal blood flow. 
 
Indices of arterial stiffness include pulse wave velocity and aortic augmentation index (AIx). 
Arterial stiffness has been reported to be an independent predictor of cardiovascular 
mortality [Laurent et al. 2001]. Increased arterial stiffness and/ or pulse wave reflections are 
both associated with the conventional cardiovascular risk factors such as obesity, smoking, 
hypertension, hypercholesterolaemia and diabetes mellitus, along with novel risk factors, 
including hyperhomocysteinaemia and raised CRP [Laurent et al. 2006].  
 
The elastic properties of large and small arteries are reduced in PAD patients compared to 
controls [Kals et al. 2006; Tai et al. 1999]. The arterial pulse wave form is also altered in 
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these patients [McVeigh et al. 1997] suggesting altered vascular tone in these patients. 
Arterial stiffness may be improved by aerobic exercise, possibly due to improved endothelial 
function or by anti-inflammatory and antithrombotic effects [Seals et al. 2008]. AIx is 
reported as being independently associated with lower ABPI [Khaleghi et al. 2007] along 
with a reduced walking distance in subjects with PAD [Brewer et al. 2007].  As with other 
novel risk factors, arterial stiffness has not yet shown any additional benefit over and above 
traditional risk factors in determining prognosis in patients with PAD. Arterial stiffness may 
in fact be a consequence of cardiovascular risk factors, age and arterial disease rather than 
being an independent risk factor in the development of PAD. 
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1.3.5 “Abnormalities of blood constituents” and Peripheral Arterial Disease 
 
Many blood constituents have been implicated in PAD development, progression and 
prognosis along with acute thrombotic complications. Examples of studies reporting 
associations between these factors and PAD are shown in table 1.3. 
 
1.3.5.1 Platelets 
 
Important thrombogenic platelet components include α-granule constituents (VWF, 
fibrinogen, factor V, thrombospondin, β-thromboglobulin), and an adhesion molecule 
expressed on α-granule membranes, P-selectin. The latter is transferred to the plasma 
membrane through membrane fusion after platelet stimulation and activation and hence, has 
been used as an index of platelet activation [Rajagopalan et al. 2007]. Cardiovascular risk 
factors, including smoking, dyslipidaemia, hypertension and diabetes mellitus all cause 
chronic endothelial injury, thus stimulating CAM expression, and resulting in increased 
platelet adhesion to the endothelium [Figure 1.2]. Acute endothelial injury or rupture of a 
complicated plaque leads to exposure of the sub-endothelium and binding of platelets via 
sub-endothelial bound VWF thus potentiating thrombosis. Altered shear stress states also 
induce platelet activation, aggregation and microparticle formation [Holme et al. 1997; Kroll 
et al. 1996; Nomura et al. 1997] further potentiating thrombogenesis.   
 
Adverse indicators of platelet function in PAD have been reported, including increased β-
thromboglobulin [Cella et al. 1979], increased platelet aggregation [Robless et al. 2003; 
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Kudoh et al. 2006], increased fibrinogen binding [Cassar et al. 2003], increased platelet P-
selectin and sP-sel [Ridker et al. 2001; Koksch et al. 2001], and an increase in platelet 
microparticles [Tan et al 2005]. Platelet and sP-sel levels also independently predict disease 
severity in PAD [Tan et al 2005]. In another study, symptomatic subjects undergoing PTA, 
demonstrated a correlation between sP-sel and re-stenosis at follow up [Taskiris et al. 1999].  
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1.3.5.2 Fibrinogen 
 
Fibrinogen is an important component of the coagulation system, as a pre-cursor of fibrin, 
and a major determinant of plasma viscosity. Fibrinogen plays an important role in platelet 
aggregation and mediates the adhesion of platelets to the endothelium via binding with 
ICAM-1 on its surface [Kamath et al. 2003].  Fibrinogen also plays a major role in 
inflammation by facilitating a chemotactic response via increased leucocyte adherence to the 
endothelium [Kamath et al. 2003]. High fibrinogen levels have been associated with 
smoking, diabetes, LDL-C and obesity, and levels are inversely correlated with HDL-C, 
alcohol use and physical activity [Kamath et al. 2003]. 
 
Fibrinogen has long been recognised as having prognostic implications for cardiovascular 
mortality. A meta-analysis reported moderately strong associations between fibrinogen 
levels and risk of coronary heart disease, stroke and other vascular (and non-vascular) 
mortality [Fibrinogen Studies Collaboration 2005]. The mechanism(s) for this relationship 
are unknown but hyperfibrinogenaemia increases platelet aggregation, as well as providing a 
ready source of fibrin. Increased fibrinogen levels favour a higher rate of fibrin-formation, 
thus leading to a tighter gel structure that most likely is more thrombogenic than structures 
formed in lower fibrinogen levels [Blann et al. 2001]. 
 
Hyperfibrinogenaemia has been associated with prevalent PAD, disease severity and with 
increased mortality risk in this disease [Ridker et al.2001; Price et al. 1999; Wattanakit et al. 
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2005; Lip et al. 2002; Vene et al. 2003]. Raised pre-interventional levels of fibrinogen are 
related to a greater risk of peripheral re-stenosis following peripheral PTA [Schillinger et al. 
2002; Roller et al. 1999], with patency rates being significantly associated with fibrinogen 
levels, independent of other factors [Laxdal et al. 2006].  Importantly, a report on the 17 year 
follow up to the Edinburgh Artery Study reported strong associations between fibrinogen 
and incident PAD over 17 years [Tzoulaki et al. 2007] independent of traditional 
cardiovascular risk factors and cardiovascular disease (defined by a history of MI, stroke or 
angina) at baseline. Another recent study reported fibrinogen to be a predictor of all-cause 
mortality risk in PAD [Bartlett et al. 2009] independent of traditional cardiovascular risk 
factors. However, fibrinogen may not improve the predictive ability over and above 
traditional cardiovascular risk factors and ABPI for PAD [Tzoulaki et al 2007; Bartlett et al. 
2009].  Tzoulaki et al. 2007 investigated the incremental benefit of considering 
inflammatory, haemostatic and rheological markers in addition to traditional cardiovascular 
risk factors and ABPI to discriminate incidental symptomatic PAD cases by calculating the 
area under the ROC curve. The area under the ROC curve in the core model using traditional 
risk factors and ABPI was 76.1% (95% CI: 71.1-81.3). When fibrinogen was entered into the 
model this increased to 77.4% (95% CI: 73.6-81.2) [Tzoulaki et al. 2007]. Despite the 
correlations between fibrinogen and cardiovascular risk, there is no convincing evidence to 
show that lowering the fibrinogen levels will result in a significant reduction in risk. 
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1.3.5.3 Fibrin D-dimer 
 
Fibrin D-dimer is a measurable breakdown product of cross-linked fibrin, and marks 
ongoing intravascular thrombogenesis and abnormal fibrin turnover. It is a specific marker 
of fibrinolysis but also reflects the severity of a hypercoagulable state [Matsuo et al. 2000]. 
D-dimer has been reported to induce the synthesis and release of inflammatory cytokines 
[McDermott et al. Circulation 2003] and has a significant association with cardiovascular 
diseases and risk factors [Danesh et al. 2001; Lassila et al. 1993]. With reference to PAD, 
high D-dimer levels have been associated with disease severity [Lee et al. 1995; Tzoulaki et 
al 2007] and functional impairment [McDermott et al.2003] but was not significantly 
associated with the development of [Tzoulaki et al. 2007] or progression of disease 
[Musicant et al. 2006; Mota et al. 2008]. In claudicants, however, raised D-dimer levels do 
predict fatal and non-fatal coronary events [Ridker et al. 1994].  Further research is required 
to determine whether lowering D-dimer levels has any effect on cardiovascular outcomes. 
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1.3.5.4 Fibrinolysis 
 
The fibrinolytic system consists of the circulating pro-enzyme plasminogen, which on 
activation to produce plasmin by tissue plasminogen activator (tPA) and urokinase, promotes 
fibrinolysis [Reiner et al. 2001]. tPA a serine protease, normally found on the endothelial 
cell surface, is secreted following vascular injury. Fibrinolysis is inhibited by the pro-
coagulant factor plasminogen activator inhibitor (PAI)-1, a serine protease inhibitor [Philipp 
et al. 1997] and hence is a marker of impaired fibrinolysis and atherothrombosis. PAI-1 is 
synthesised by a number of different cells, but it is endothelial derived PAI-1 that is 
primarily responsible for its levels measured in the plasma [Sobel 1999; Loskutoff et al. 
1993]. 
 
Endothelial dysfunction results in activation of endothelial cells, generating an imbalance 
between tPA and PAI-1, which creates a pro-coagulant surface. Although these factors are 
found at the endothelial surface, they are usually measured as markers of fibrinolysis and not 
as indices of endothelial dysfunction per se [Felmelden et al. 2005]. 
 
Elevated plasma PAI-1 decreases fibrinolysis and enhances thrombosis, and antibodies 
directed against PAI-1 prevent the progression of thrombosis [Philipp et al. 1997]. PAI-1 has 
also been detected in the intima of atheroma, thus supporting its role in the pathogenesis of 
this condition [Philipp et al. 1997]. Plasma PAI-1 is influenced by a number of hormones 
and cytokines [Cessari et al 1999] and has been associated with hyperglycaemia, 
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hypertriglyceridaemia and insulin resistance [Reiner et al. 2001; Devaraj et al. 2003], which 
are all components of the metabolic syndrome. Both tPA and PAI-1 have previously been 
associated with prevalent PAD and severity of disease and PAI-1 activity has been correlated 
with re-stenosis after PTA [Roller et al. 1999; Sawa et al. 1994].  Although tPA was not 
associated with incident PAD in the Edinburgh Artery Study, elevated tPA levels have been 
associated with the presence of and increasing severity of PAD [Tzoulaki et al. 2007]. 
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1.3.5.5 Lipoprotein (a) 
 
Lipoprotein (a) (Lp(a)) is a large protein molecule that consists of two components: an LDL-
like particle and an attached apolipoprotein(a) (apo(a)) [Kronenberg et al. 1999]. Due to its 
structural similarity to plasminogen, Lp(a) inhibits plasminogen binding to fibrin and 
endothelial cells by inhibiting tPA [Loscalzo et al. 1990], and therefore fibrinolysis (and 
promoting thrombosis) [Paraskevas et al. 2008; Palabrica et al. 1995]. Lp(a) accumulates in 
atheroma and may impair endothelial function and induce smooth muscle proliferation 
[Reiner et al. 2001]. Little research into the prognostic benefit of Lp(a)  in PAD exists. Lp(a) 
has been reported to be an independent risk factor for PAD [Cheng et al. 1997] as well as 
severity of disease [Cheng et al. 1997; Tseng et al. 2004].   
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1.3.5.6 Inflammatory factors 
 
Inflammation plays a major role in all stages of atherogenesis [Figure 1.2] [Ross 1999; Stary 
et al. 1995]. Inflammation occurs in response to a variety of stimuli and is also associated 
with many traditional cardiovascular risk factors, including dyslipidaemia, hypertension, 
diabetes mellitus, obesity and infection [Ross 1999; Libby et al. 2002] [Figure 1.2].  
 
Of the wide range of inflammatory indices, IL-6 and CRP have probably been most 
investigated. IL-6 is a pro-inflammatory cytokine that induces a prothrombotic state by 
increasing expression of fibrinogen, TF, Factor VIII and VWF [Tzoulaki et al. 2007]. IL-6 
also activates endothelial cells and their adhesiveness by up-regulating E-selectin, ICAM-1 
and VCAM-1, thus leading to increased leucocyte-endothelial binding and increasing 
platelet production [Tzoulaki et al. 2007]. CRP is a circulating acute phase protein 
synthesised by the liver, and its release is stimulated by IL-6 and other pro-inflammatory 
cytokines along with promoting monocyte chemotaxis and TF expression [Devaraj et al. 
2003]. 
 
CRP has pro-atherogenic effects on all cellular components of the endothelium. It inhibits 
endothelial cell NO synthase resulting in reduced bioavailability of NO and decreased 
endothelial dependent vasodilatation. CRP increases expression of ICAM-1 and VCAM-1, 
whose effects are discussed above, and increases production of PAI-1, which inhibits 
fibrinolysis [American Diabetes Association 2003; Vinik et al. 2001].  
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IL-6 and CRP are associated with PAD development, progression and severity of disease 
[Ridker et al. 2001; Devaraj et al. 2003; Tzoulaki et al. 2005; Allison et al. 2006, Armitage et 
al. 2006; Riba et al. 2004]. Elevated CRP levels are also associated with functional 
impairment [McDermott et al.2003] and increased thrombotic complications in symptomatic 
PAD [Hogj et al. 2008]. In the Edinburgh Artery Study, CRP was one of the few markers 
significantly associated with PAD after 17 years follow-up, even after adjusting for 
cardiovascular risk factors [Tzoulaki et al. 2007]. As with fibrinogen, Lp(a) and haematocrit, 
CRP provided very little prognostic information for incident PAD to that obtained by 
cardiovascular risk factors and ABPI [Tzoulaki et al. 2007]. IL-6 only showed weak 
associations and were attenuated when these risk factors were accounted for [Tzoulaki et al. 
2007]. 
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1.3.5.7 Homocysteine 
 
Homocysteine is a highly reactive, sulphur containing amino acid formed as a by-product of 
methionine metabolism.  Adverse effects of homocysteine include vascular endothelial 
injury [Wall et al. 1980], increased adhesion molecule expression [Silverman et al. 2002] 
smooth muscle proliferation, and oxidation of LDL-C, which contributes to a prothrombotic 
vascular endothelial microenvironment [Moghadasian et al. 1997; Welch et al. 1998]. 
 
Homocysteine has been associated with an increased risk of PAD and lower ABPI 
measurements in a previous meta-analysis [Boushey et al. 1995] but this finding has been 
disputed [Taylor et al. 2003]. In the Multi-Ethnic Study of Atherosclerosis, homocysteine 
was significantly associated with PAD, even after adjustment for traditional risk factors 
[Allison et al. 2006]. Elevated homocysteine levels have also been associated with lower 
patency rates following revascularisation procedures and lower mean amputation free 
survival [Heneghan et al. 2008]. As homocysteine levels increase following an acute 
thrombotic event, it is difficult to know whether increased thrombosis is due to elevated 
homocysteine or vice versa. This may be the reason why a link between elevated 
homocysteine and PAD has not been conclusively confirmed. 
 
61 
 
1.3.6 “Abnormal Blood Flow” and Peripheral Arterial Disease 
 
Quantification of the flow properties of blood can be made by measuring haemorrheological 
indices, and by measuring wall shear stress. Examples of studies reporting positive 
associations with PAD can be found in table 1.3. 
 
1.3.6.1 Haemorrheological indices 
 
Haemorrheological indices that have been investigated previously in PAD include blood 
viscosity (influenced by erythrocytes, leucocytes and platelets) and plasma viscosity and its 
determinants, including fibrinogen, VWF and lipoproteins [Tzoulaki et al. 2007; Fibrinogen 
Studies Collaboration 2005; Lowe et al. 1993]. Haematocrit, blood viscosity, plasma 
viscosity and fibrinogen have each been reported to be significantly related to the severity of 
PAD; for example, blood viscosity and fibrinogen remained significantly associated with 
ABPI on multiple regression analysis [Lowe et al.1993]. Blood viscosity and its 
determinants are also correlated with CCIMT, in a linear fashion [Lee et al.1998]. In the 
Edinburgh Artery Study, all rheological markers were significantly increased at baseline in 
all subjects who developed PAD over 17 years follow up [Tzoulaki et al. 2007]. Plasma 
viscosity is an independent risk factor for progression of atherosclerosis in claudicants 
[Smith et al. 1998]. The effect of haemorrheological indices on PAD in the Edinburgh Artery 
Study was modest and was considerably reduced after adjusting for traditional risk factors 
[Tzoulaki et al. 2007]. These indices alone are therefore unlikely to offer additional clinical 
value in PAD risk prediction.  
62 
 
1.3.6.2 Wall Shear stress (WSS) 
 
WSS is the force that contrasts friction applied to the blood by the vascular wall [Van Der 
Loo et al. 2005]. Its two components are shear rate (the rate at which adjacent layers of fluid 
move with respect to each other) and blood viscosity (the capacity of the blood to offer 
resistance to flow) [Gori et al. 2007]. Important determinants of WSS are geometric factors, 
such as bifurcations, tortuosity and aneurysms, as well as various biological and systemic 
factors, such as systolic blood pressure and NO [Gori et al. 2007; Shaaban et al. 2000].  
 
Both the synthesis and release of various prothrombotic and pro-inflammatory mediators and 
the secretion and release of endothelial defences (e.g. NO and prostacyclin) are shear 
dependent [Lowe 2003/2004]. Specific arterial sites, such as branches, bifurcations and 
curvatures cause specific alterations in the flow of blood, resulting in decreased WSS and 
increased turbulence [Ross 1999]. Decreased WSS is associated with decreased NO synthase 
production, reduced endothelial cell repair, increased reactive oxygen species (ROS), 
increased endothelial cell permeability to LDL-C, increased leucocyte adhesion (via ICAM-
1 and VCAM-1), and an increase in apoptosis and smooth muscle proliferation [Cunningham 
et al. 2005; Niwa et al. 2004; Chiu et al. 2004; Walpola et al. 1995].   The impaired normal 
laminar shear stress that occurs at bifurcations and branches may reduce local production of 
endothelial-derived NO leading to less endogenous atheroprotective mechanisms at these 
sites [Libby et al. 2002].  These sites are therefore more susceptible to atherosclerosis.  
 
WSS is associated with traditional risk factors, but only smoking, age and triglycerides 
remained significantly associated with this on multivariate analysis [Spring et al. 2006]. An 
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inverse relationship that exists between WSS and CCIMT has been reported [Irace et al. 
2004]. The IMT in normal abdominal aorta necropsy specimens from young adults 
correlated significantly with mean, minimum and oscillatory WSS [Asakura et al. 1990; 
Gnasso et al. 1997; Zarins et al. 1993], suggesting a role of this marker even in the early 
stages of atherogenesis. Common carotid artery WSS is a local risk factor for PAD and is 
reduced in patients with symptomatic disease [Van Der Loo et al. 2005, Spring et al. 2006] 
and aneurysms [Spring et al. 2006].   
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1.3.7 Summary of Virchow’s Triad and Peripheral Arterial Disease 
 
The pathophysiological processes involved in PAD and its symptomatic manifestations are 
atherogenesis and thrombogenesis. There is evidence that abnormalities in the three 
components of Virchow’s Triad are related to the severity and prognosis of PAD. Subjects 
afflicted with this common disease have a high morbidity and mortality from 
atherothrombotic events. This may partly be explained by the on-going endothelial and 
enhanced coagulation activation that occurs in these subjects causing a hypercoagulable or 
pro-thrombotic state.  Attention to this state may possibly provide answers to the future 
management of this condition. 
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1.4 Angiogenesis and Peripheral Arterial Disease 
 
1.4.1 Introduction 
 
Angiogenesis is the formation of new blood vessels that results from stimulation of 
endothelial cells by vascular growth factors. Pathological disruption of this process is a 
hallmark of vascular overgrowth or vascular insufficiency. Angiogenesis is initiated by a 
number of different stimuli, including hypoxia, inflammation, mechanical factors such as 
wall shear stress and stretch. These stimuli, either directly or indirectly, activate endothelial 
cells by initiating autocrine or paracrine production and release of growth factors and 
cytokines. The angiogenic process is complex and not completely understood, but a number 
of growth promoting factors have been found to regulate the induction of angiogenesis. Of 
the numerous angiogenic markers identified, several have been associated with PAD, some 
also being investigated with regards to their therapeutic application. 
 
Angiogenesis is frequently observed in atherosclerotic lesions [Post 2008] and is a feature of 
development and progression of disease [Jeziorska 1999; Moreno 2004].  This process is 
driven by mediators, including vascular endothelial growth factor (VEGF), angiogenin and 
angiopoietins, produced by a number of different cells in a variety of conditions [Caine et al. 
2006]. Angiogenesis is especially frequent in advanced disease activity and may thus 
characterise atherosclerotic lesions at high risk of haemorrhage or rupture [Kolodgie 2003; 
Moreno 2004, McCarthy 1999; Mofidi 2001]. 
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1.4.2 Vascular Endothelial Growth Factor (VEGF) 
 
VEGF is a mitogen and is perhaps the most important growth factor promoting endothelial 
cell proliferation and angiogenesis. VEGF is expressed in virtually all vascularised tissues 
and is secreted in the vascular wall by endothelial and smooth muscle cells. It has been 
suggested that low physiological VEGF levels are needed for the maintenance of vascular 
homeostasis [Maharaj et al. 2006]. Pathological states, such as hypertension, 
hypercholesterolaemia and atherosclerosis also up-regulate VEGF expression [Makin et al. 
2003], therefore its levels are increased in these conditions. 
 
Hypoxia is known to be one of the stronger inducers of angiogenesis, and is perhaps the 
strongest influence of VEGF and expression of its receptors (Flt-1 ((FMS-like tyrosine 
kinase-1 or VEGF-receptor-1)) and Flk-1 (Fetal liver kinase-1 or VEGF-receptor-2))) and 
other growth factors in PAD, including fibroblastic growth factors (FGF) 1 and 2 and 
platelet derived growth factor (PGDF). VEGF transcription is also influenced by 
hypoglycaemia and acidosis and is further stimulated by other growth factors, including 
FGF-2, PDGF-2, transforming growth factor- beta (TGF-β) and Placental growth factor 
(PlGF). The ischaemic environment which exists in PAD causes binding of hypoxia 
inducible factor 1-α to the hypoxia response area in the VEGF gene promoter region.  The 
increased VEGF which ensues, after binding to Flk-1, causes a tyrosine kinase signalling 
cascade in endothelial cells that stimulates production of other growth factors that variously 
stimulate vessel permeability, proliferation and survival, migration and finally differentiation 
into mature blood vessels.  
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VEGF has been demonstrated to be increased in patients with PAD [Makin et al. 2003; 
Roller et al. 2001; Belgore et al. 2001] and has been implicated in the progression of 
atherosclerosis [Khuraana et al. 2005; Cucina et al. 2003; Inoue et al. 1998]. VEGF was 
found to have the greatest expression in more advanced atherosclerotic arteries compared to 
early lesions and normal controls, representing a more hypoxic environment which exists in 
these subjects. 
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1.4.3 Angiopoietins   
 
The angiopoietins (Angiopoietin (Ang)-1 and Ang-2) are angiogenic growth factors specific 
for endothelium. Ang-1 and Ang-2 are ligands for the Tie-2 receptor and contribute to the 
regulation of vascular permeability, inflammation and angiogenesis [Chon et al. 2004, Van 
der Heijen et al. 2010, Jones et al. 2001]. Cleavage of the extra-cellular domain of Tie-2 by 
endothelial cells occurs in response to inflammation and results in circulating sTie2, a 
process which is reduced by hypoxia [Van der Heijen et al. 2010]. In acute inflammatory 
states, sTie2 in the plasma is bound by Ang-1 preferentially over Ang-2 due to its higher 
affinity for the receptor, leading to greater binding of Ang-2 to endothelial Tie-2 and 
increasing endothelial permeability [Ven der Heijen et al. 2010]. In the presence of hypoxia 
there is less cleavage of Tie-2 from the endothelial surface, less plasma binding of Ang-
1/sTie-2, leading to preferential Ang-1/Tie-2 endothelial binding to Ang-2, which accelerates 
vessel maturation [Post et al. 2008].  
 
Ang-1 acts in conjunction with and potentiates the effects of VEGF in the initiation and 
acceleration of the process of angiogenesis, being involved in both endothelial cell 
recruitment and proliferation. Ang-2 is a naturally occurring antagonist for both Ang-1 and 
the Tie-2 receptor. It is expressed only at sites of vascular remodelling. Ang-2 in the 
presence of VEGF, promotes a rapid increase in capillary diameter, remodelling the basal 
lamina and new vessel growth, evidenced by sprouting of existing blood vessels. In contrast, 
if VEGF is inhibited, Ang-2 leads to endothelial cell death and vessel degradation. 
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Levels of circulating Ang-1 and Ang-2 have been shown to be raised and associated with 
cardiovascular risk in patients with PAD [Findley 2008] and other manifestations of 
atherosclerosis, including heart failure, acute coronary syndromes and hypertension 
[Felmelden et al. 2003a; Felmelden et al. 2003b; Nadar et al. 2005; Lim et al. 2004; Chong 
et al. 2004; Lee et al. 2004].  
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1.4.4 Angiogenin 
 
Angiogenin is a small polypeptide implicated in angiogenesis. Angiogenin may function as a 
tRNA-specific ribonuclease and has been thought to be an indicator of endothelial damage 
related to progression of vascular disease. Angiogenin binds actin on the surface of 
endothelial cells and its plasma levels are dependent on the presence of an angiogenic 
stimulus [Tello-Montoliu et al. 2006]. Its levels would therefore be expected to be associated 
with sTie2 and angiopoietins. Once bound angiogenin is endocytosed and translocated to the 
nucleus thereby promoting the endothelial invasiveness necessary for angiogenesis. 
Angiogenin is normally found in the vasculature but in some physiological and pathological 
conditions, including PAD [Burgmann et al. 1996], its levels increase in blood, stimulating 
endothelial cells to produce new vessels [Bond et al. 1990]. Several studies have suggested 
that angiogenin and other angiogenic factors could promote atherosclerosis and potentially 
de-stabilise plaques by promoting intra-lesional angiogenesis [Moreno et al. 2004, Khurana 
et al. 2005]. 
 
Elevated angiogenin levels have been found to be higher in those with severe PAD, 
compared to mild and moderate disease [Burgmann et al. 1996]. Therefore angiogenin could 
potentially be an indicator of endothelial damage related to progression of vascular disease. 
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1.4.5 Angiogenesis and Thrombogenesis 
  
Over the past decade there has been increasing investigation into the association between 
angiogenesis and thrombogenesis. The importance of TF in thrombogenesis has been 
described above. Most of this research has been in the field of tumour growth and metastasis.  
For example, increases in TF have been found to be an indicator of both hepatic metastasis 
and prognosis in colorectal carcinoma and the expression of TF in sarcoma cells, up-
regulates the VEGF gene [Abe et al. 1999] and treatment of endothelial cells with VEGF 
leads to the up-regulation of tissue factor mRNA and its subsequent expression at the cell 
membrane [Camera et al. 1999]. The regulation of the TF gene is controlled by several 
transcription factors activated by inflammatory cytokines (IL-1β and TNF-α), oxidised 
LDL-C and endotoxin. In vitro, angiogenic growth factors, e.g. PDGF, FGF and 
transforming growth factor beta or epidermal growth factor can induce TF expression in 
fibroblasts and smooth muscle cells. This further supports an association between 
thrombogenesis and angiogenesis. 
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1.4.6 Angiogenesis and Atherogenesis 
 
The process of atherogenesis has been described above. The link between angiogenesis and 
atherogenesis is apparent in that they both involve the endothelium. Whilst VEGF may play 
a role in vascular disease progression by initiating and propagating angiogenesis, VEGF has 
also been found to progressively increase in atherogenesis; though this is likely to be 
secondary to hypoxia and inflammation in growing lesions.  
 
By increasing vascular permeability, VEGF may provide an easier passage for inflammatory 
cells migrating into the developing atheroma within the intima and media [Dvorak et al. 
1995]. Factors promoting inflammation cause chronic endothelial injury impairing normal 
endothelial function, the first established step in the atherogenic pathway. Inflammation and 
inflammatory markers have previously been found to stimulate FGF and VEGF expression 
following myocardial necrosis [Sunderkotter et al. 1991a; Sunderkotter et al.1991b]. VEGF 
can also stimulate and recruit other macrophages to stimulate the inflammatory response 
further, which further stimulates angiogenesis. 
 
In vitro research has shown co-localisation of Ang-2 and VWF exclusively in Wiebel-Palade 
bodies, the primary storage granule of VWF in endothelial cells.  VWF and Ang-2 export 
parallel each other, following the same temporal kinetic and may imply co-regulation 
making them functionally related [Fiedler et al. 2004; Hannah et al. 2002; van den Eijnden-
Schrauwen et al. 1997]. 
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Another example of the link between angiogenesis and atherogenesis is the elevated numbers 
of vaso-vasorum found in atherosclerotic plaques. Vaso-vasorum derived microvessels do 
not extend to the intima of normal arteries, penetrating only the adventitia and outer media 
[Geiringer 1951]. As the vessel wall thickness increases in the setting of vascular disease, 
proliferation of vaso-vasorum and intimal neo-angiogenesis is observed. In fact, intimal neo-
vascularisation has been reported as being an almost ubiquitous feature of atherosclerotic 
disease, correlating with both histological grade and symptoms [Chen et al. 1999; Fleiner et 
al. 2004]. It is thought that this process is the consequence of hypoxia within the vessel wall. 
As vascular disease progresses, it is perhaps the ensuing increase in hypoxia that is 
responsible for the increase in microvessel density within the atheroma. Indeed plaque 
angiogenesis is associated with more rapidly progressive and unstable vascular disease 
[Moulton 2002]. 
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1.4.7 The Endothelium: A link between angiogenesis, atherogenesis and 
thrombogenesis 
 
The three processes of angiogenesis, atherogenesis and thrombogenesis are intrinsically 
linked together in that they all affect and take place within the endothelium. Even before 
vascular disease is apparent, cardiovascular risk factors are at play in these 
pathophysiological processes. By reducing the bioavailability of NO and through production 
of ROS increasing oxidative stress and reducing flow mediated vasodilatation and increasing 
shear stress, various cardiovascular risk factors potentiate a thrombogenic and atherogenic 
microenvironment. This is exemplified by elevations in TF, platelet activation and 
aggregation, hyperfibrinogenaemia and disordered fibrinolysis. The pro-atherogenic effects 
of cardiovascular risk factors include the promotion of inflammation causing chronic 
endothelial activation and injury, resulting in dysfunction and damage. This is illustrated by 
elevations in VWF, TM and cellular adhesion molecules. As mentioned above, increases in 
oxidative stress resulting from hypoxia, and continued inflammation and endothelial 
activation, stimulates angiogenesis. 
 
As atheromatous changes progress, along with further increases in VWF and reduction in 
FMD, subjects develop a coagulopathy with hyperfibrinogenaemia and further platelet 
irregularities. As patients develop symptomatic disease there is further expression of CAM at 
the endothelial cell surface and further elevations in VWF (which may reflect normal 
replacement of dead endothelial cells or release from platelets as they form a thrombus) [Lip 
et al. 2004]. 
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All of the above processes result in flow irregularities, stenoses and occlusions. Elevated 
VEGF may reflect the development of collaterals to assist blood flow in these circumstances. 
It may also reflect the increased numbers of vaso-vasorum in the arterial media or increased 
vascularity within the atheroma itself.  Indeed plaque neo-angiogenesis may be a crucial 
factor for plaque development and rupture [Celleti et al. 2001], illustrated by the fact than an 
increase in plaque microvessels has been correlated with more severe disease and plaques 
with the greatest risk or rupture or haemorrhage. 
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1.4.8 Summary of Angiogenesis in Peripheral Arterial Disease 
 
A greater understanding of the molecular mechanisms involved in the development and 
progression of PAD and improvements in biochemical techniques has shown that the 
processes of angiogenesis, atherogenesis and thrombogenesis are seemingly related. A new 
vascular triad (the Birmingham ‘Vascular Triad’ [Figure 1.3] [Lip et al. 2004]), with the 
endothelium integral, has been proposed.  
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Figure 1.3: Thrombogenesis, atherogenesis and angiogenesis in vascular disease: the 
Birmingham ‘Vascular Triad’ [Lip et al. 2004] 
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CHAPTER 2 
 
THE PROJECT RATIONALE AND HYPOTHESIS 
 
2.1 Project rationale 
 
Within the UK, the epidemiology of PAD is well documented amongst the white population 
(e.g. Edinburgh Artery Study [Fowkes et al. 1991]) but there is paucity of literature on other 
ethnic groups. This represents a major, clinically important gap in knowledge because there 
is good reason to believe that ethnicity will have an important effect on the prevalence, 
distribution and severity of PAD. 
 
Ethnic minority groups make up 7.9% of the general population of the UK [Gill et al. 2007] 
with Asian/Asian British (3.97%) and Black/Black British (1.96%) being the largest  of these 
groups [National Statistics Online]. Previous population based studies in other countries 
have shown variations in the prevalence of PAD amongst different ethnic groups [Table 1.1]. 
Limited data on PAD in Indians suggest its prevalence is lower in this group than in 
Europeans [Premalatha et al. 2000; UKPDS 1994; Mohan et al. 1995; Chaturvedi et al. 
2007]. Likewise, US studies have found the prevalence of PAD in African Americans to be 
higher on the whole than in white group [Allison et al. 2006; Criqui et al. 2005]. 
 
A greater understanding of the prevalence and severity of PAD amongst Black and minority 
ethnic groups in the UK is required for the planning and delivery of clinically and cost-
effective treatment of this common condition within an ethnically diverse society. In the 
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longer term, accurate epidemiologic data will also help target prevention strategies on those 
at highest risk. 
 
2.2 Primary Aim of Research 
 
To improve the understanding of the epidemiology and pathophysiology of peripheral 
arterial disease in South Asians (i.e. those originating from India, Pakistan and Bangladesh) 
and Blacks (i.e. those originating from the Caribbean and sub-Saharan Africa) living in 
Birmingham, United Kingdom. 
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2.3 Hypotheses 
 
Hypotheses proposed for this thesis are summarised as follows: 
1. Translated versions of the Edinburgh Claudication Questionnaire in the following 
languages: Urdu, Bengali, Hindi, Punjabi and Gujarati will have equivalent 
sensitivity and specificity to that found in the Edinburgh Artery Study [Chapter3.1] 
 
2. There will be a difference in prevalence of PAD (Defined by Ankle Brachial Index 
(ABPI) <0.9) between South Asians and Blacks [Chapter 3.2] 
 
3. Ethnic differences will exist in associations between traditional clinical 
cardiovascular risk factors (Smoking, diabetes mellitus, dyslipidaemia and 
hypertension) and PAD in South Asians and Blacks [Chapter 3.2]  
 
4. Amongst South Asians and Blacks ethnic differences will exist in common carotid 
intima-media thickness, PAD and its association with  
a. traditional cardiovascular risk factors [Chapter 3.3] 
b. circulating markers of inflammation, haemostasis and thrombosis (CRP, IL-6, 
D-dimer, sP-sel, VWF) and CCIMT and PAD [Chapter 3.4] 
 
5. Ethnic differences will exist in plasma expression of angiogenic markers (Ang-1, 
Ang-2, Angiogenin, sTie2) between South Asians, Blacks and Whites [Chapter 4.1] 
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6.  Ethnic differences will also exist in the association of angiogenic markers with 
traditional cardiovascular risk factors and cardiovascular disease [Chapter 4.1] 
 
7. Ang-1, Ang-2, sTie2 and angiogenin levels will be higher in subjects with at least 
one cardiovascular risk factor compared to healthy controls, with a further increase in 
those with clear cardiovascular disease [Chapter 4.1] 
 
 
.
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2.4 Study Designs 
 
2.4.1 Sub-study to Ethnic Echocardiographic Heart of England Screening (E-
ECHOES) Study 
 
2.4.1.1 Aim of sub-study to E-ECHOES 
 
The aim of this study was to establish an estimate of the prevalence of PAD amongst South 
Asian and Black subjects living in Birmingham, UK and make associations between 
traditional cardiovascular risk factors, novel risk factors and this disease. Furthermore the 
aim was to see if there are any ethnic differences in associations between these risk factors 
and PAD, which might explain any difference in disease prevalence. 
 
2.4.1.2 Participant Recruitment 
 
572 subjects participating in the E-ECHOES Study between March 2008 and February 2009 
were recruited into this sub-study. The E-ECHOES [Gill et al. 2009] study is a cross-
sectional population survey of a sample of South Asian (i.e. those originating from India, 
Pakistan or Bangladesh) and Black (i.e. those originating from the Caribbean and sub-
Saharan Africa) residents of Birmingham aged 45 years and over. The majority of the South 
Asian and Black groups in the UK reside in metropolitan areas particularly inner cities such 
as Birmingham [Gill et al. 2007]. Recruitment was undertaken from September 2006 to 
August 2009 from 20 primary care centres. This entailed a two-staged process with an initial 
sample of primary care centres known to have high proportion of these minority ethnic 
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patients and then a sample using the practice age-sex register. As ethnic group collection is 
not routinely collected in primary care, multiple methods were used to identify potential 
subjects. Potential SAs were identified using the Nam Pechan software [Bradford Health 
Authority and City of Bradford Metropolitan District Council] based upon subject name and 
visual inspection by Dr Gill [Cummins et al. 1999]; and for Black subjects practice staff 
were consulted [see Figure 2.1][Gill et al. 2011]. It was important to establish correct ethnic 
classification of subjects prior to screening as any misclassification may have affected 
subsequent analyses. 
 
84 
 
Figure 2.1: Flow of Participants through E-ECHOES study [Gill et al. 2011] 
 
 
 
 
 
 
[Bradford Health Authority and 
City of Bradford Metropolitan 
District Council] 
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The general practitioner then reviewed the lists to ensure that only South Asian and Black 
subjects were included and excluded any whom they considered it inappropriate to approach; 
for example, due to terminal illness or dementia. Potential subjects were mailed an invitation 
letter, a reminder and telephoned up to 3 times inviting them to participate in the study. All 
potentially eligible subjects were asked their ethnic group before booking an appointment. 
 
This study complies with the Declaration of Helsinki and the Walsall Local Research Ethics 
Committee reviewed and approved the protocol (05/Q2708/45). Verbal and written consent 
was obtained from all participants. 
 
The student was not involved in the initial recruitment process for the E-ECHOES Study. 
The student was a member of the data collection team for E-ECHOES between March 2008 
and February 2009. During this time all patients seen by the student had interviewer-led 
questionnaire, anthropometric measurements, blood sampling, ABPI and CCIMT 
measurements performed by the student. 
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2.4.1.3 Sub-study to E-ECHOES Measurements 
 
To maximise recruitment all eligible subjects were invited to attend for an assessment at 
their local primary care centre. Data obtained included an interview-administered 
questionnaire, full physical examination, ECG and echocardiogram. ABPI and CCIMT 
measurements were undertaken by the student. Interpreters were used as required. Self-
reported diagnoses were confirmed with practice medical notes.   
 
The questionnaire included the following data: age; date of birth; address; post code; self-
determined ethnicity; religion; place of birth; migration history; languages spoken; level of 
education; alcohol consumption; cigarette smoking including other tobacco use; exercise 
assessment; history of illness in self and family; current medication; dyspnoea scoring 
leading to New York Heart Association functional classification All these measures are 
based on existing surveys such as the Health Survey for England [Erens et al. 2001] and the 
Fourth National Survey of Ethnic Minorities in Britain [Modood et al. 1997]. Information on 
co-morbidity (myocardial infarction, angina, hypertension, heart failure, stroke, diabetes) 
was obtained.  
 
Subjects were defined as having hypertension if they were previously known to have 
hypertension from medical records, using anti-hypertensive medication, or whose mean of 3 
blood pressure recordings after 5 minutes rest was greater than 140/90. Similarly, subjects 
were defined as having diabetes mellitus if their medical records stated it or if they were 
using anti-diabetic medication. Subjects were defined as being illiterate if they never 
attended school in any country. Former smokers are those who have previously smoked 
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tobacco but stopped >1 year prior to assessment. Smokers who stopped <1 year prior to 
assessment were defined as current smokers. 
 
At physical examination, the following measurements were undertaken using standard 
procedures: Height, weight, body mass index, resting pulse, systolic and diastolic blood 
pressure using an automated sphygmomanometer (OMRON 715IT), and waist measurement. 
The height of the JVP was assessed; the heart auscultated for murmurs and added sounds, 
and the chest examined for signs of congestion and other abnormalities. Hepatomegaly, 
ascites and peripheral oedema were also examined for. A resting 12 lead ECG (Mortara ELI 
150) was recorded. 
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2.4.1.4 Common Carotid Artery Intima Medial Thickness (IMT) Assessment 
 
492 Participants in this sub-study to E-ECHOES had Common Carotid Intima Medial 
Thickness measured using B-mode ultrasound scanning. All measurements were performed 
by the student using semi-automated software with the subject supine, using a portable 
Vivid-i machine (GE Healthcare, Chalfont St Giles, UK). This software has previously been 
validated in the measurement of IMT [Kanters et al. 1997; Gepner et al. 2000; Stein et al. 
2005] and has been shown to be an accurate measure of IMT even with limited training. 
Each carotid was examined in the transverse and longitudinal scan planes. Measurement of 
IMT was made from the longitudinal scan plane in a 1cm segment at the point on the far wall 
of the common carotid artery between 1.5 and 2.5 cm proximal to the bifurcation, with the 
vessel wall parallel to the transducer face. This showed the intima-medial boundaries most 
clearly. IMT was measured at this point because the accuracy of visualisation of the intima-
medial boundaries is greater and IMT tends to be less variable in the common carotid artery 
than it is in more distal segments [Folger et al. 1987; Zierler et al. 1987]. A three lead ECG 
trace was recorded simultaneously with the B-mode images. Three recordings were made in 
the end-diastolic phase for both the mean and maximum CCIMT on both sides of the neck 
with a gated ECG. In 7 of the 492 subjects, the student could only measure CCIMT on one 
side. The mean and maximum CCIMT on the measured side was used in subsequent 
analyses. In the remaining 485 subjects the side with the largest CCIMT value was used in 
subsequent analyses.  
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2.4.1.5 CCIMT reproducibility 
 
Prior to measuring any of the study participants, I underwent training in the measurement of 
CCIMT using the Vivid-i by a consultant medical physicist and also by attending a Vascular 
Ultrasound course (Axiom Ultrasound, Imperial College London). Following a period of 
training, measurements undertaken by me were validated in a study against a consultant 
medical physicist (AL) familiar with CCIMT measurement, by scanning 30 carotids for 
mean and maximum CCIMT blinded to the operator’s results. Bland-Altman Plots [Bland & 
Altman 1995] of CCIMT measurements made by me and the consultant medical physicist 
were analysed. No significant differences were found at a level of 5% between me and the 
medical physicist’s results. The difference between my measurements and the medical 
physicist’s measurements were 1.84% for mean CCIMT and 2.4% for maximum CCIMT, 
which was considered acceptable.  Bland-Altman plots are shown in Figures 2.2 and 2.3. 
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Figure 2.2: Bland-Altman [Bland & Altman 1995] Plot of mean CCIMT between PB 
and AL 
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Bland-Altman Plot of mean CCIMT between PB vs. AL
 
PB: Philip Bennett; AL: Dr Lovick (Consultant medical physicist) 
Grid lines showing 95% confidence interval. This value was determined by 1.96 x 0.02529 
[Standard deviation] = 0.0496  
 
The difference between my measurements and the medical physicist’s measurements were 
1.84% for mean CCIMT. 
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Figure 2.3: Bland-Altman [Bland & Altman 1995] Plot of maximum CCIMT between 
PB and AL 
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PB: Philip Bennett; AL: Dr Lovick (Consultant medical physicist) 
Grid lines showing 95% confidence interval. This value was determined 1.96 x 0.02709  
[Standard deviation]  = 0.053 
 
The difference between my measurements and the medical physicist’s measurements were 
2.4% for maximum CCIMT. 
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2.4.1.6 PAD Assessment 
 
The presence of PAD was assessed by measurement of Ankle Brachial Pressure Index 
(ABPI). This was measured after 5 minutes rest in the supine position with a continuous 
Doppler device (Super Dopplex II, Huntleigh Healthcare), 8 MHz probe and a manual 
sphygmomanometer. Systolic blood pressure in the brachial artery was measured in both 
arms using a blood pressure cuff and Doppler detection in the antecubital fossa. Systolic 
blood pressure was recorded 3 times in each arm. Systolic blood pressure in the left and right 
dorsalis pedis and posterior tibial arteries was then measured in a blood pressure cuff applied 
just proximal to the malleoli. For each pressure measurement, the pulse was located using 
the Doppler probe and the cuff then inflated until the pulse was obliterated. The cuff was 
then deflated slowly and the pressure noted when the pulse detected by the Doppler probe re-
appeared. ABPI was calculated for each leg as the ratio of the higher of the two systolic 
pressures at the ankle and the average of the left and right brachial systolic pressures, unless 
there was a discrepancy ≥10mmHg in blood pressure values between the 2 arms, in which 
case the higher side systolic pressure was used. To standardise the blood pressure 
measurements all recordings were performed by myself, who had previously been trained in 
the measurement of ABPI by a consultant vascular surgeon. 
 
A reduced ABPI in symptomatic patients confirms the existence of haemodynamically 
significant occlusive disease between the heart and ankle, with a lower ABPI indicating a 
greater haemodynamic severity of occlusive disease. ABPI values ≤0.9 in one or both legs 
were considered diagnostic of PAD. The leg with the lowest ABPI was used in subsequent 
analyses. As brachial and ankle systolic blood pressures are intrinsically variable 
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measurements, multiple measurements were taken avoid the risk of misclassification of a 
subject with PAD, based on ABPI <0.9. The absence of PAD was defined as levels from 
0.91 – 1.39 in the absence of re-vascularisation of the lower limbs.  In some patients with 
diabetes, renal insufficiency, or other diseases that cause vascular calcification, the tibial 
vessels at the ankle become non-compressible. This leads to a false elevation of the ankle 
pressure. These patients typically have an ABPI >1.40 and, in some of these patients, the 
Doppler signal at the ankle cannot be obliterated even at cuff pressures of 300 mmHg. ABPI 
values ≥1.4 were therefore excluded from the analysis. 
 
The reproducibility of ABPI varies in the literature but it is significant enough that reporting 
standards require a change in ABPI of 0.15 in an isolated measurement for it to be 
considered clinically relevant, or >0.1 if associated with a change in clinical status [Norgren 
et al. 2007].  
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2.4.1.7 Intermittent Claudication Assessment 
 
Subjects eligible for participation in the validation of the Edinburgh Claudication 
Questionnaire in South Asian languages, or in English, completed this in their chosen 
language either independently or with the aid of an interpreter reading the questionnaire as 
written.   
 
The presence of intermittent claudication (IC) was defined by the criteria of the Edinburgh 
Claudication Questionnaire (ECQ) (Figure 2.4) [Leng et al. 1992]. Translated versions of 
this questionnaire were used in the chosen language of the patient if this was not English: 
Urdu, Punjabi, Hindi Gujurati and Bengali. The translated versions were validated as part of 
this research (Chapter 3.1). PAD was considered asymptomatic when ABPI <0.9 and the 
ECQ showed no IC. It was considered to be symptomatic if the ECQ suggested definite or 
atypical claudication. 
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Figure 2.4: Edinburgh Claudication Questionnaire [Leng et al. 1992] 
 
(1) Do you get a pain or discomfort in your leg(s) when you walk? Yes ⁭ No ⁭ 
If you answered "Yes" to question (1), please answer the following questions. Otherwise you 
need not continue 
(2) Does this pain ever begin when you are standing still or sitting? Yes ⁭ No ⁭ 
(3) Do you get it if you walk uphill or hurry?   Yes ⁭ No ⁭ 
(4) Do you get it if you walk at an ordinary pace on the level? Yes ⁭ No ⁭ 
(5) What happens to it if you stand still?  
a. usually continues for more than 10 minutes   ⁭ 
b. usually disappears in 10 minutes or less   ⁭ 
(6) Where do you get this pain or discomfort?   
Mark the place (s) with an ‘X’ on the diagrams below 
   Front       Back 
                                     
Definition of positive classification requires all of the following responses: "Yes" to (1), 
"No" to (2), "Yes" to (3), grade 1 "No" to (4), grade 2 "Yes" to (4). If these criteria are 
fulfilled, a definite claudicant is one who indicates the pain is in the calf, regardless of 
whether pain is also marked at other sites; a diagnosis of atypical claudication is made if the 
pain is marked in the thigh or buttock, in the absence of any calf pain. Subjects should not be 
considered to have claudication if pain is indicated in the hamstrings, feet, shins, joints or 
appears to radiate in the absence of any pain in the calf. 
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2.4.1.8 Blood sampling 
 
If consent was granted, a random blood sample was obtained by atraumatic venepuncture 
and stored at 4°C for up to 4 hours before transportation to the central laboratory for storage 
at -70°C for batch analysis. Initial analyses include renal function and lipids using routine 
automated methodology using reagents from Roche Diagnostics within a clinical 
Biochemistry laboratory (Lewes, UK). Similarly, HbA1c was measured using semi-
automated HPLC methodology (Menarini, Berkshire, UK). In addition, a full blood count 
was tested.  
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2.4.1.9 Enzyme-Linked Immunosorbant Assay (ELISA) 
 
Blood was stored at 4°C for up to 4 hours before transportation to the central laboratory. It 
was then spun down at 1500 x g; the supernatant was then frozen at -70ºC for future batch 
analysis. Samples were tested for haemostatic cardiovascular risk factors using an 
established automated immunoassay technique using commercially available assays: VWF 
(Dako, Ely, UK), IL-6 (R&D systems reagents, Abingdon, UK), CRP (Biokit, SA, 
Barcelona, Spain), soluble P-selectin (R&D systems, Abingdon, UK). Intra-assay and inter-
assay variances of all assays were <5% and <10% respectively. Lower limits of detection 
were IL-6: 9.375 pg/ml, sP-sel: 125 pg/ml, VWF: 65 iu/dl, CRP: 0.71 mg/l. 
 
I personally assisted with the preparation of the supernatant and also assisted with the 
ELISAs for the haemostatic indices. After a period of training, I plotted all of the results on 
graphs using standard controls to obtain the values used in subsequent analyses. 
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2.4.1.10 Statistical Analysis 
 
Statistical analysis was carried out using Minitab version 15 (State Coll, PA, USA). Data 
were summarised using mean, median, standard deviation and inter-quartile range for 
continuous parameters.  The statistical analysis in this thesis followed standard statistics as a 
whole using univariate and multivariate analysis. These analyses will be addressed in the 
subsequent results chapters. The univariate analyses for differences in continuous variables 
for 2 groups are Student’s t-test and Mann-Whitney U test and Chi-squared test for 
categorical data.  Paired t-test was used to compare the values in either side of the neck and 
either leg. In cases where less than 5 participants were used in analysis Fisher’s exact test 
was used. Spearman rank correlation coefficient was calculated to test the association 
between the CCIMT and a number of risk factors. Moving data forwards from univariate 
analyses into multivariate analyses automatically adjusts for multiple significance testing, 
i.e. a Bonferroni correction. Univariate analyses for 3 groups using ANOVA or Krusskal-
Wallis is effectively a t-test or Mann-Whitney U test with a Bonferroni correction. 
 
In forming models of analyses I’ve referred to a textbook by Altman (1991). In discussing 
the need for multiple significance testing (e.g. Bonferroni correction) in this cross-sectional, 
community based study I have read the papers by Bland & Altman, Rothman, Michels & 
Rosner and Greenland and Robins [Bland & Altman 1995, Rothman 1990, Michels & 
Rosner 1996, Greenland & Robins 1991]. 
 
Rothman stated, “Adjustments for multiple comparisons shields some observed associations 
from more intensive scrutiny by labelling them as chance findings, thereby defeating the 
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purpose of scientists” [Rothman 1990]. The increase in type 2 error accompanying 
adjustments for multiple comparisons dismisses potentially important associations by 
reducing sensitivity [Rothman 1990]. Michels and Robins state, “Cross-sectional studies are 
used to find undiscovered associations” and suggest that all associations could be studied 
and comparisons specified. By doing this further hypotheses will be generated for further 
investigation [Michels & Robins 1996]. They further state, “By adjusting for further 
comparisons and raising the significance level to unreachable heights would make every 
sensible investigation impossible” and conclude with, “The key to the sensible handling of 
data is careful interpretation of observed associations rather than artificial erection of 
barriers” [Michels & Robins 1996]. They use the Framingham study and the National Health 
and Nutrition Examination Survey (NHANES) as examples of large epidemiological studies 
which did not adjust for multiple significance testing as it was not feasible; results of which 
have been well published in peer reviewed journals. Finally, Bland & Altman suggest that 
when the data are not independent, as they are all on the same subjects using variables which 
may not be independent, the Bonferroni method is inappropriate as it will be highly 
conservative and may miss real differences [Bland & Altman 1995]. Following my reading 
of the above papers and consulting with Dr Blann, statistician in the Thrombosis, 
Haemostasis and Vascular Biology Unit in the University of Birmingham Department of 
Clinical Medicine, a p-value <0.05 was deemed to be significant in this thesis. 
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2.4.2 Hospital Based Study 
 
2.4.2.1 Aim of hospital based study 
 
The aim of this study was to investigate the plasma expression of markers of angiogenesis in 
3 ethnic groups (South Asians, Blacks and White Europeans) in healthy volunteers, people 
with cardiovascular risk factors with no overt disease and in people with established 
cardiovascular disease. Furthermore the aim was to see if the plasma expression of 
angiogenic markers differs between these ethnic groups and differs across a spectrum of 
health and disease.  
 
2.4.2.2 Participant Recruitment 
 
Between October 2008 and September 2009 subjects were recruited into this study from 3 
ethnic groups: South Asians (People originating from India, Pakistan and Bangladesh), 
Blacks (People originating from the Caribbean and sub-Saharan Africa) and Whites (White 
Europeans). Eligibility criteria are documented below. 
 
Participants with symptomatic peripheral arterial disease (TIA or PAD) were recruited from 
Sandwell & West Birmingham Hospitals NHS Trust Department of Vascular Surgery. All 
had radiologically confirmed disease and either attended intermittent claudication clinics or 
attended for open surgery for peripheral arterial disease (Femoral-popliteal bypass, femoral-
distal bypass, femoral endarterectomy, aorto-femoral bypass, axillo-femoral bypass, femoral-
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femoral crossover, major limb amputation or carotid endarterectomy). Subjects having 
endovascular procedures were not included. 
 
Risk factor controls were recruited from Sandwell & West Birmingham Hospitals NHS 
Trust Department of Medicine from patients attending cardiology and hypertension clinics. 
These participants had at least one cardiovascular risk factor (Hypertensive, Diabetic, 
Hypercholesterolaemia, Smokers) but not symptomatic PAD, excluded by Ankle Brachial 
Pressure Index (ABPI) >1.  
 
Healthy volunteers were recruited from relatives of patients attending outpatient clinics or 
for elective general surgery at Sandwell & West Birmingham Hospitals NHS Trust and also 
from subjects participating in the E-ECHOES Study (See chapter 2.4.1.2 on page 82). 
Healthy volunteers were screened for cardiovascular risk factors and PAD, by medical 
history, medications history, and brachial blood pressure measurement and by measuring 
ABPI after 5 minutes in the supine position (Same technique mentioned above). Healthy 
volunteers were included if they had ABPI >1 and no cardiovascular risk factors. 
 
Exclusion criteria for all subjects were infectious diseases, rheumatoid arthritis and other 
chronic inflammatory disorders, sepsis, malignancy, haemodynamically significant valvular 
heart disease, atrial fibrillation, renal failure, immunity-modulating drugs and hormone 
replacement therapy, recurrent venous thromboembolism, congestive cardiac failure, 
multiple sclerosis and anaemia. 
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The study was approved by Birmingham East, North & Solihull Local Research Ethnics 
Committee (08H1/20639) and written informed consent was granted from all study 
participants. 
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2.4.2.3 Clinical Assessment 
 
Demographic data and medical history were collected using a standard interviewer-led 
questionnaire. Subjects were defined as having hypertension if they were previously known 
to have hypertension from medical records, using anti-hypertensive medication, or whose 
mean of 3 blood pressure recordings after 5 minutes rest was greater than 140/90. Similarly, 
subjects were defined as having diabetes mellitus if, their medical records stated it or if they 
were using anti-diabetic medication. Former smokers are those who have previously smoked 
tobacco but stopped >1 year prior to assessment. Smokers who stopped <1year prior to 
assessment will be defined as current smokers 
 
All measurements (height, weight, body mass index, systolic and diastolic blood pressure 
and resting pulse) in study participants were undertaken by the student.  
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2.4.2.4 Blood Sampling 
 
All subjects having vascular surgical procedures had venous blood drawn from the 
antecubital fossa within 24 hours prior to surgery by myself. Blood was stored on ice for a 
maximum of 2 hours before being spun down at 1500 x g; the supernatant was then frozen at 
-70ºC for future batch analysis. Samples were tested for angiogenic markers using 
commercially available immunoassays: (R&D systems Europe LTD Duosets): Angiopoietin-
1, Angiopoietin-2, sTie2 receptor, Angiogenin. Intra-assay and inter-assay variances of all 
assays were <5% and <10% respectively.  Lower limits of detection were 3.79ng/ml for 
Ang-1, 0.12ng/ml Ang-2, 0.09ng/ml Angiogenin and 1ng/ml sTie-2. 
 
I personally assisted clinical scientists at Sandwell & West Birmingham NHS Trust in the 
preparation of ELISAs. After a period of training I then plotted all of the results on graphs 
using standard controls to obtain the values used in subsequent analyses. 
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 2.4.2.5 Statistical Analysis 
 
Data were summarised using mean, median, standard deviation (SD) and inter-quartile range 
[IQR] for continuous parameters, as appropriate. Student’s t-test or the Mann-Whitney U test 
was used for differences in continuous variables and Chi-squared test and Fisher’s exact test 
for categorical data. One way ANOVA was used to assess whether there were any 
differences between the 3 ethnic groups as a whole for continuous variables and Kruskal–
Wallis test was used for non-parametric data, with Tukey’s post-hoc analysis performed for 
inter-group differences. Section 2.4.1.10 (page 96) explains the rationale for not adjusting for 
multiple significance testing and as such, a p-value <0.05 was deemed to be significant. 
Statistical analyses were carried out using Minitab version 15 (State Coll, PA, USA). 
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CHAPTER 3: 
 
SUB-STUDY TO ETHNIC ECHOCARDIOGRAPHIC HEART OF ENGLAND 
SCREENING (E-ECHOES) STUDY 
 
3.1 Validation of the Edinburgh Claudication Questionnaire in 1
st
 generation Black 
African-Caribbean and South Asian UK migrants 
 
3.1.1 Abstract 
 
Objectives: To determine the diagnostic accuracy of the Edinburgh Claudication 
Questionnaire (ECQ) in diagnosing intermittent claudication (IC) in 1
st
 generation Black 
African-Caribbean UK migrants. To determine the diagnostic accuracy of translated versions 
of the ECQ in diagnosing IC in 1
st
 generation South Asian UK migrants 
Methods: Subjects were recruited from the Ethnic-Echocardiographic Heart of England 
Screening (E-ECHOES) study; a community based screening survey for heart failure in 
minority ethnic groups. Translated versions of the ECQ were prepared following a 
recognised protocol. All participants attending screening between October 2007 and 
February 2009 were asked to complete the ECQ in the language of their choice (English, 
Punjabi, Bengali, Urdu, Hindi or Gujarati). Subjects answering ‘yes’ to experiencing leg pain 
or discomfort on walking (ECQ question one) were asked to return to have Ankle Brachial 
Pressure Index (ABPI) measured within 2 weeks of initial assessment. For the purposes of 
this study an ABPI<0.9 in either leg was diagnostic for PAD and an ABPI<0.9 in 
combination with ECQ answers suggestive of IC (ECQ positive) was diagnostic for IC. 
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Results: 154 out of 2831 subjects participating in E-ECHOES (5.4%) were eligible to 
participate in this sub-study as they reported leg pain on exertion (‘yes’ to question one of 
the ECQ), for which 74.3% returned for ABPI measurement within 2 weeks of initial 
assessment. Non-returners were younger than subjects returning for ABPI measurement 
(59[9] vs. 65[11] years; p = 0.015). Punjabi, English and Bengali questionnaires identified 
participants with IC, so these versions of the ECQ were assessed in this study. The 
sensitivities (SN), specificities (SP), positive (PPV) and negative (NPV) predictive values 
were calculated for each version of the ECQ. English: SN: 50%; SP: 68%; PPV: 43%; NPV: 
74%. Punjabi: SN: 50%; SP: 87%; PPV: 43%; NPV: 90%. Bengali: SN: 33%; SP: 50%; 
PPV: 13%; NPV: 73%. There were significant differences in diagnostic accuracy between 
the 3 versions (Punjabi: 83.8%; Bengali: 45%; English: 62.2%; p < 0.0001). No significant 
differences were found in sensitivity and specificity between illiterate and literate 
participants in any of the questionnaires and there was no significant difference in sensitivity 
and specificity between those under and over 60 years of age completing the ECQ. 
Conclusions: This chapter’s findings suggest that the ECQ is not as sensitive or specific a 
diagnostic tool for diagnosing IC in 1st generation Black African-Caribbean and South 
Asian UK migrants than in the Edinburgh Artery Study. This reflects the findings of other 
diagnostic questionnaires in these minority ethnic groups. Whether this is due to linguistic 
differences in describing pain or due to a lack of physical activity to bring on symptoms of 
IC or due to a difference in methodology in diagnosing PAD is not known.  
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3.1.2 Introduction 
 
Peripheral arterial disease (PAD) is an important healthcare problem in developed nations 
and is associated with considerable morbidity and mortality. IC is the most common 
symptomatic manifestation of PAD, and typically occurs in up to one third of patients with 
this disease [Norgren et al. 2007].  IC is characterised by pain, aching or cramping in the 
calf, buttock, hip or thigh on ambulation that resolves upon rest. Symptoms arise from an 
inadequate blood supply to the peripheral arteries of the legs that result in anaerobic 
metabolism and build-up of lactic acid within the muscles. Only about a quarter of patients 
with IC will ever significantly deteriorate [Norgren et al. 2007].  
 
Ankle brachial pressure index (ABPI) is the gold standard for the assessment of both 
asymptomatic and symptomatic PAD [Hirsch et al. 2006]. A value of <0.9 is indicative of 
PAD, with sensitivity and specificity of 95% for detecting angiogram positive disease 
[Dormandy et al. 2000; Hummel et al. 1978; Matzke et al. 2003]. Intermittent claudication 
can be diagnosed with the use of a questionnaire along with evidence of PAD. The 
Edinburgh Claudication Questionnaire (ECQ) was first validated by Leng et al. 1992 after 
noting that the previous WHO/Rose questionnaire had low sensitivity [Leng et al. 1992]. 
This patient administered questionnaire was administered to a predominantly European 
population and was found to be 91.3% sensitive and 99.3% specific for IC in comparison to 
a doctor made diagnosis [Leng et al. 1992]. Whilst there is always a potential for spectrum 
bias affecting the performance of a diagnostic text, the ECQ has been found to have 
excellent reliability and reproducibility after repeating the questionnaire at 6 months (Leng et 
al. 1992).  The ECQ has been validated in French and Brazilian Portuguese [Lacroix et al. 
2002; Aboyans et al. 2000; Makdisse et al. 2007] and in English in a community based study 
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in the Netherlands [Bendermacher et al. 2006] though not amongst languages of the Indian 
Sub-continent or amongst Black Caribbeans.  
 
Studies have shown that questionnaires designed to diagnose cardiovascular diseases in 
European populations may not always be applicable in an ethnically diverse population 
[Fischbacher et al. 2001; Sorlie et al. 1996]. In order to meet the healthcare needs of the 
diverse populations which exists in the UK [Gill et al. 2007] it is important to know if any 
differences exist in the reporting of symptoms of disease and also whether current diagnostic 
tools designed in European populations are applicable in the diagnosis of disease in other 
ethnic groups.    
 
The purpose of this study was to determine the diagnostic accuracy of the ECQ to diagnose 
IC, defined by ABPI <0.9 and ECQ answers suggestive of IC, in languages of the Indian 
sub-continent and also in English speaking Black African-Caribbean groups. As such only 
subjects reporting leg pain i.e. symptomatic disease were investigated in this chapter. 
Asymptomatic PAD is investigated elsewhere in this thesis. 
 
3.1.3 Hypothesis to be tested 
 
Translated versions of the Edinburgh Claudication Questionnaire in the following languages: 
Urdu, Bengali, Hindi, Punjabi and Gujarati will have equivalent sensitivity and specificity to 
that found in the Edinburgh Artery Study. 
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3.1.4 Patients & Methods 
 
Translation of Edinburgh Claudication of Questionnaire 
A diagrammatic representation of the translation process for each South Asian language is 
shown in figure 3.1. The original ECQ was formally translated into each of Hindi, Punjabi, 
Gujurati, Urdu and Bengali. For each translation a consortium comprising 3 bilingual 
healthcare professionals and a lay person was used to assess grammatical and semantic 
equivalence. A general consensus was made between these 4 people as to whether 
amendments needed to be made to the original translation. If so, the suggested amendments 
were sent back to the initial independent translator and a new version was produced. Once a 
translation was deemed to be acceptable, it was then independently back-translated into 
English. The back-translated version was then compared to the original English version of 
the ECQ. All translations were found to be grammatically and semantically equivalent. 
Translated versions of the ECQ are shown in Figure 3.2. 
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Figure 3.1: Schematic illustrating Edinburgh Claudication Questionnaire translation 
sequence 
 
Formal Translation of Edinburgh 
Claudication Questionnaire by Applied 
Language Solutions* into Punjabi, Urdu, 
Bengali, Hindi, Gujurati version 1.0 
(Translator 1) 
Translation discussed amongst group of 3 
bilingual healthcare professionals and lay 
persons   
Amendments made and agreed upon by 
aforementioned group 
Amendments sent back to translator 1 and 
version 2.0 produced 
Version 2.0 checked by aforementioned 
group 
Version 2.0 sent to Applied Language 
Solutions* (Translator 2) to be back-
translated into English 
Version 2.0 compared with original ECQ for 
grammatical/ semantic equivalence by 
researcher team 
If acceptable version 2.0 was used in 
validation exercise 
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Figure 3.2: Edinburgh Claudication Questionnaire (ECQ) and Translations (Leng et al. 
1992) 
 3.2.1 Original English Version of ECQ  
(1) Do you get a pain or discomfort in your leg(s) when you walk? Yes ⁭ No ⁭ 
If you answered "Yes" to question (1), please answer the following questions. Otherwise you 
need not continue 
(2) Does this pain ever begin when you are standing still or sitting? Yes ⁭ No ⁭ 
(3) Do you get it if you walk uphill or hurry?    Yes ⁭ No ⁭ 
(4) Do you get it if you walk at an ordinary pace on the level?  Yes ⁭ No ⁭ 
(5) What happens to it if you stand still?  
c. usually continues for more than 10 minutes    ⁭ 
d. usually disappears in 10 minutes or less    ⁭ 
(6) Where do you get this pain or discomfort?   
Mark the place (s) with an ‘X’ on the diagrams below 
   Front       Back 
                                     
Definition of positive classification requires all of the following responses: "Yes" to (1), 
"No" to (2), "Yes" to (3), grade 1 "No" to (4), grade 2 "Yes" to (4). If these criteria are 
fulfilled, a definite claudicant is one who indicates the pain is in the calf, regardless of 
whether pain is also marked at other sites; a diagnosis of atypical claudication is made if the 
pain is marked in the thigh or buttock, in the absence of any calf pain. Subjects should not be 
considered to have claudication if pain is indicated in the hamstrings, feet, shins, joints or 
appears to radiate in the absence of any pain in the calf. 
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3.2.2  ECQ- Bengali Translation 
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3.2.3 ECQ- Gujurati Translation 
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3.2.4 ECQ - Hindi Translation 
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3.2.5 ECQ- Punjabi Translation 
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3.2.6 ECQ- Urdu Translation 
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Study Design &Recruitment 
This was a sub-study of the E-ECHOES UK community survey screening South Asian and 
Black African-Caribbean residents of Birmingham aged 45years or over for heart failure, 
described in detail in Chapter 2.4.1.2 on page 83. 
 
All subjects screened between October 2007 and February 2009 were asked to complete the 
ECQ in their chosen language. Subjects reporting leg pain or discomfort on walking 
(answering ‘yes’ to question one of ECQ) were subsequently invited back for ABPI 
assessment within 2 weeks of their initial assessment. The study was approved by the local 
research and ethics committee and written informed consent was obtained from all patients. 
Figure 3.3 is a diagrammatic representation of the recruitment process. 
 
Questionnaire Validation 
Patients attending for assessment as part of E-ECHOES were asked to complete the ECQ in 
their preferred language, including English (Figure 3.3). All literate patients completed the 
questionnaire independently and illiterate patients were provided with a bilingual interpreter 
if required and the questions were read out to them as written. Participants responding 
negatively to question one of the ECQ (“Do you get a pain or discomfort in your leg(s) when 
you walk?”) in any language were not included in the analysis. 
 
PAD Assessment 
A description of how PAD was assessed is found in section 2.4.1.6 on page 92.  
 
 
119 
 
Results of the Edinburgh Claudication Questionnaire 
The diagnosis of a positive questionnaire was made on the basis of the original guidelines – 
see figure 3.2.  The respondent must have answered yes to question 1, no to question 2, yes 
to question 3, usually disappears in less than 10 minutes to question 5 and in question 6, 
mark the calf, thigh or buttock regions. A negative questionnaire was one that did not have 
this exact combination. Question 4 was only used to define the severity of claudication if 
present.  
 
Definition of Intermittent Claudication 
A positive questionnaire along with an ABPI <0.9 would be diagnostic of intermittent 
claudication for the purpose of this study. 
 
Statistical analysis 
Questionnaire performance was assessed using Minitab 15 (State Coll, PA, USA). The 
sensitivity, specificity, positive predictive value, negative predictive values were calculated. 
Diagnostic accuracy was then calculated by dividing the number of individuals under correct 
classification on the ECQ by the total number of subjects assessed. Data with a continuous 
variation were subjected to the Anderson-Darling test to determine mode of distribution. If 
normally distributed, such data is summarised using mean and standard deviation, and if 
non-normally distributed by median and inter-quartile range. One way ANOVA was used to 
assess whether there were any differences in continuous variables between the 3 groups 
(speakers of English, Punjabi or Bangladeshi). Fisher’s exact test was used in 2x2 tables 
between participants with ABPI <0.9 and participants without for each question of the ECQ 
to determine whether any particular question was responsible for contributing to the 
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differences in overall sensitivity and specificity of the study questionnaires. Significance was 
defined as p<0.05. 
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3.1.5 Results 
 
All subjects (n=2831) screened as part of E-ECHOES between October 2007 and February 
2009 were asked to complete the ECQ in their chosen language. 154 participants (5.4%) 
answering ‘yes’ to question one “Do you get pain or discomfort in your leg(s) when you 
walk?” were invited to attend for a subsequent assessment of ABPI of which, 74.3% of 
eligible participants attended (Figure 3.3). 
 
Figure 3.3: Diagrammatic representation of recruitment process 
 
  
 
Subjects screened by E-ECHOES between October 2007 
and February 2009 (n=2831) All subjects asked to complete 
ECQ in their chosen language 
Subjects returning for ABPI measurement 
(n=113) 
English 
ECQ (n= 37) 
Bengali 
ECQ (n= 20) 
Punjabi 
ECQ (n= 37) 
Urdu ECQ 
(n= 17) 
Hindi  
ECQ (n= 0) 
Gujurati  
ECQ (n= 2) 
Used in Validation Exercise 
Eligible participants (n=154) 
All subjects answering ‘yes’ to question one of ECQ 
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Demographic data for attendees and non-returners is shown in table 3.17. Non-returners 
were significantly younger (59 standard deviation [SD][9] vs. 65[11] years; p=0.015) and 
had significantly more Gujurati speakers (14.3 vs. 1.8%; p=0.003). There were no 
differences in cardiovascular risk factors and illiteracy rate between those participating in 
validation exercise and those not. 
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Table 3.1: Characteristics of subjects eligible for participation in validation study 
 
Variable 
ABPI attendees (n=113) 
(SD) 
Non-returners (n=41) 
(SD) p-value 
Age 65(11) 59 (9) 0.015 
Male (%) 53 52 0.916 
Illiteracy (%) 29.5 31 0.875 
Language    
-Bengali (%) 17.7 10.7 0.371 
-English (%) 32.7 46 0.175 
-Guajarati (%) 1.8 14.3 0.003 
-Punjabi (%) 32.7 25 0.429 
-Urdu (%) 15 3.6 0.088 
mean SBP (mmHg) 138 (25) 135 (16) 0.62 
mean DBP (mmHg) 77 (12) 79 (8) 0.585 
BMI 29 (5) 31 (5) 0.06 
Ever Smoker (%) 56.6 58.6 0.846 
Current Smoker (%) 15.3 31 0.057 
Hypertensive (%) 65.5 69 0.732 
Diabetic (%) 50 34.5 0.145 
CAD (%) 35.5 25 0.301 
CBVD (%) 16.1 13.8 0.762 
    
 
SD: Standard deviation; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: 
body mass index; CAD: coronary artery disease; CBVD: cerebrovascular disease 
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The total number of respondents completing each version of the ECQ is illustrated in figure 
3.3. All participants completing the ECQ in English were 1
st
 generation Black Caribbeans. 
All participants completing the translated versions were 1
st
 generation South Asian migrants. 
Of the 6 languages, only English, Punjabi and Bengali had participants with ABPI <0.9 and 
ECQ suggestive of claudication, so these were used in the questionnaire validation in this 
pilot study.  
 
The mean age of participants in this study was 65 years of whom 53% were males and 
29.5% were illiterate. PAD was evident in 21.2% [95% CI: 14.7-29.7] of subjects whom 
gave a positive response to ECQ question one and subsequently invited back for ABPI 
assessment. Intermittent claudication was present in 8.8% [95% CI: 4.9-15.5] of these 
participants. There was no significant age difference between those with PAD and those 
without. The participant demographics of those completing each version of the ECQ are 
shown in table 3.2.  
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Table 3.2: Demographic details of subjects by language of Edinburgh Claudication 
Questionnaire 
 
Variable 
English* 
(SD) [IQR] 
n=37 
Punjabi 
(SD)[IQR] 
n=37 
Bengali (SD) 
[IQR] 
n=20 
p-value 
 
Age (years) 67 (9) 66 (13) 64 (9) 0.577 
% Male 55.9 41.7 66.7 0.192 
% Illiteracy 0 45.9 50 <0.0001 
Age of leaving school 16 [15-17] 15 [9-17] 11 [8-15] 0.648 
% Higher education 2.7 2.7 5 0.874 
% ABPI <0.9 32.4 16.6 20 0.237 
% IC 16.2 8.1 5.0 0.345 
ABPI 0.95 1.03 0.98 0.155 
Diabetes mellitus (%) 65.4 34.5 58.8 0.062 
Hypertension (%) 73.9 60 70.6 0.532 
Ever Smoker (%) 61.1 40.5 57.9 0.182 
Current Smoker (%) 14.8 20.6 10.5 0.616 
Coronary artery disease 
(%) 37 28.1 52.6 0.216 
Cerebrovascular disease 
(%) 24.1 9.4 11.8 0.251 
Body Mass Index 30.4 (5.5) 28.2 (5.4) 28.2 (4.3) 0.271 
Waist circumference (cm) 92.6 (14.8) 94 (13.9) 97.4 (11.5) 0.488 
 
SD: standard deviation; ABPI: ankle brachial pressure index; IC: intermittent claudication; * 
1
st
 Generation Black Caribbean UK migrants. Data presented as mean (SD) or percentage. 
Illiteracy: people who never attended school in any country 
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Punjabi Questionnaire: 
37 Subjects completed this translated version (Table 3.3). Their mean age was 66 (3) years 
and 41.7% were male. 49.5% were illiterate and required a bilingual translator to read and 
interpret the subjects’ responses (Table 3.2). For subjects attending school, the median age of 
leaving education was 15 [inter-quartile range (IQR) 9-17] years, with only 2.7% attending 
higher education (Table 3.2). The sensitivity of the Punjabi ECQ was 50%, specificity 87%, 
positive predictive value (PPV) 43% and negative predictive value 90% (Table 3.4). The 
diagnostic accuracy of this version was 83.8%. This study attempted to look for differences 
in sensitivity and specificity between illiterate (sensitivity 33.3%; specificity 92.9%) and 
literate (sensitivity 66.6%; specificity 86.7%) subjects. There were no differences in 
diagnostic accuracy between these 2 groups (84.2 vs.83.3%). I also attempted to investigate 
whether age would affect the sensitivity and specificity of the ECQ and found subjects under 
the age of 60 years had higher sensitivity (100 vs. 50%) but lower specificity (83.3 vs.93%) 
than those older than 60 years. However due to very small numbers of true claudicants 
significance was not reached. No differences in diagnostic accuracy between those under or 
over 60 years were reported (<60 years: 84.6%; >60 years: 84.2%).  
 
Bengali Questionnaire: 
20 Subjects completed the Bengali translation (Table 3.3), in which the mean age was 64 (9) 
years and 66.7% were male (Table 3.2). 50% were illiterate, and required a bilingual 
translator to complete the questionnaire, and of those attending school the median age of 
leaving was 11 [IQR 8-15] years (Table 3.2). Only 5% attended higher education. The 
sensitivity and specificity of this translation were 33.3% and 50% respectively and PPV and 
NPV were 11% and 73% respectively (Table 3.4). The diagnostic accuracy of the Bengali 
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ECQ was 45%. None of the illiterate Bengali speakers had ABPI <0.9 and so this study 
could not compare the sensitivity of this questionnaire between those attending school and 
those whom never attended. The specificity between the former and latter was 66.7 and 50% 
respectively but this failed to reach statistical significance. Likewise no Bengali subjects 
below the age of 60 had ABPI<0.9 and no significant difference in sensitivity was found 
with age. Diagnostic accuracy did not differ significantly between the 2 groups (<60years: 
50%; >60 years: 58.3%). 
 
English Questionnaire: 
37 Subjects completed the original English version of the ECQ, all of whom were African 
Caribbean. Their mean age was 67 (9) years and 55.9% were male (Table 3.2). All subjects 
attended school and the median age of leaving school was 16 [IQR 15-17] years (Table 3.2). 
2.7% attended higher education. Sensitivity and specificity were 50 % and 68% respectively 
and PPV and NPV were 43 % and 74% (Table 3.4). The diagnostic accuracy of this version 
was 62.2%. The sensitivity of the ECQ in those under 60 and over 60 years of age were 50 
vs. 55.6% respectively and specificity were 100 vs. 75% respectively but results were not 
significant due to the low number of subjects. The diagnostic accuracy was 66.7% for 
<60years and 56.7% >60 years of age. 
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Table 3.3: 2x2 Tables illustrating the ECQ results and ABPI measurements 
 
 ABPI <0.9 ABPI >0.9 
ECQ positive A B 
ECQ negative C D 
 
ECQ positive + ABPI<0.9 (a) = Intermittent Claudication 
Sensitivity = a / (a+c) 
Specificity = d / (b+d) 
Positive predictive value = a / (a+b) 
Negative predictive value = d / (c+d) 
Diagnostic accuracy = (a+d)/ (a+b+c+d) 
 
3.3.1 English (n=37) 
 ABPI <0.9 ABPI >0.9 
ECQ positive 6 8 
ECQ negative 6 17 
 
 
3.3.2 Punjabi (n=37) 
 ABPI <0.9 ABPI >0.9 
ECQ positive 3 4 
ECQ negative 3 27 
 
 
3.3.3 Bengali (n=20) 
 ABPI <0.9 ABPI >0.9 
ECQ positive 1 8 
ECQ negative 3 8 
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Table 3.4: Sensitivity, Specificity, Positive and Negative predictive values of the 
Edinburgh Claudication Questionnaire 
 
Language 
Sensitivity(%) 
[95% CI] 
Specificity(%) 
[95% CI] 
PPV(%)  
[95% CI] 
NPV(%) 
[95% CI] 
English* 50 [22-78] 68 [50-86] 43 [16-68] 74 [55-91] 
Punjabi 50 [10-90] 87 [75-99] 43 [5-79] 90 [79-100] 
Bangladeshi 33.3 [0-86] 50 [26-75] 13 [0-31] 73 [45-99] 
 
* 1
st
 Generation Black Caribbean UK migrants; PPV: positive predictive value; NPV: 
negative predictive value; CI: confidence interval 
 
  
Overall Cohort: 
There was no difference in age, sex distribution and prevalence of cardiovascular risk factors 
between the English, Punjabi and Bengali ECQ groups. There were also no differences in 
body mass index and waist circumference in these 3 groups. There were significant 
differences in illiteracy between South Asian participants and African Caribbean subjects 
(Table 3.2). However there was no statistically significant difference in the sensitivity and 
specificity of the ECQ between illiterate and literate subjects. Of those attending school no 
statistically significant differences were found in median age of leaving and proportion of 
people attending higher education.  
 
This study investigated the sensitivity and specificity of each of the questions 2 to 6 in the 
ECQ (Table 3.5). In all languages question 3, “Do you get it [Pain] when you walk uphill or 
hurry?” was the most sensitive. The least sensitive question was question 5, pertaining to 
duration of pain. This question was overall the most specific in the diagnosis of intermittent 
claudication. 
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Table 3.5: Sensitivity, Specificity, Positive and Negative predictive values of each 
question of the Edinburgh Claudication Questionnaire 
 
3.5.1: English (n=37) 
 
ECQ Question Sensitivity (%) Specificity (%)  PPV (%)  NPV (%)  
Q2 25 44 8 75 
Q3 100 20 19 100 
Q4 75 44 20 90 
Q5 41.7 48 13 81 
Q6 66.7 20 14 76 
 
3.5.2: Punjabi (n=37) 
ECQ Question Sensitivity (%)  Specificity (%)  PPV (%)  NPV (%)  
Q2 50 45.2 7 91 
Q3 100 32.3 8 100 
Q4 100 32.3 11 100 
Q5 66.7 64.5 14 96 
Q6 83.3 22.6 9 94 
 
3.5.3: Bengali (n=20) 
ECQ Question Sensitivity (%)  Specificity (%)  PPV (%)  NPV (%)  
Q2 75 62.5 10 98 
Q3 100 62.5 5 100 
Q4 75 40 6 97 
Q5 25 50 3 93 
Q6 100 62.5 5 100 
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3.1.6 Discussion 
 
This study has shown that translated versions of the ECQ into South Asian languages and the 
original English version in 1
st
 generation Black Caribbean migrants have lower sensitivity 
and specificity than the original version [Leng et al. 1992] but similar levels reported in other 
populations [Lacroix et al. 2002; Bendermacher et al. 2006]. This study also reports 
significant differences in diagnostic accuracy between the Punjabi, Bengali and English 
versions. This study differs from the study by Leng et al. in that I used ABPI, an objective 
measure of PAD, defined by a value<0.9, rather than a doctor made diagnosis of PAD based 
on history taking alone. 
 
The ECQ was developed and validated as part of the Edinburgh Artery Study [Leng et al. 
1992] with the objective of improving the sensitivity of the WHO/Rose Claudication 
Questionnaire [Rose 1962]. The researchers questioned 300 participants over the age of 55 
with leg pain and reported 91.3% sensitivity and 99.3% specificity of the ECQ at diagnosing 
intermittent claudication. The original ECQ was used in large observational study 
investigating people presenting to their general practitioner with symptoms suggestive of IC, 
in the Netherlands, which reported a much lower sensitivity of 56.2% [Bendermacher et al. 
2006].  Makdisse et al. recently published a Brazilian Portuguese version of the ECQ and 
reported 85% sensitivity and 93% specificity [Makdisse et al. 2007]. Previously Aboyans et 
al. published a French version with 86.5% sensitivity and 95.6% specificity [Aboyans et al. 
2000] which was subsequently repeated by Lacroix et al., who reported a marked difference 
in the questionnaire’s sensitivity at 47% [Lacroix et al. 2002]. 
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Studies have previously shown that questionnaires designed to diagnose cardiovascular 
disease in White European populations may not always be applicable in an ethnically diverse 
population [Fischenbacher et al. 2001; Sorlie et al. 1996; Raczynski et al. 1993]. The 
preliminary findings of this study suggest the ECQ is not a sensitive or specific diagnostic 
tool for IC in Black African-Caribbean and South Asian groups. This reflects the findings of 
other researchers using the Rose Angina questionnaire [Fischenbacher et al. 2001; Sorlie et 
al. 1996]. It is possible that South Asians and African Caribbeans may describe pain 
differently than white European populations, which may account for the apparent differences 
in sensitivity and specificity when compared to Leng et al. [Leng et al. 1992].  Indeed it has 
previously been reported that the Rose Angina questionnaire has a lower sensitivity and 
specificity in South Asians than in white Europeans [Fischenbacher et al. 2001];  site of pain 
and duration of pain being least likely to score a positive response to Rose Angina 
questionnaire in both South Asian men and women. This study found question 5 of the ECQ, 
pertaining to duration of pain to have the least sensitivity of all of the questions in the ECQ 
in all versions, which may partly explain the low sensitivity and specificity found overall. 
People of African descent have also been reported to be less likely to score positively to 
angina using the Rose questionnaire and less likely to seek treatment than white group 
[Raczynski et al. 1993].  
 
This study used an objective measure (ABPI) to diagnose PAD rather than clinical 
assessment only, and its findings of lower sensitivity and specificity, positive and negative 
predictive values of the ECQ when compared to Leng et al. are comparable to other 
population surveys [Lacroix et al. 2002; Bendermacher et al. 2006]. The Edinburgh artery 
study used clinical assessment (i.e. patient history), rather than ABPI, to diagnose PAD and 
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as such there would be an increased chance of matching ECQ results with the presence of 
PAD as both diagnoses would have focussed on history of symptomatic disease. Using an 
objective measure such as ABPI would put patients with ABPI<0.9 but ECQ negative as 
being false positives and patients representing symptoms of IC (ECQ positive) but ABPI>0.9 
would be classed as false negatives, which would lower the sensitivity and specificity and 
overall accuracy of the questionnaire in its current form. 
 
Limitations 
The main limitation of this study was recruitment of participants answering ‘yes’ to question 
one of the ECQ and subsequent re-attendance for ABPI measurement. As such the results 
found in this study lack statistical power and so firm conclusions regarding the sensitivity 
and specificity of the ECQ in the groups studied can’t be made. Previous studies used more 
symptomatic participants in their validation exercises [Makdisse et al. 2007; Bendermacher 
et al. 2006]. However, as the E-ECHOES study [Gill et al. 2009] was based within primary 
care and screened all eligible subjects whether or not they were symptomatic with 
cardiovascular disease; only 5.4% of the 2831 E-ECHOES subjects were eligible to take part 
in this sub-study. It was not possible to measure ABPI on all 2831 subjects and I 
acknowledge I may have missed people with asymptomatic PAD. However, the purpose of 
this study was to validate a diagnostic tool to detect symptomatic PAD, in the form of 
intermittent claudication, rather than detect asymptomatic PAD and so not measuring ABPI 
on the remainder of the 2831 subjects who did not report leg pain on exertion shouldn’t have 
affected its results. The attempt to validate the ECQ in several languages meant the number 
of expected cases of IC in each language questionnaire was going to be low. Of the eligible 
participants, only 74.3% returned for ABPI assessment. This may have resulted in responder 
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bias and may have affected the validity of the ECQ. Potential differences in participant 
characteristics between non-returners and those participating in the validation exercise were 
analysed and suggest that the significantly younger age of the former group may have 
resulted in work-related commitments preventing a return visit for ABPI measurement. 
However, the younger age group might also have had a lower risk of PAD and therefore may 
not have yielded more cases of IC. It is possible the inclusion of illiterate participants may 
have contributed to the low sensitivity, specificity and diagnostic accuracy of the ECQ 
versions. However, this study found no significant differences in these groups. It is also 
possible that the age of participants may have contributed to the diagnostic accuracy of the 
questionnaires. However this study found no significant differences. This study’s findings 
must be interpreted with caution however due to aforementioned sample size limitations. 
 
Another limitation is that ABPI alone was used as a diagnostic tool for PAD, rather than 
confirming the diagnosis with imaging. As such, subjects with arterial calcification may have 
had falsely elevated ABPI, contributing to some of the false negative results, which may 
have masked an underlying diagnosis of claudication.  Other diseases potentially affecting 
our population, such as Takayasu disease, would not have been detected by ABPI alone and 
as such may have also contributed to the false negatives that were found in this study.  
 
Another limitation of this study is that for intermittent claudication to manifest, patients must 
exercise sufficiently to experience pain. Various surveys have reported much lower levels of 
physical activity amongst British South Asians than in the general population, especially 
among women and older people [Hayes et al. 2006, Fischbacher et al. 2004]. There is a lack 
of literature on levels of physical activity amongst Black Caribbean UK migrants [Health 
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Survey for England 2004]. The lack of sufficient physical activity amongst study participants 
to produce symptoms from PAD might explain the high level of false negatives found in this 
study. 
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3.1.7 Conclusion 
 
This study’s findings suggest the original English ECQ is not a sensitive or specific tool in 
the diagnosis of intermittent claudication in UK Black African Caribbean migrants. Punjabi 
and Bengali versions also did not show high sensitivity and specificity when compared to the 
Edinburgh Artery Study. The implications of this are that medical professionals should be 
cautious when applying healthcare questionnaires designed in one population group to other 
groups because of the risk of spectrum bias. The low sensitivity this study reported means 
that subjects with a questionnaire not indicative of IC can’t be ruled out as having IC and the 
low specificity means that subjects with a questionnaire suggestive of IC can’t be ruled in as 
having this condition. The low sensitivity and specificity may thus over of under-represent 
the true extent of IC in the subjects investigated in this study. Furthermore, questionnaires 
that rely upon physical activity to produce symptoms, such as the ECQ, should be avoided in 
populations known to have low levels of physical activity as they are likely to miss the true 
extent of symptomatic disease. Larger studies, involving minority ethnic groups, need to be 
performed before firm conclusions can be made about the utility of the ECQ in non-White 
groups.  
 
The high concordance between cardiovascular risk factors and leg pain reported in this sub-
study should prompt clinicians to perform an objective assessment of PAD, such as ABPI, in 
suspicious patients presenting to primary and secondary care independent of whether they 
fulfil the definition of IC based on the ECQ. Subjects with ABPI <0.9 should undergo 
further investigations to confirm the diagnosis and if appropriate, should be commenced on 
best medical therapy. 
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3.2 The contribution of Cardiovascular Risk Factors to Peripheral Arterial Disease 
in South Asians and Blacks 
 
3.2.1 Abstract 
 
Objectives: To determine whether differences exist in prevalence of peripheral arterial 
disease (PAD) between South Asians (people originating from India, Pakistan and 
Bangladesh) and Blacks (Black Caribbean and Black African), the two largest minority 
ethnic groups in the UK. To determine if associations with cardiovascular risk factors and 
PAD differ between these two ethnic groups. 
Methods: 572 (356 South Asian and 216 Black) subjects ≥45 years took part in this sub-
study to a community screening project, the Ethnic-Echocardiographic Heart of England 
Screening (E-ECHOES) study. All subjects completed an interviewer-led questionnaire, 
anthropometric measurements and blood sampling. Ankle brachial pressure index (ABPI) 
was calculated and PAD was diagnosed by ABPI <0.9. 
Results: The mean age was 62 years overall with no difference between the two ethnic 
groups. The prevalence of PAD was 13.2% [95% confidence interval (CI) 9.7–16.7] in South 
Asians and 10.2% (95% CI 6.2–14.2) in Blacks with no significant difference between the 
two ethnic groups. No statistically significant differences in ABPI were found between 
South Asians and Blacks overall and in men. However, the prevalence of PAD was higher 
(16.3 vs. 6.1%; p = 0.011) and ABPI lower (1.01 (0.12) vs. 1.04 (0.13); p=0.039) in South 
Asian women compared to Black women, which could not be explained by the prevalence of 
traditional cardiovascular risk factors. On multivariate analysis male sex (p=0.008), SBP 
(p=0.017), diabetes (p=0.022) and smoking (p=0.037) were all independent predictors of 
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PAD in South Asians. In Blacks only age (p=0.003) was an independent predictor of PAD, 
while a non-significant trend between smoking (P=0.056) and PAD was found. 
Conclusion: The prevalence of PAD is similar in South Asians and Blacks, and similar to 
levels reported in pre-dominantly White populations. South Asian women appeared to have a 
higher prevalence of PAD than Black women, which is not explained by traditional 
cardiovascular risk factors. Further, greater powered, research is required in order to 
investigate possible socio-demographic or genetic reasons for this finding. 
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3.2.2 Introduction 
 
Peripheral arterial disease (PAD) is an important healthcare problem in developed nations 
and is associated with considerable morbidity and mortality. PAD is the disease process 
resulting from obstruction of large peripheral arteries, exclusive of the coronary and 
intracranial cerebrovascular system, most commonly due to atherosclerosis [Norgren et al. 
2007]. Most typically, it is referred to in relation to the lower limbs.  PAD is an indicator of 
widespread atherosclerosis in other vascular territories, including the cerebral and coronary 
circulations [Norgren et al. 2007] and considerable overlap exists between them [CAPRIE 
steering committee 1996; Pasternak et al. 2004]. 
 
Several population based studies [Fowkes et al. 1991; Meijer et al. 1998; Diehm et al. 2004] 
based on predominantly white populations have found the prevalence of PAD to be between 
6 to 18% over the age of 55. The prevalence rises with age and has been found to be 
approximately 20% in people over 70 years of age [Regensteiner et al. 2002] and up to 60% 
in the over 85 age group [Meijer et al. 1998]. However, little is known about the prevalence 
of PAD in non-White populations. The aim of this study was to estimate the prevalence of 
PAD in the two largest UK minority ethnic groups (South Asians and Blacks) and make 
associations with traditional cardiovascular risk factors. South Asians (People originating 
from India, Pakistan and Bangladesh) and Blacks (Black Caribbean and Black African) 
comprise 75% of minority ethnic groups within the UK [Gill et al. 2007; National Statistics 
Online]. In order to meet the healthcare needs of the diverse population which exists in the 
UK, it is important to know if any differences in disease epidemiology exist between 
different minority ethnic groups. 
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3.2.3 Hypotheses to be tested 
 
There will be a difference in prevalence of PAD (Defined by Ankle Brachial Index (ABPI) 
<0.9) between South Asians and Blacks. 
 
Ethnic differences will exist in associations between traditional cardiovascular risk factors 
(Smoking, diabetes mellitus, dyslipidaemia and hypertension) and PAD in South Asians and 
Blacks. 
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3.2.4 Patients and Methods 
 
Study Design &Recruitment 
Details of the study design and recruitment into the E-ECHOES study and into this sub-
study are described in detail in Chapter 2.4.1.2 on page 82. 
 
Clinical Assessment 
Demographic data and medical history were collected using a standard questionnaire and 
recording form. Data were derived from both the subject and their medical records. All 
clinical assessments were performed at the same visit. Subjects were defined as having 
hypertension if they were previously known to have hypertension from medical records, 
using anti-hypertensive medication, or whose mean of 3 blood pressure recordings after 5 
minutes rest was greater than 140/90. Similarly, subjects were defined as having diabetes 
mellitus if, their medical records stated it or if they were using anti-diabetic medication. 
Subjects were defined as being illiterate if they never attended school in any country. Former 
smokers are those who have previously smoked tobacco but stopped >1 year prior to 
assessment. Smokers who stopped <1year prior to assessment will be defined as current 
smokers. 
 
PAD Assessment 
A description of how PAD was assessed is found in section 2.4.1.6 on page 92.  
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Laboratory Assessment 
If consent was granted, blood was drawn from the antecubital fossa using the Vacutainer 
system. Random blood was analysed for full blood count, urea and electrolytes, liver 
function tests, glucose, HbA1c and total cholesterol and triglycerides.  Consent for blood 
sampling was obtained in 269 out of 572 (47%) of this sub-study to E-ECHOES (143 out of 
356 (40.2%) South Asians and 126 out of 216 (58.3%) Blacks).  
 
Statistical Analysis 
Statistical analysis was undertaken using Minitab version 15 (State Coll, PA, USA). Data 
were summarised using mean, median, standard deviation and inter-quartile range for 
continuous parameters. Student’s t-test and Mann-Whitney U test were used for differences 
in continuous variables and Chi-squared test for categorical data. Spearman rank correlation 
coefficient was calculated to test the association between the ABPI and a number of risk 
factors. Based on previous reports on the dangers of multiple significance testing in cross-
sectional studies described in chapter 2.4.1.10, a Bonferroni correction was not performed 
and a p-value <0.05 was deemed significant. In order to test the hypothesis that ethnic 
differences will exist in associations between traditional cardiovascular risk factors and PAD 
in South Asians and Blacks, these were entered into multivariate analyses along with other 
variables significant on univariate analysis.  
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3.2.5 Results 
 
Between March 2008 and February 2009, 574 subjects (358 South Asians and 216 Blacks) 
were recruited, aged between 45 and 100 years; 2 subjects with ABPI >1.39, were excluded, 
bringing the total analysed to 356 South Asians and 216 Blacks.    The ethnic breakdown of 
the South Asian group was: 40.4% Pakistani, 38.9% Indian, 16.9% Bangladeshi and 2.8% 
East African Asian, which is broadly representative of the distribution of these ethnic groups 
within Birmingham, UK [Neighbourhood statistics].The South Asian group were analysed as 
one group rather than separately as Indian, Pakistani and Bangladeshi in a hope to improve 
the statistical power of any findings.  
 
Table 3.6 shows clinical, demographic and ABPI characteristics of the 2 groups. The South 
Asian group had more first generation migrants, greater illiteracy, higher serum triglycerides 
and HbA1c and lower HDL-Cholesterol and less ever smokers than Blacks. In the whole 
sample, 69 subjects had PAD; 47 were South Asians whilst 22 were Black. 
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Table 3.6: Characteristics of study subjects by Ethnic Group 
 
Variable South Asian 
 n=356 (SD)[IQR] 
Blacks n=216 
(SD) [IQR] 
p-value 
Age (years) 61 (11) 63 (11) 0.108 
Male (%) 58.7  46.8 0.005 
1st generation migrants (%) 98.6 86.1 <0.0001 
Illiteracy (%) 30.1 0 <0.0001 
Body Mass Index 28 (4.9) 29.5 (5.8) 0.001 
Waist circumference (cm) 98.4 (13.1) 97.6 (12.8) 0.452 
Mean SBP (mmHg) 142 (20) 145 (18) 0.085 
Mean DBP (mmHg) 82 (11) 83 (10) 0.43 
Pulse Pressure (mmHg) 60 (16) 62 (17) 0.137 
Resting Pulse rate (bpm) 80 (13) 78 (13). 0.042 
CAD (%) 12.9 6.5 0.01 
CBVD (%) 3.7 4.8 0.5 
Diabetes (%) 30.6 27.3 0.4 
Hypertension (%) 70.8 75.5 0.224 
Never Smoker (%) 71.9 51.9 <0.0001 
Ex-Smoker (%) 16.6 27.3 0.002 
Current Smoker (%) 11.5 20.8 0.003 
Antiplatelet medication usage 
(%) 
34.8 33.8 0.8 
Cholesterol lowering 
medication (%) 
48 42.6 0.2 
Triglycerides (mmol/l) 2.0 [1.3-2.7] 
¥ 
 1.36 [0.7-2.2] 
ҝ
  <0.0001 
LDL-C (mmol/l)  2.3 [1.8-2.9] 
¥
  2.52 [1.8-3.1] 
ҝ
 0.297 
HDL-C (mmol/l)   1.1 [0.8-1.2] 
¥
  1.32 [1.1-1.6] 
ҝ
  <0.0001 
Total Cholesterol (mmol/l)  4.4 [3.8-5.2] 
¥
 4.63 [3.7-5.3]
 ҝ
  0.295 
HbA1c (%) 6.7 (1.3) 
¥
  6.1 [5.7-6.6]
ҝ
  0.0007 
lowest side ABPI 1.02 (0.1) 1.04 (0.1) 0.11 
ABPI <0.9 (%) 13.2 10.2  0.283 
 
SBP: systolic blood pressure; DBP: diastolic blood pressure, PP: pulse pressure; LDL-C: low 
density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: 
glycosylated haemoglobin, ABPI: ankle brachial pressure index; BPM: beats per minute; 
CAD: coronary artery disease; CBVD: cerebrovascular disease; 
¥
: n=143; 
ҝ
: n=126; IQR: 
Inter-quartile range; SD: standard deviation 
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South Asians 
In South Asians, the prevalence of PAD was 13.2% (95% CI: 9.7-16.7) overall, with no 
significant gender difference (16.3% in women (95% CI: 10.1-21.9) and 11% in men (95% 
CI: 6.8-15.2)). Table 3.7 illustrates univariate comparisons of the South Asian subjects by 
sex. Women were older on migration to the UK (23 vs. 22 years; p=0.04) and had a higher 
body mass index (BMI) than men (29.1 vs. 27.2; p<0.0001). The prevalence of illiteracy in 
the language of origin was high in both groups but statistically significantly higher in women 
(40.1% vs. 23%; p=0.001). Men were more likely to be hypertensive (76.1% vs. 63.3%; 
p=0.009), and diabetic (34.9% vs. 25.2%; p=0.05) with worse diabetic control (HbA1c 
6.93% vs. 6.36%; p= 0.007) than women.  Men were also more likely to have ever smoked 
(45.5% vs. 3.4%; p<0.0001) and be current smokers (18.7% vs. 1.4%; p<0.0001).  
 
The higher proportion of men on antiplatelet (43.1% vs. 23.1%; p<0.0001) and cholesterol 
lowering medication (52.6% vs. 41.5%; p=0.038) may reflect the greater prevalence of 
cardiovascular risk factors in this group. 
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Table 3.7: Univariate Comparisons between male and female South Asian subjects 
 
Variable Male  
n=209 (SD) [IQR] 
Female n=147 
(SD) [IQR] 
p-value 
Age (years) 61 (11) 60 (11) 0.495 
Illiteracy (%) 23 40.1 0.001 
Body Mass Index 27.2 29.1 <0.0001 
Waist circumference (cm) 97.9 (12.4) 99.2 (14) 0.374 
Mean SBP (mmHg) 144 (20) 140 (20) 0.106 
Mean DBP (mmHg) 84 (11) 80 (11) 0.005 
Pulse Pressure (mmHg) 60 (16) 60 (16) 0.898 
Resting Pulse rate (bpm) 80 (13) 80 (13) 0.877 
CAD (%) 15.3 9.5 0.109 
CBVD (%) 5.3 3.4 0.404 
Diabetes (%) 34.9 25.2 0.05 
Hypertension (%) 76.1 63.3 0.009 
Ever Smoker (%) 45.5 3.4 <0.0001 
Current Smoker (%) 18.7 1.4 <0.0001 
Antiplatelet medication usage 
(%) 
43.1 23.1 <0.0001 
Cholesterol lowering 
medication (%) 
52.6 41.5 0.038 
Triglycerides (mmol/l) 2.01 [1.28-2.81]
 ¥
 1.93 [1.33-2.62]
ҝ
 0.565 
LDL-C (mmol/l)  2.44 [1.59-2.76]
 ¥
 2.24 [2-3.11]
 ҝ
 0.09 
HDL-C (mmol/l)  0.97 [0.77-1.14]
 ¥
 1.14 [1.03-1.34]
ҝ
 <0.0001 
Total Cholesterol (mmol/l)  4.29 [3.54-4.95]
 ¥
 4.56 [3.96-5.51]
ҝ
 0.072 
HbA1c (%) 6.93 (1.29)
 ¥
 6.36 (1.11)
 ҝ
 0.007 
ABPI 1.03 (0.14) 1.01 (0.12) 0.133 
ABPI <0.9 (%) 11 16.3 0.144 
 
SBP: systolic blood pressure; DBP: diastolic blood pressure, PP: pulse pressure; LDL-C: low 
density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: 
glycosylated haemoglobin, ABPI: ankle brachial pressure index; CAD: coronary artery 
disease; CBVD: cerebrovascular disease; 
¥
: n= 89; 
ҝ
: n=52; IQR: Inter-quartile range; SD: 
standard deviation 
147 
 
Univariate comparisons between PAD and non-PAD groups in South Asian subjects are 
shown in Table 3.8. On univariate analysis, subjects with PAD were older than those 
without, were more likely to be male, had lower ABPI and had higher SBP and PP. 
 
Table 3.8: Univariate comparisons between PAD and non-PAD groups in South Asian 
subjects 
 
Variable  PAD  
n=47 (SD) [IQR] 
Non-PAD  
n=309 (SD) [IQR] 
p-value 
Age (years) 64 (11) 60 (11) 0.039 
Male (%) 70.2 34.6 <0.0001 
lowest side ABPI 0.8 (0.1) 1.06 (0.11) <0.0001 
BMI 28.2 (3.7) 27.9 (5) 0.142 
mean SBP (mmHg) 150 (21) 141 (19.9) 0.005 
Pulse Pressure (mmHg) 69 (18) 58 (16) 0.001 
Hypertensive (%) 74.5 70.2 0.55 
Diabetic (%) 21.3 32.4 0.125 
CAD (%) 8.5 13.2 0.36 
CBVD (%) 4.3 4.9 0.858 
Total Cholesterol (mmol/l) 4.26 [3.2-5.2]
¥
  4.37 [3.8-5.2]
 ҝ
 0.363 
LDL-C (mmol/l) 2.13 [1.4-2.8]
¥
  2.31 [1.8-2.9]
 ҝ
 0.303 
HDL-C (mmol/l) 0.9 [0.7-1.4]
¥
 1.06 [0.9-1.2]
 ҝ
 0.410 
Triglycerides (mmol/l)  2.1 [0.9-3.2]
¥
 1.99 [1.3-2.7]
 ҝ
  0.838 
HbA1c (%) 6.9 [6.2-9.2]
¥
 6.3 [6.0-7.0] 
ҝ
  0.107 
Ever smoker (%) 21.3 29.1 0.265 
Illiteracy (%) 21.3 31.4 0.157 
 
SBP: systolic blood pressure; DBP: diastolic blood pressure, PP: pulse pressure; LDL-C: low 
density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: 
glycosylated haemoglobin, ABPI: ankle brachial pressure index; CAD: coronary artery 
disease; CBVD: cerebrovascular disease; IQR: Inter-quartile range; SD: standard deviation; 
¥
: n=14; 
ҝ
: n=129 
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Table 3.9 illustrates possible predictors of PAD in South Asians on binary logistic 
regression. Using PAD as the response, adjusting for traditional cardiovascular risk factors 
the following variables were entered into multivariate analysis: Age, sex, SBP, diabetes and 
smoking history. Due to the low level of blood sampling, cholesterol (TC, LDL-C or HDL-
C) was not adjusted for or entered into the multivariate model. With the categorical variables 
the OR reflects the log transformed odds of a subject with, for example, diabetes having 
PAD. For continuous variables (SBP and age) the dataset was standardised around the mean 
value and standard deviation. The OR in this circumstance is the log transformed odds of 
having PAD with every unit rise (e.g. every unit rise in mmHg or year of age) in the 
variable.  
 
In the multivariate model in table 3.9 male sex, SBP, diabetes and smoking were all 
independent predictors of PAD in South Asians. 
 
Table 3.9: Possible Predictors of PAD on multivariate analysis in South Asians 
 
Variable Odds Ratio 95% CI p-value 
Male sex 2.81 1.31-6.04 0.008 
SBP 1.02 1.001-1.04 0.017 
Diabetes mellitus 2.14 1.12-4.12 0.022 
Smoking 1.72 1.03-2.87 0.037 
Age 1.02 0.99-1.05 0.115 
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Table 3.10 investigates possible independent predictors of ABPI on linear regression 
analysis. Traditional cardiovascular risk factors were adjusted for. The following variables 
were included in the model: age, sex, SBP, diabetes and smoking. Due to the low level of 
blood sampling, cholesterol (TC, LDL-C or HDL-C) was not adjusted for or entered into the 
model. 
 
Of the variables entered into the multivariate model in table 3.10, SBP, male sex, age and 
smoking were independent predictors of ABPI. 
 
Table 3.10: Possible predicators of ABPI on linear regression in South Asian subjects 
 
Variable p-value 
SBP <0.0001 
Male sex 0.005 
Age 0.03 
Smoking 0.043 
Diabetes mellitus 0.095 
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Blacks 
In Blacks, the prevalence of PAD was 10.2% overall (95%CI: 6.2-14.2) and was statistically 
significantly higher in men (14.9% (95%CI: 8.04-21.7) vs. 6.1% (95%CI: 1.7-10.3); 
p=0.034). Table 3.11 illustrates univariate comparisons between male and female Black 
subjects. 
 
Women had higher BMI than men (31 vs. 27.7; p<0.0001) and a larger waist circumference 
(99.2 vs. 95.8cm; p=0.049). Whilst no difference was found in total cholesterol, LDL-C and 
triglycerides, women had higher HDL-C (p=0.034). Men were more likely to ever had 
smoked (68.3% vs. 30.4%; p<0.0001) and be current smokers (31.7% vs. 11.3%; p<0.0001).  
 
There was no difference in the prevalence of hypertension and diabetes and no difference in 
the proportion of each sex taking antiplatelets and cholesterol lowering medication. All 
Black subjects attended school. 
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Table 3.11: Univariate comparisons between male and female Black Subjects 
 
Variable Male (n=101) 
 (SD) [IQR] 
Female (n=115) 
(SD) [IQR] 
p-value 
Age (years) 64 (11) 62 (11) 0.212 
Illiteracy (%) 0 0 * 
Body Mass Index 31 (6.3) 27.7 (4.6) <0.0001 
Waist circumference (cm) 95.8 (11.7) 99.2 (13.5) 0.049 
Mean SBP (mmHg) 147 (19) 142 (18) 0.086 
Mean DBP (mmHg) 83 (10) 83 (10) 0.743 
Pulse Pressure (mmHg) 64 (17) 60 (17) 0.093 
Resting Pulse rate (bpm) 75 (10) 80 (15) 0.002 
CAD (%) 5.9 7.8 0.587 
CBVD (%) 4 4.3 0.887 
Diabetes (%) 30.7 29 0.748 
Hypertension (%) 79.2 72.2 0.231 
Antiplatelet medication usage (%) 38.6 29.6 0.161 
Ever Smoker (%) 68.3 30.4 <0.0001 
Current Smoker (%) 31.7 11.3 <0.0001 
Cholesterol lowering medication 
(%) 
47.5 38.3 0.170 
Triglycerides (mmol/l) 1.2 [0.92-2.43]
 ¥
 1.43 [0.7-2.05]
 ҝ
 0.784 
LDL-C (mmol/l)  2.22 [1.6-2.94]
 ¥
 2.57 [1.89-3.13]
ҝ
 0.098 
HDL-C (mmol/l)  1.24 [0.87-1.5]
 ¥
 1.37 [1.13-1.69]
ҝ
 0.034 
Total Cholesterol (mmol/l)  4.48 [3.54-5.2]
 ¥
 4.69 [3.86-5.42]
ҝ
 0.107 
HbA1c (%) 6.52 (1.24)
¥
 6.37 (1.59)
 ҝ
 0.529 
lowest side ABPI 1.04 (0.15) 1.04 (0.13) 0.844 
ABPI <0.9 (%) 14.9 6.1 0.034 
 
SBP: systolic blood pressure; DBP: diastolic blood pressure, PP: pulse pressure; LDL-C: low 
density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: 
glycosylated haemoglobin, ABPI: ankle brachial pressure index; CAD: coronary artery 
disease; CBVD: cerebrovascular disease; 
¥
: n=54; 
ҝ
: n=75; *: too small sample size for 
analysis; IQR: Inter-quartile range; SD: standard deviation 
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Table 3.12 illustrates univariate comparisons between PAD and non-PAD groups in Black 
subjects. Subjects with PAD were significantly older and had lower ABPI and lower BMI 
than those without PAD. Subjects with PAD were also more likely to be hypertensive and 
therefore had higher SBP and PP than those without. 
 
Table 3.12: Univariate comparisons between PAD and non-PAD groups in Black 
subjects 
 
Variable  PAD  
(n=22) (SD) [IQR] 
Non-PAD  
(n=194) (SD) [IQR] 
p-value 
Age (years) 71 (12.4) 62 (11) 0.001 
Male (%) 54.5 45.4 0.44 
lowest side ABPI 0.75 (0.1) 1.07 (0.1) <0.0001 
BMI 28.7 (5) 29.6 (5.9) 0.029 
mean SBP (mmHg) 155 (18) 144 (18) 0.012 
Pulse Pressure (mmHg) 75 (20) 60 (16) 0.003 
Hypertensive (%) 95.5 73.2 0.021 
Diabetic (%) 31.8 26.8 0.617 
CAD (%) 4.5 7.2 * 
CBVD (%) 4.5 4.1 * 
Total Cholesterol 
(mmol/L)  
4.68 [3.9-5.4]
¥
  4.6 [3.7-5.3]
 ҝ
  0.769 
LDL-C (mmol/l) 2.73 [2.1-3.4]
¥ 
 2.5 [1.8-3.1]
 ҝ
  0.836 
HDL-C (mmol/l) 1.35 [0.9-1.7]
¥
  1.32 [1.1-1.6]
 ҝ
  0.808 
Triglycerides (mmol/l)  1.4 [0.2-2]
¥
  1.36 [0.9-2.2]
 ҝ
  0.463 
HbA1C (%) 6.24 [5.9-12.8]
¥
  6.1 [5.7-6.6]
 ҝ
  0.594 
Ever smoker (%) 40.9 49 0.391 
 
SBP: systolic blood pressure; DBP: diastolic blood pressure, PP: pulse pressure; LDL-C: low 
density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: 
glycosylated haemoglobin, ABPI: ankle brachial pressure index; CAD: coronary artery 
disease; CBVD: cerebrovascular disease; IQR: Inter-quartile range; SD: standard deviation 
¥: n=10; ҝ: n=116; *: too small sample size for analysis 
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Table 3.13 illustrates possible independent predictors of PAD on binary logistic regression in 
Blacks. As with the South Asian group PAD was used as the response.  Adjusting for 
traditional cardiovascular risk factors the following variables were entered into multivariate 
analysis: Age, sex, SBP, diabetes and smoking history. Due to the low level of blood 
sampling, cholesterol (TC, LDL-C or HDL-C) was not adjusted for or entered into the 
model. Of the variables entered into the multivariate model, Age was the only variable 
independently predictive of PAD. 
 
Table 3.13: Possible Predictors of PAD on multivariate analysis in Blacks 
 
Variable Odds Ratio 95% CI p-value 
Age 1.08 1.03-1.14 0.003 
Smoking 2.05 0.98-4.28 0.056 
Diabetes mellitus 1.78 0.66-4.83 0.254 
SBP 1.01 0.99-1.04 0.287 
Male sex 0.65 0.21 – 2.02 0.457 
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Table 3.14 investigates possible independent predictors of ABPI on linear regression 
analysis. Traditional cardiovascular risk factors were adjusted for. The following variables 
were included in the model: age, sex, SBP, diabetes and smoking. Due to the low level of 
blood sampling, cholesterol (TC, LDL-C or HDL-C) was not adjusted for or entered into the 
model. SBP and smoking were the only variables that remained independent predictors of 
ABPI on linear regression analysis. 
 
Table 3.14: Possible predictors of ABPI in Black subjects on linear regression 
 
Variable p-value 
SBP 0.001 
Smoking 0.031 
Age 0.126 
Male sex 0.249 
Diabetes mellitus 0.709 
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Ethnic comparisons in PAD groups: 
No statistically significant differences were found in the prevalence of PAD (ABPI <0.9) 
between South Asians and Blacks when both sexes were combined (Respectively 13.2 (9.7-
16.7) % vs. 10.2 (6.2-14.2) %; p=0.283). Likewise there was no difference when comparing 
ABPI between the 2 ethnic groups (South Asian 1.04(0.14) vs. Black 1.02(0.13); p=0.110) 
(Figure 3.4). South Asian women had a greater prevalence of PAD (16.3% vs. 6.1%; 
p=0.011) than Black women and lower ABPI (1.01 (0.12) vs. 1.04 (1.13) respectively; 
p=0.039). No statistically significant difference in prevalence of PAD was found between 
South Asian and Black men (11% vs. 14% respectively; p=0.47). No statistically significant 
differences were found in ABPI either (South Asian 1.03 (0.14) vs. Black 1.04 (0.15); 
p=0.638). 
 
Overall Blacks with PAD were older than South Asians with this disease (71 vs. 64 years; 
p=0.028) and had more prevalent hypertension (95.5% vs. 74.9%; p=0.038) and South 
Asians had greater illiteracy (21.3 vs. 0%; p<0.0001). None of the other demographic 
variables were significantly different between the two PAD groups (Tables 3.8 & 3.12). 
 
Amongst the female subjects the only statistically significant differences in prevalence of 
traditional cardiovascular risk factors was in the proportion of current (p=0.001) and ever 
smokers (p<0.0001) for which South Asian women reported a lower prevalence than Black 
women. South Asian women also had lower HDL-C (p=0.003) and higher triglycerides 
(p=0.018) than Blacks women. South Asian women also had much higher levels of illiteracy 
(p<0.0001). 
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Amongst the male subjects, no statistically significant differences were found in prevalence 
of hypertension and diabetes. However Blacks had a higher prevalence of current (p<0.0001) 
and ever (p=0.011) smokers and South Asian men had lower levels of HDL-C (p=0.001).  
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Figure 3.4 illustrates ABPI comparisons by sex and ethnic group. No statistically significant 
differences were found in ABPI between the 4 groups over all. However South Asian 
women have statistically significantly lower ABPI than Black women.  
 
Figure 3.4: ABPI comparisons by sex and ethnic group 
 
Ethnic Group
femalemale
South AsianBlackSouth AsianBlack
1.07
1.06
1.05
1.04
1.03
1.02
1.01
1.00
0.99
A
B
P
I
95% CI for the Mean
 
ABPI Values: a: 1.04 (0.15); b: 1.03 (0.14); c: 1.04 (0.13); d: 1.01 (0.12); p=0.115 on 
ANOVA. Difference between Black females (c) and South Asian females (d) p<0.05 on 
Tukey’s post hoc analysis 
a 
b 
c 
d 
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3.2.6 Discussion 
 
To date there is a paucity of data on PAD amongst minority ethnic groups, in particular 
amongst South Asians. This pilot study shows that the prevalence of PAD is similar amongst 
the South Asian and Black groups and indeed similar to previously published prevalence 
data in other populations [Premalatha et al. 2000, Criqui et al. 2005; UK Prospective 
Diabetes Study Group 1994; Mohan et al. 1995, Chaturvedi et al. 2007; Collins et al. 2005; 
McDermott et al. 2005], which supports the validity of this study. 
 
This study reports findings similar to existing literature in that the rates of ever smokers and 
current smoking is lower in South Asians than in Blacks, overall and in each sex and that 
men are more likely to be smokers than women in both ethnic groups [HSE 2004]. This 
study observed that smoking was an independent predictor of ABPI and of PAD in South 
Asians, which differs from the findings of a previous Indian population study [Premalatha et 
al. 2000]. The data from this study also shows smoking to be an independent predictor of 
ABPI in Blacks but whilst there was a trend towards smoking being a significant predictor of 
PAD (p=0.056) in this group it failed to reach statistical significance, which may be due to 
the low numbers of subjects with PAD in this small cross-sectional study. 
 
The prevalence of diabetes in this study was much higher in South Asians and in Blacks than 
in previous studies [Chaturvedi et al. 1994; Diabetes in the UK 2004].  In diabetic patients, 
the risk of PAD is increased by age, duration of DM and blood glucose control [Selvin et al. 
2006; UK Prospective Diabetes Study Group 1998]. This study found that the OR of having 
PAD in the presence diabetes in South Asians was twofold higher than those with normal 
ABPI, which reflects results found in India [Premalatha et al. 2000]. The lack of an 
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independent association between diabetes and ABPI in South Asians could possibly be due 
to the fact that subjects with diabetes may have falsely elevated ABPI due to vascular 
calcification. Whilst the prevalence of diabetes in this study of predominantly 1
st
 generation 
South Asian migrants was much higher than in those living in India, the mean age of 
participants in this study was also much older, which may partly explain this finding.  
 
Amongst Blacks, this study failed to find statistically significant differences in the 
prevalence of diabetes in subjects with PAD on univariate analysis and no independent 
associations between diabetes and PAD or ABPI on multivariate analyses. This may either 
be because there is no association between these variables in this ethnic group; it might be 
because of falsely elevated ABPI amongst the diabetic subjects or might be due to the small 
numbers of participants in this study. This finding might also be because of the high 
prevalence of co-existent hypertension with diabetes which meant that any possible 
independent associations were lost. Further research is needed to investigate possible reasons 
for the findings of this study. 
 
The most frequent dyslipidaemia associated with PAD are raised triglyceride levels and low 
HDL-cholesterol [Smith et al.2004]. In the literature, South Asians appear to have a less 
favourable lipid profile than other ethnic groups, with lower HDL-Cholesterol and higher 
triglycerides [Chaturvedi et al. 1994; Health Survey for England 1999, Miller et al. 1984; Li 
et al. 2006; Zoratti et al. 1998], which become more pronounced on migration from the 
Indian subcontinent [Bhatnagar et al. 1995; Patel et al. 2006]. On the other hand Blacks have 
a more favourable lipid profile [Miller et al. 1984; Allison et al. 2006; Whincup et al. 2002; 
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Lip et al. 2007]. This study reflects previous reports of the differences in lipid profile 
between ethnic groups.  
 
Several components of blood pressure, including PP, SBP and diastolic blood pressure 
(DBP) have been shown to be independent cardiovascular risk factors. Hypertension is 
known to be a risk factor for both symptomatic and asymptomatic PAD [Murabito et al. 
1997; Dieter et al. 2002]. Hypertension is well known to be more prevalent in Blacks, 
compared to South Asian and White ethnic groups [Agyemang et al. 2003] in the UK. The 
prevalence of hypertension in this study was very high in both ethnic groups. Previous (pre-
dominantly white population based) studies have shown that 35-55% of patients with PAD 
also had hypertension at presentation [Cheng et al. 1999; Vidi et al. 1996; Makin et al. 
2001].  However, US studies have shown that among patients with PAD, the prevalence of 
hypertension was higher in African Americans than in Whites, and lower in Asians [Collins 
et al. 2003; Criqui et al.2005]. This study found Blacks with PAD had a significantly higher 
prevalence of hypertension than South Asians with PAD.  
 
This study found no significant differences in the prevalence of hypertension between the 
PAD and normal ABPI groups in South Asians on univariate analysis but when blood 
pressure was analysed as a continuous variable, both SBP and PP were higher in the PAD 
group. On multivariate analysis, SBP was an independent predictor of both PAD and ABPI 
suggesting this variable might be important for a reduced ABPI and subsequent development 
of PAD. However causal associations cannot be made in this cross-sectional study.  
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 In Blacks a difference was found in the prevalence of hypertension between the PAD and 
normal ABPI groups on univariate analysis. Subjects with PAD also had higher SBP and PP 
than those with normal ABPI. On multivariate analysis while SBP didn’t remain an 
independent predictor of PAD on logistic regression, possibly due to the low number of 
subjects with PAD, when ABPI was analysed as a continuous variable SBP was found to be 
the most statistically significantly associated independent predictor of ABPI on linear 
regression. This suggests that even in the presence of other cardiovascular risk factors, SBP 
could be very important in the development of a reduced ABPI and therefore subsequent 
PAD. However, as with the South Asian group, causal associations cannot be made from this 
cross-sectional study. 
 
Another important finding of this study is that the prevalence of coronary artery disease 
(CAD) and cerebrovascular disease (CBVD) was low in the study subjects. As expected 
South Asians had trend towards more prevalent CAD than Blacks but there was no 
difference in CBVD. The prevalence and presence of co-existent CAD and CBVD with PAD 
was very low and not different to the non-PAD group in both ethnic groups on univariate 
analysis. While PAD has been reported as conferring a greater risk of developing CAD and 
CBVD in predominantly white populations [Golomb et al. 2006; Criqui et al. 1998, 
Dormandy et al. 1999], the findings of this study support data previously reported from India 
[Premalatha et al. 2000].  
 
The prevalence of both asymptomatic and symptomatic PAD in this study is similar to 
previous reports in various populations [Premalatha et al. 2000, Criqui et al. 2005; UK 
Prospective Diabetes Study Group 1994; Mohan et al. 1995; Chaturvedi et al.2007; Collins 
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et al. 2005; McDermott et al.2005; Ramos et al. 2009]. Importantly it found no difference in 
PAD prevalence, or indeed ABPI, between South Asians and Blacks overall. However, 
South Asian women were found to have statistically significantly lower ABPI than Black 
women and a greater prevalence of PAD. Of the traditional cardiovascular risk factors 
investigated in this study, no differences were reported in prevalence of diabetes and 
hypertension and smoking was significantly lower amongst South Asian women than their 
black counterparts. In fact, dyslipidaemia was the only less favourable characteristic in the 
former ethnic group with lower HDL-C and higher triglycerides. The apparent finding of this 
study could be due to a more sedentary lifestyle which exists amongst South Asian women 
when compared to Blacks, although this was not measured as part of the study. It might also 
be due to the higher level of illiteracy in the former group and therefore reduced access to 
healthcare and primary prevention strategies. It might also be due to genetic differences in 
predisposition to PAD. However, due to the low numbers of participants and the cross-
sectional nature of this study it is impossible to make firm conclusions. Further, better 
powered studies investigating possible explanations for this study’s findings are necessary to 
find the answer. 
 
This prevalence of PAD in the South Asian subjects differs from the low rate of PAD 
reported in the only Indian epidemiological study [Premalatha et al. 2000]. However the 
average age of participants in this study was considerably older and reflects the fact that 
PAD is predominantly a disease of the elderly. In both the South Asian and Black groups, 
subjects with PAD were statistically significantly older than those with normal ABPI on 
univariate analyses, with a greater age difference being found amongst the Black subjects. 
Indeed age was negatively correlated with ABPI ( r=  -0.17; p=0.001 and r= -0.157; p=0.021 
163 
 
in Blacks and South Asians respectively). On multivariate analyses age was not an 
independent predictor of PAD but was a statistically significant predictor of ABPI whereas 
in Blacks PAD was the most statistically significant independent predictor of PAD but not of 
ABPI. Clearly age is important in the development of PAD in both ethnic groups; however 
with increasing age comes the prevalence of more comorbidity which might make 
independent associations more difficult to find. 
 
Factors which may play a role in explaining apparent differences in PAD prevalence are 
patient education, access to healthcare and communication issues.  It has been thought that 
the higher prevalence of PAD in African Americans over Whites is due to level of education, 
income and access to healthcare, and once these are accounted for, African Americans are no 
more likely to have PAD than Whites [Collins et al.2005]. In the UK, where healthcare is 
free at the point of access, Black ethnicity has not been found to be associated with higher 
prevalent PAD than Whites.  
 
Disparities in health and healthcare clearly exist among minority ethnic groups in the UK 
[Diabetes in the UK, 2004]. It is estimated that there are over 300,000 people from 4 
established communities within the UK (Indian, Pakistani, Bangladeshi, and Chinese) unable 
to converse adequately with their healthcare professional [Gill et al. 2009]. South Asian 
women in particular maybe more disadvantaged in communicating their problems to health 
professionals. This may partly explain the lower prevalence of PAD reported previously [UK 
PDS 1994; Chaturvedi et al. 2007].   
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Another explanation for the apparent difference in PAD prevalence in South Asian and 
Black women could be the possibility of a genetic pre-disposition to cardiovascular disease 
and indeed to the development of vascular disease in different territories. South Asians living 
in the UK have a higher incidence of and mortality from CAD than Europeans [Balarajan et 
al. 1991; Balarajan et al. 1996; Raleigh et al. 1997] and Blacks have a higher incidence of 
and mortality from CBVD and less CAD [Balarajan et al. 1991; Balarajan et al. 1996; 
Raleigh et al. 1997]. While previous studies have suggested the prevalence of PAD is lower 
in South Asians [Premalatha et al. 2000; UKPDS 1994; Chaturvedi et al. 2007; Mohan et al. 
1995], there are very little epidemiological data on this subject. Further, greater powered, 
research investigating any apparent differences in risk factor prevalence and their 
associations with ABPI and PAD are required before firm conclusions can be made 
regarding whether ethnic differences exist in the prevalence of PAD. 
 
Limitations 
ABPI measurement was used as a surrogate indicator of PAD in this study. A value of<0.9 is 
considered a reliable method for detecting PAD and it has been shown to be 95% sensitive 
and specific for detecting angiogram positive disease [Dormandy et al. 2000; Hummel et al. 
1978; Matzke et al. 2003]. This study was fully intended to be a small pilot study so that 
preliminary data could be obtained in order to plan a much larger epidemiological study in 
the UK. As a consequence, participant numbers were small which may have affected 
associations between ABPI as a continuous variable, PAD and risk factors. Consent for 
blood was low, especially in South Asians, but comparable to those found in national 
surveys [Health Survey for England 1999]. 
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Due to the cross-sectional design of this study causal associations between socio-
demographic variables and PAD could not be reported. One must therefore be cautious when 
interpreting the data. Another limitation of this study is that of responder bias. Whilst all 
eligible South Asian and Black subjects were invited to take part in the E-ECHOES study, 
patients could respond via a free-phone telephone number or return a stamped addressed 
envelope. To minimise response bias especially from non-English speakers, subjects were 
telephoned and a verbal explanation was provided.   Another possible bias may come from 
the fact that ethnic minority participants with co-morbidities, such as hypertension and 
diabetes, may be more likely to attend for screening than their healthier counterparts, which 
may have reflected the high prevalence of these co-morbidities in this study. This may also 
explain the lack of independent associations between traditional cardiovascular risk factors 
ABPI and PAD on multivariate analyses. 
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3.2.7 Conclusion 
 
This study in South Asians and Blacks found equivalent rates of PAD to those previously 
reported in White populations. However the prevalence of PAD in South Asian women was 
higher and the ABPI was lower than in Black women. These findings could not be explained 
by the prevalence of traditional cardiovascular risk factors.  Further, greater powered, studies 
are required to see whether socio-demographic factors or genetic markers play the greater 
role in the development and progression of PAD in different ethnic groups. 
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3.3 Ethnic differences in Common Carotid Intima-Media Thickness, and the 
relationship to Cardiovascular Risk Factors and Peripheral Arterial Disease 
 
3.3.1 Abstract 
 
Objectives: To compare the mean and maximum common carotid intima–media thickness 
(CCIMT) in Blacks (Black Caribbean and Black African) and South Asians (People 
originating from India, Pakistan and Bangladesh) in a population survey and make 
associations with established cardiovascular risk factors and peripheral arterial disease 
(PAD). 
Methods: A subset of 492 (293 South Asians and 199 Blacks) out of 572 participants aged 
≥45 years recruited in a sub-study to the Ethnic-Echocardiographic Heart of England 
Screening (E-ECHOES) epidemiological study had mean and maximum CCIMT measured. 
A questionnaire, anthropometric measurements and Ankle Brachial Pressure Index (ABPI) 
and Intermittent Claudication assessments were made. 
Results: Black participants had greater mean but not maximum CCIMT when compared to 
South Asians overall, in men and in women on univariate analysis (All p<0.05). Black 
ethnicity was an independent predictor of mean and maximum CCIMT after adjusting for 
traditional cardiovascular risk factors on multivariate analysis (Both p<0.05). After adjusting 
for age, ethnicity and traditional cardiovascular risk factors, the presence of PAD remained 
independently predictive of mean (p=0.019) and maximum (p=0.012) CCIMT on 
multivariate analysis. 
Conclusions: Black ethnicity is related to greater mean and maximum CCIMT when 
compared to South Asians after adjusting for traditional cardiovascular risk factors. The 
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presence of PAD independently predicts mean and maximum CCIMT adjusting for ethnicity, 
age and cardiovascular risk factors. 
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3.3.2 Introduction 
 
In the UK, South Asians (people originating from India, Pakistan and Bangladesh) and 
Blacks (Black African and Black Caribbean) have a higher cardiovascular disease burden 
when compared to white Europeans [Cappuccio et al. 2003]. South Asians in particular have 
an excess mortality from coronary artery disease (CAD), stroke and end-stage renal disease 
[Wild et al. 1997; Balarajan et al. 1991] and Blacks a higher mortality from stroke and end-
stage renal disease [Wild et al. 1997; Balarajan et al. 1991] than white Europeans. Often, 
cardiovascular and cerebrovascular events occur in individuals without known pre-existing 
cardiovascular disease [Fowkes et al. 2008]. It is therefore important to accurately identify 
those subjects at highest risk in an apparently healthy population, who might benefit from 
targeted preventative measures [Price et al. 2007].  
 
Non-invasive markers that allow identification of sub-clinical atherosclerosis, include ABPI 
and carotid artery intima-medial thickness (IMT).  An ABPI value <0.9 has long been used 
as a surrogate marker for peripheral arterial disease (PAD) with 95% sensitive and 
specificity for detecting angiogram positive disease [Dormandy et al. 2000; Hummel et al. 
1978; Matzke et al. 2003]. The ABPI, however, is also an indicator of generalised 
atherosclerosis being associated with higher rates of CAD and cerebrovascular disease 
(CBVD) [Newman et al. 1993a], as well as cardiovascular risk factors [Newman et al. 
1993a].  Common Carotid artery IMT (CCIMT) is an index of pre-clinical atherosclerosis 
[D’Agostino et al. 1996]. CCIMT has been associated with conventional cardiovascular risk 
factors, such as smoking, diabetes mellitus and LDL cholesterol [Markus et al. 2001; Mohan 
et al. 2000]. An increase in CCIMT is associated with greater cardiovascular endpoints 
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including stroke, CAD and with both asymptomatic and symptomatic PAD [D’Agostino et 
al. 1996; Pasternak et al. 2004; Allan et al. 1997; McDermott et al.2005]. Both common and 
internal CCIMT have been shown to be much higher in patients with PAD, at least in 
predominantly white European populations [McDermott et al.2005]. 
 
Studies have previously shown some ethnic and racial variations in CCIMT [D’Agostino et 
al. 1996; Markus et al. 2001; McDermott et al. 2005; Zheng et al. 1997; Kuller et al. 1998].  
For example, Blacks have significantly greater CCIMT than Whites, after adjustments for 
cardiovascular risk factors [D’Agostino et al. 1996; Kuller et al. 1998] but no difference or a 
lower internal carotid artery IMT was found in these studies. A study investigating PAD 
found no difference in carotid artery IMT between Indian Asians and Europeans [Chaturvedi 
et al. 2007] in contrast to a previous study [Anand et al. 2000]. Given that South Asians and 
Blacks comprise 75% of minority ethnic groups in the UK [National Statistics Online]. In 
order to meet the healthcare needs of the diverse population which exists in the UK, it is 
important to know if any differences in disease epidemiology exist between different ethnic 
groups. 
 
The aim of this study was to determine whether any differences in CCIMT exist between the 
two largest UK minority ethnic groups (South Asians and Blacks) and to see whether its 
relationships between cardiovascular risk factors and PAD differ. There is currently no 
agreement as to whether mean CCIMT (an average IMT measured over a 1cm segment of 
artery) or maximum CCIMT (the highest focal IMT measurement in a 1cm segment) confers 
the highest cardiovascular risk and so both measurements were taken for analysis.  
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3.3.3 Hypotheses to be tested 
 
Ethnic differences will exist in mean and maximum CCIMT measurements between South 
Asians and Blacks.  
 
Ethnic differences will exist between mean and maximum CCIMT and their associations 
with traditional cardiovascular risk factors and PAD in South Asians and Blacks. 
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3.3.4 Patients and Methods 
 
Study design and recruitment 
Details of the study design and recruitment into the E-ECHOES study and into this sub-
study are described in detail in Chapter 2.4.1 2 on page 82. 
 
Clinical Assessment 
Demographic and medical history was collected using a standard questionnaire and 
recording form. Data were derived from both the patient and their medical records. All 
clinical assessments were performed at the same visit. An in-depth description of the clinical 
assessment that was undertaken is described in Chapter 2.4.1.3 on page 86. 
 
Common Carotid Artery Intima Medial Thickness (CCIMT) Assessment 
CCIMT assessment is described in Chapter 2.4.1.4 on page 88.  
 
PAD Assessment 
A description of how PAD was assessed is found in section 2.4.1.6 on page 92.  
 
Blood Sampling 
If consent was granted, blood was drawn from the antecubital fossa using the Vacutainer 
system. Blood was analysed for full blood count, urea and electrolytes, liver function tests, 
random glucose and random total cholesterol and triglycerides. Consent was obtained for 
blood sampling in 237 out of 492 (48.2%) of the study cohort (117 out of 292 (39.9%) South 
Asians and 117 out of 199 (58.8%) Blacks). 
 
173 
 
Statistical Analysis 
Statistical analysis was carried out using Minitab version 15 (State Coll, PA, USA). Data 
were summarised using mean, median, standard deviation and inter-quartile range for 
continuous parameters. Student’s t-test or the Mann-Whitney U test was used for differences 
in continuous variables and Chi-squared test for categorical data. Paired t-test was used to 
compare the values in either side of the neck. Spearman rank correlation coefficient was 
calculated to test the association between the CCIMT and a number of risk factors. Based on 
previous reports on the dangers of multiple significance testing in cross-sectional studies, a 
Bonferroni correction was not performed and a p-value <0.05 was deemed significant. In 
order to test the hypothesis that ethnic differences will exist in associations between 
traditional cardiovascular risk factors and mean and maximum CCIMT in South Asians and 
Blacks, these were entered into multivariate analyses.  
 
 
 
 
174 
 
3.3.5 Results 
 
Between March 2008 and February 2009, 492 subjects (293 South Asians and 199 Blacks) 
were recruited into this sub-study to the E-ECHOES study. The mean age of South Asians 
was 61(12) years and 60.4% were males compared to 62(12) years and 46.7% males in 
Blacks (p=0.237 and p=0.003 respectively). Of 492 subjects, 7 patients only had CCIMT 
measurements taken from 1 side, which was used in the analysis - for the remainder - the 
highest side was used in the subsequent analysis. Due to the lack of consensus as to whether 
mean or maximum CCIMT is the more important indicator of vascular disease, I investigated 
possible associations between both of these and traditional cardiovascular risk factors, 
vascular disease states (PAD, CAD and IC) and treatment for vascular disease (antiplatelet 
and cholesterol lowering medication).  
 
Table 3.15 shows clinical, demographic and mean and maximum CCIMT characteristics of 
the two groups. The South Asian group included more men, more 1
st
 generation migrants, 
greater levels of illiteracy, higher serum triglycerides and lower HDL-cholesterol compared 
to the Blacks. Black subjects had a higher proportion of current and ever smokers and higher 
body mass index (BMI) than South Asians. 
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Table 3.15: Clinical, demographic and CCIMT characteristics by Ethnic Group 
 
Variable South Asian* 
 n=293 (SD) 
Blacks n=199  
(SD) 
p-value 
Age (years) 61 (12) 62 (12) 0.237 
Male (%) 60.4  46.7 0.003 
1st generation migrants (%) 98.6 84.9 <0.0001 
Illiteracy (%) 27.9 0 <0.0001 
BMI 27.8 (4.64) 29.5 (5.75) 0.001 
Waist circumference (cm) 97.8 (12.6) 97.6 (12.7) 0.839 
SBP (mmHg) 143 (20) 144.5 (18) 0.377 
DBP (mmHg) 82 (11) 83 (10) 0.495 
PP (mmHg) 61 (16) 62 (16) 0.543 
PAD (%) 14.7 10.6 0.182 
CAD (%) 14 7 0.016 
CBVD (%) 3.8 4.5 0.672 
Diabetes (%) 34.8 28.1 0.12 
Hypertension (%) 71.3 73.9 0.537 
Antiplatelet medication usage (%) 36.5 31.7 0.266 
Cholesterol lowering medication (%) 49.1 41.7 0.104 
Never Smoker (%) 71.3 51.8 <0.0001 
Ex-smoker (%) 16.7 26.1 0.011 
Current Smoker (%) 12 22.1 0.003 
Triglycerides (mmol/l) 1.85 [1.3-2.7] 
¥ 
 1.34 [0.8-2.2] 
ҝ
 0.0002 
LDL-C (mmol/l)  2.31 [1.8-2.6] 
¥
 2.53 [1.8-3.1] 
ҝ
 0.339 
HDL-C (mmol/l)  1.11 (0.37) 
¥
 1.37 (0.45) 
ҝ
 <0.0001 
Total Cholesterol (mmol/l)  4.5  (1.1) 
¥
 4.6 (1.1) 
 ҝ 
0.413 
HbA1c (%) 6.7 (1.2) 
ҹ
 6.4 (1.5) 
җ
 0.116 
Mean CCIMT (mm) 0.61 (0.13) 0.64 (0.14) 0.022 
Maximum CCIMT (mm) 0.73 (0.16) 0.75 (0.16) 0.113 
 
 
SD: standard deviation; SBP: systolic blood pressure; DBP: diastolic blood pressure, PP: 
pulse pressure; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein 
cholesterol; HbA1c: glycosylated haemoglobin,; PAD: peripheral arterial disease; CAD: 
coronary artery disease; CBVD: cerebrovascular disease; CCIMT: common carotid intima 
medial thickness; 
¥
: 117; 
ҝ
: n=115; 
ҹ
 : n=120; 
җ
 : n=117 
 
*The ethnic breakdown of the South Asian cohort was 40.4% Pakistani, 38.9% Indian, 
16.9% Bangladeshi and 2.8% East African Asian, which is representative of the distribution 
of these ethnic groups within Birmingham [Population Estimates by Ethnic Group 2007]. 
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South Asians: 
Analysis according to sex is illustrated in table 3.16.  South Asian women had a statistically 
significantly lower prevalence of hypertension (p=0.01), diabetes (p=0.036) and were less 
likely to have ever smoked (p<0.0001) or be current smokers (p<0.0001) than men.  They 
were also less likely to be taking antiplatelets (p=0.001), with a non-statistically significant 
trend towards lower usage of cholesterol lowering medication (p=0.056). South Asian men 
had a statistically significantly lower mean (p=0.001) and maximum (p=0.005) CCIMT than 
South Asian men. 
 
In an attempt to establish which of mean and maximum CCIMT better reflected a greater 
cardiovascular disease burden, overt vascular disease and possible effects of treatment I 
investigated these associations with univariate and multivariate analyses. Associations 
between categorical and continuous variables on univariate analysis are shown in table 3.17 
and 3.18 respectively. Of the traditional cardiovascular risk factors, the presence of 
hypertension was significantly associated with higher mean and maximum CCIMT 
(p<0.0001 for both) and both SBP and PP correlated strongly with both of these (all 
p<0.0001) on univariate analyses. Prevalent diabetes and HbA1c were also associated with 
both mean (p=0.044 and p=0.022 respectively) and maximum (p=0.047 and 0.042 
respectively) CCIMT on univariate analyses as was having ever smoked (p=0.002 (mean) 
and p=0.018(maximum)). 
 
Of the continuous variables studied, SBP and PP (discussed above), age (p<0.0001 for both), 
total cholesterol (p=0.006 (mean) and p=0.012 (maximum)) and LDL-C (p=0.007 (mean) 
and p=0.003 (maximum)) were significantly associated with both mean and maximum 
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CCIMT on univariate analyses. Correlations between continuous variables and mean and 
maximum CCIMT are displayed graphically in figures 3.5-3.10. In this study SBP was 
strongly correlated with PP (r=0.83; p<0.0001). 
  
The presence of co-existent PAD was statistically significantly associated with higher mean 
(p=0.035) and maximum (p=0.003) CCIMT on univariate analyses and the presence of co-
existent CAD was associated with greater mean CCIMT (p=0.043) with a non-significant 
trend for a higher maximum CCIMT (p=0.079). 
 
Patients are usually started on antiplatelet and cholesterol lowering medication when they 
either have overt cardiovascular disease or are at high cardiovascular risk. One would expect 
that subjects taking these medications would therefore have greater mean and maximum 
CCIMT, a marker of pre-clinical atherosclerosis, which was found in this study (All p<0.05). 
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Table 3.16: Characteristics of the South Asian group by sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SD: standard deviation; IQR; inter-quartile range; SBP: systolic blood pressure; DBP: 
diastolic blood pressure, PP: pulse pressure; LDL-C: low density lipoprotein cholesterol; 
HDL-C: high density lipoprotein cholesterol; HbA1c: glycosylated haemoglobin; CAD: 
coronary artery disease; CBVD: cerebrovascular disease; CCIMT: common carotid intima 
medial thickness; Max: maximum. 
¥
: n=76; 
ҝ
: n=79; 
ҹ
: n=41;
Variable South Asian  
Male (SD) [IQR] 
(n= 177)  
South Asian  
Female (SD) [IQR] 
(n=116)  
p-value 
Age (years) 61 (11) 61 (12) 0.56 
BMI 27.2 (4.3) 28.7 (5.00) 0.006 
SBP (mmHg) 144 (19) 141 (21) 0.133 
DBP (mmHg) 84 (11) 80 (11) 0.002 
PP (mmHg)   60 (15) 61 (17) 0.837 
Hypertension (%) 76.8 62.9 0.01 
Never Smoker (%) 54.8 96.6 <0.0001 
Ex-Smoker 
 >1 year (%) 
26.6 1.7 <0.0001 
Current Smoker  18.6 1.7 <0.0001 
Diabetes (%) 39.5 27.6 0.036 
HbA1c 6.9 (1.2)
 ҝ
 6.3 (1.1)
 ҹ
 0.023 
Total Cholesterol 4.5 (1.1)
¥
 4.6 (1.0) 
 ҹ
 0.399 
LDL-C 2.24 [1.7-2.8]
¥
 2.44 [2-3]
 ҹ
 0.145 
HDL-C 1.04 (0.33)
¥
 1.24 (0.39) 
 ҹ
 0.006 
Triglycerides 1.95 [1.3-2.8] 
¥
 1.74 [1.2-2.6]
 ҹ
 0.313 
Cholesterol 
Lowering 
medication (%) 
53.7 42.2 0.056 
Antiplatelet 
medication (%) 
44.1 25 0.001 
CAD (%) 16.9 10.3 0.115 
CBVD (%) 4.5 2.6 0.394 
PAD (%) 12 19 0.093 
mean IMT 0.63 (0.14) 0.58 (0.12) 0.001 
max IMT 0.75 (0.16) 0.7 (0.15) 0.005 
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Table 3.17: Categorical variables associated with mean and maximum CCIMT in South Asians on univariate analysis 
 
Variable   Maximum  
CCIMT(mm) 
(SD) 
 
p- value 
Mean  
CCIMT (mm) 
(SD) 
p-value 
Cardiovascular risk factors  N     
Diabetes Yes 102 0.76 (0.17)  0.63 (0.14)  
 No 191 0.72 (0.15) 0.047 0.6  (0.13) 0.044 
Ever smoker Yes  84 0.77 (0.16)  0.65 (0.14)  
 No 209 0.72 (0.16) 0.018 0.59 (0.13) 0.002 
Hypertension Yes 209 0.76 (0.15)  0.63 (0.13)  
 No 84 0.66 (0.16) <0.0001 0.56 (0.12) <0.0001 
Cardiovascular disease states       
CAD Yes 42 0.77 (0.16)  0.65 (0.13)  
 No 251 0.72 (0.16) 0.079 0.6 (0.13) 0.043 
PAD Yes 43 0.79 (0.19)  0.66 (0.16)  
 No 250 0.72 (0.15) 0.03 0.6 (0.13) 0.035 
Vascular disease treatment       
Use of cholesterol lowering drugs Yes 144 0.75 (0.15)  0.63 (0.13)  
 No 149 0.71 (0.17) 0.023 0.59 (0.13) 0.008 
Use of antiplatelet medication Yes 107 0.76 (0.16)  0.64 (0.14)  
 No 186 0.71 (0.14) 0.014 0.59 (0.13) 0.012 
Values are mean (SD); SD: standard deviation; PAD: peripheral arterial disease; CAD: coronary arterial disease; IC: intermittent claudication 
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Table 3.18 illustrates univariate correlations between continuous variables and mean and 
maximum CCIMT in South Asians. Age, SBP, PP, Total cholesterol, LDL-C, HbA1c all 
correlated with mean and maximum CCIMT. 
 
 
Table 3.18: Correlations between continuous variables and CCIMT in South Asians on 
univariate analysis 
 
 
Variable r-value mean IMT 
p-value 
r-value max IMT 
p-value 
Age 0.39 <0.0001 0.32 <0.0001
 
SBP 0.22 <0.0001 0.21 <0.0001
 
PP 0.26 <0.0001 0.23 <0.0001
 
Total Cholesterol -0.25 0.006 -0.23 0.012 
LDL-C -0.25 0.007 -0.28 0.003 
HDL-C -0.13 0.167 -0.14 0.127 
Triglycerides -0.02 0.814 -0.01 0.924 
HbA1c 0.19 0.042 0.21 0.022 
ABPI -0.10 0.097 -0.11 0.073 
 
 
SBP: systolic blood pressure; PP: pulse pressure; LDL-C: low density lipoprotein 
cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: glycosylated 
haemoglobin; CCIMT: common carotid intima medial thickness; Max: maximum; ABPI: 
ankle brachial pressure index.  
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Table 3.19 illustrates variables entered into a linear regression model as possible 
independent predictors of mean and maximum CCIMT in South Asians. Adjusting for 
traditional cardiovascular risk factors, the following variables were entered into the 
multivariate analysis: Sex, age, SBP, diabetes, smoking. Due to the low level of blood 
sampling, cholesterol (Total, LDL or HDL) and HbA1c were not adjusted for or entered into 
the model. Of the variables entered into multivariate analysis, age and SBP were 
independent predictors of both mean and maximum CCIMT and smoking was an 
independent predictor of mean CCIMT. 
 
Table 3.19: Variables entered into multivariate analysis as possible independent 
predictors of mean and maximum CCIMT in South Asians 
 
Variable Mean CCIMT p-value  Max CCIMT  p-value 
Age <0.0001  <0.0001 
Smoking 0.046  0.288 
SBP 0.048  0.049 
Sex 0.066  0.07 
Diabetes 0.336  0.274 
 
SBP: systolic blood pressure 
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The following figures illustrate significant univariate correlations between continuous 
variables and mean CCIMT in South Asians. 
 
Figure 3.5: Correlation between mean CCIMT vs. age in South Asians 
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r = 0.39; p<0.0001 
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Figure 3.6: Correlation between mean CCIMT vs. mean Systolic Blood Pressure in 
South Asians 
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r = 0.22; p<0.0001 
 
Figure 3.7: Correlation between mean CCIMT vs. Pulse Pressure in South Asians 
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r = 0.26; p<0.0001 
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The following figures illustrate significant correlations between continuous variables and 
maximum CCIMT in South Asians. 
 
Figure 3.8: Correlation between maximum CCIMT vs. Age in South Asians 
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r = 0.32; p<0.0001 
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Figure 3.9: Correlation between maximum CCIMT vs. mean Systolic Blood Pressure in 
South Asians 
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r = 0.21; p<0.0001 
 
Figure 3.10: Correlation between maximum CCIMT vs. Pulse Pressure in South Asians 
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r = 0.23; p<0.0001 
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Figure 3.11: Correlation between SBP and PP in South Asians 
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r = 0.83; p<0.0001 
 
 
 
187 
 
Blacks: 
Analysis according to sex is present in table 3.20.  Black women had statistically 
significantly higher BMI than Black men (p<0.0001) and were less likely to have ever 
smoked (p<0.0001). No differences were found in prevalence of hypertension or diabetes.  
Black women had statistically significantly lower mean (p=0.008) and maximum (p=0.01) 
CCIMT than Black men. 
 
Univariate associations between categorical and continuous variables and mean and 
maximum CCIMT are illustrated in tables 3.21 and 3.22 respectively. Of the traditional 
cardiovascular risk factors, diabetes was statistically significantly associated with mean 
(p=0.004) and maximum (p=0.011) CCIMT and HbA1c was positively correlated with them 
both (p=0.003 and p=0.004 respectively). Whilst hypertension was not associated with 
significantly higher mean and maximum CCIMT per se, SBP (p=0.004 (mean); p=0.003 
(maximum)) and PP (p<0.0001 (mean); p<0.0001 (maximum)) were both statistically 
significantly associated with them on univariate analysis. Smoking was not statistically 
significantly associated with higher CCIMT in Blacks. 
 
Amongst the vascular disease states, PAD was significantly associated with higher mean 
(p=0.022) and maximum (p=0.033) CCIMT. As with the South Asians this study found that 
people taking cholesterol lowering medication (p=0.002 (mean); p=0.003(maximum)) and 
antiplatelets (p=0.001 (mean); p=0.003 (maximum)) had higher CCIMT on univariate 
analysis. 
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Table 3.20: Characteristics of Black subjects by sex 
Variable Black  
Male (SD) 
[IQR] 
(n=93)  
Black  
Female (SD) [IQR] 
(n=106)   
p-value 
Age (years) 63 (11) 61 (11) 0.214 
BMI 27.8 (4.5) 31 (6.3) <0.0001 
SBP (mmHg) 147 (18) 143 (18) 0.092 
DBP (mmHg) 83 (10) 83 (10) 0.709 
PP (mmHg) 64 (15) 60 (16) 0.087 
Hypertension (%) 77.4 70.8 0.286 
Never Smoker (%) 31.2 69.8 <0.0001 
Ex-smoker (%) 35.5 17.9 0.005 
Current Smoker (%) 33.3 12.3 <0.0001 
Diabetes (%) 29 26 0.645 
HbA1c 6.5 (1.3) 
Ә
 6.3 (1.6)
#
 0.351 
Total Cholesterol 4.4 (1.1)
 җ
 4.8 (1.1)
 ^
0.028 
LDL-C 2.2 [1.6-2.9]
 җ
 2.7 [2-3.1]
^
 0.04 
HDL-C 1.24 [0.9-1.5]
 җ
 1.45 (0.45)
^
 0.04 
Triglycerides 1.3 [0.9-2.3]
 җ
 1.43 [0.7-2.0]
^
 0.78 
Cholesterol 
Lowering 
medication (%) 
45.2 38.7 0.355 
Antiplatelet 
medication (%) 
36.6 27.4 0.164 
CAD (%) 5.4 8.5 0.391 
CBVD (%) 4.3 4.7 0.888 
PAD (%) 15.1 6.6 0.053 
mean IMT (mm) 0.67 (0.14) 0.61 (0.13) 0.008 
max IMT (mm) 0.79 (0.17) 0.73 (0.15) 0.01 
 
SD: standard deviation; IQR; inter-quartile range; SBP: systolic blood pressure; DBP: 
diastolic blood pressure, PP: pulse pressure; LDL-C: low density lipoprotein cholesterol; 
HDL-C: high density lipoprotein cholesterol; HbA1c: glycosylated haemoglobin; CAD: 
coronary artery disease; CBVD: cerebrovascular disease; CCIMT: common carotid intima 
medial thickness; Max: maximum. 
¥
: n=76; 
ҝ
: n=79; 
ҹ
: n=41; 
җ
: n=47; 
Ә
 : n=51;
   ^
 : n=68; 
#
 : 
n=66. 
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Table 3.21: Categorical variables and CCIMT in Blacks 
 
Variable   Maximum  
CCIMT(mm)  
(SD) 
 
p-value 
Mean  
CCIMT (mm) 
(SD)  
p-value 
Cardiovascular 
risk factors 
 N     
Diabetes Yes 56 0.81 (0.17)  0.68 (0.15)  
 No 143 0.73 (0.16) 0.004 0.62 (0.13) 0.011 
Ever smoker Yes  96 0.76 (0.18)  0.64 (0.15)  
 No 103 0.75 (0.15) 0.743 0.63 (0.13) 0.542 
Hypertension Yes 147 0.76 (0.17)  0.64 (0.14)  
 No 52 0.73 (0.15) 0.186 0.62 (0.12) 0.187 
Cardiovascular 
disease states 
      
CAD Yes 14 0.85 (0.26)  0.72 (0.21)  
 No 185 0.75 (0.15) 0.172 0.63 (0.13) 0.154 
PAD Yes 21 0.86 (0.2)  0.72 (0.18)  
 No 178 0.74 (0.15) 0.022 0.62 (0.13) 0.033 
       
       
Vascular disease 
treatment 
      
Cholesterol  Yes 83 0.8 (0.18)  0.67 (0.15)  
Lowering No 116 0.72 (0.15) 0.002 0.61 (0.13) 0.003 
Medication       
       
Antiplatelets Yes 63 0.81 (0.17)  0.68 (0.14)  
 No 136 0.73 (0.16) 0.001 0.62 (0.13) 0.003 
       
       
       
       
 
Values are mean (SD); SD: standard deviation; PAD: peripheral arterial disease; CAD: 
coronary arterial disease; IC: intermittent claudication 
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Table 3.22: Correlations between continuous variables and CCIMT in Blacks on 
univariate analysis 
 
Variables r-value mean IMT 
p-value 
r-value max IMT 
p-value 
Age 0.36 <0.001 0.38 <0.0001
 
SBP 0.20 0.004 0.21 0.003
 
PP 0.29 <0.0001 0.30 <0.0001
 
Total Cholesterol -0.02 0.863 -0.002 0.981 
LDL-C -0.06 0.556 -0.06 0.484 
HDL-C -0.01 0.955 -0.05 0.609 
Triglycerides 0.03 0.775 0.09 0.354 
HbA1c 0.27 0.003 0.26 0.004 
ABPI -0.10 0.146 -0.10 0.146 
 
SBP: systolic blood pressure; PP: pulse pressure; LDL-C: low density lipoprotein 
cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: glycosylated 
haemoglobin; CCIMT: common carotid intima medial thickness; Max: maximum; ABPI: 
ankle brachial pressure index.  
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Univariate correlations between variables and mean and maximum CCIMT in Blacks are 
displayed graphically in figures 3.12-3.17. 
 
Figure 3.12: Correlation between mean CCIMT vs. Age in Blacks 
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r = 0.36; p<0.0001 
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Figure 3.13: Correlation between mean CCIMT vs. mean Systolic Blood Pressure in 
Blacks 
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r = 0.20; p = 0.004 
Figure 3.14: Correlation between mean CCIMT vs. Pulse Pressure in Blacks 
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r = 0.29; p<0.0001 
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The following figures illustrate univariate correlations between continuous variables and 
maximum CCIMT in Blacks. 
 
Figure 3.15: Correlation between maximum CCIMT vs. Age in Blacks 
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r = 0.38; p<0.0001 
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Figure 3.16: Correlation between maximum CCIMT vs. mean Systolic Blood Pressure 
in Blacks 
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r = 0.21; p = 0.003 
Figure 3.17: Correlation between maximum CCIMT vs. Pulse Pressure in Blacks 
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r = 0.30; p<0.0001 
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Figure 3.18 illustrates that SBP correlates strongly with PP in Black subjects. 
 
Figure 3.18: Correlation between SBP and PP in Blacks 
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r=0.844; p<0.0001 
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Adjusting for traditional cardiovascular risk factors, the following variables were entered 
into the multivariate analysis: Sex, age, SBP, diabetes, smoking. Due to the low level of 
blood sampling, cholesterol (Total, LDL or HDL) and HbA1c were not adjusted for or 
entered into the model. Results of the multivariate analysis are shown in table 3.23. Only age 
was a statistically significant predictor of mean and maximum CCIMT.  
 
 
Table 3.23:  Variables entered into multivariate analysis as possible independent 
predictors of mean and maximum CCIMT in Blacks 
 
 
Variable Mean CCIMT p-value Maximum CCIMT p-value 
Age <0.0001 <0.0001 
Sex 0.055 0.060 
Diabetes 0.099 0.055 
SBP 0.275 0.264 
Smoking 0.793 0.900 
SBP: systolic blood pressure 
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Comparing South Asians and Blacks: 
On univariate analysis when comparing South Asians and Blacks, mean CCIMT differed 
significantly when compared overall and by sex (Figure 3.19). Black subjects overall had 
higher mean CCIMT (0.64 vs. 0.61mm; p=0.022) than South Asians, as did both the male 
(0.67 vs. 0.63mm; p=0.04) and female (0.61 vs. 0.58mm; p=0.044) subjects. There was no 
difference in maximum CCIMT between the ethnic groups overall, or between the male or 
female groups (Figure 3.20). 
 
In an attempt to see if ethnicity is an independent predictor for mean and maximum CCIMT 
it was entered into a multivariate model, adjusting for traditional cardiovascular risk factors 
and found ethnicity to be a statistically significant independent predictor of both maximum 
(p=0.036) and mean (p=0.02) CCIMT.  
 
Because CCIMT is a marker of pre-clinical atherosclerosis this study wanted to investigate if 
having cardiovascular disease, in the form of PAD was associated with higher mean and 
maximum CCIMT. Univariate comparisons between subjects of each ethnic group with and 
without PAD and mean and maximum CCIMT are illustrated in figure 3.21.  In order to see 
if PAD was a significant predictor of mean and maximum CCIMT independent of ethnicity 
and the presence of cardiovascular risk factors this study entered it into a multivariate model 
adjusting for traditional risk factors and found that PAD was a statistically significant 
independent predictor of both mean (p=0.019) and maximum (p=0.012) CCIMT. When 
adjusting for age, the strongest predictor of CCIMT in both South Asians and Blacks, PAD 
was still a statistically significant independent predictor of mean (p=0.04) and maximum 
(p=0.026) CCIMT. 
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Figure 3.19: Interval Plot illustrating mean CCIMT by sex and ethnicity 
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Figure 3.20: Interval Plot illustrating maximum CCIMT by sex and ethnicity 
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Figure 3.21: Interval Plot illustrating CCIMT (3.22.1: mean; 3.22.2: maximum) in 
South Asians and Blacks with and without PAD (Based upon ABPI<0.9) 
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3.3.6 Discussion 
 
This study reports comparisons between CCIMT, cardiovascular risk factors and PAD in 
predominantly first generation UK South Asian and Black migrants. There is no generalised 
consensus on whether mean or maximum (focal) thickness is of more importance in 
determining cardiovascular risk but I suggest that the mean CCIMT over a 1cm segment may 
better reflect generalised atherosclerosis than CCIMT at a focal point. This is because 
cardiovascular risk factors, acting upon various aspects of Virchow’s triad give rise to a 
hypercoagulable and atherogenic state. Before overt vascular disease manifests endothelial 
dysfunction occurs, which doesn’t usually occur focally, although predominates around 
bifurcations and vascular tributaries. As there is no consensus however this study has made 
associations with both mean and maximum CCIMT. As there is no accepted normal 
reference range for CCIMT, associations were made using this as a continuous variable, 
rather than a dichotomous one.  
 
In answer to the study hypothesis, ethnicity predicted both mean and maximum CCIMT, 
after adjusting for traditional cardiovascular risk factors. Black subjects had statistically 
significantly higher mean but not significantly higher maximum CCIMT than South Asians 
overall and in each sex.  Previous studies that found CCIMT is significantly increased in 
Black populations after controlling for cardiovascular risk factors [D’Agostino et al. 1996; 
Markus et al. 2001; Kuller et al.1998] support the validity of this study’s findings. This study 
also found that mean had significantly higher CCIMT on univariate analysis, which supports 
previous data [Allan et al. 1997] and while there was a trend towards men having higher 
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mean and maximum CCIMT on multivariate analysis this did not retain independence after 
adjusting for traditional cardiovascular risk factors. 
 
CCIMT was associated with traditional risk factors in both ethnic groups although ethnic 
differences appeared to exist in both univariate and multivariate analyses. Amongst South 
Asian participants, hypertension was statistically significantly associated with increased both 
mean and maximum CCIMT on univariate analysis and SBP and PP were positively 
correlated with both mean and maximum CCIMT on univariate analysis, supporting 
previous literature [Zanchetti et al. 2001; Rossi et al. 2000; Pauletto et al. 1999]. As PP is a 
product of SBP and DBP its associations with CCIMT would be expected to be similar to 
SBP. The very strong correlation coefficients between these two measurements in South 
Asians and Blacks reflect this finding. SBP remained an independent predictor of both mean 
and maximum CCIMT in South Asians after adjusting for traditional cardiovascular risk 
factors. 
 
Amongst Black participants, the presence of hypertension was not significantly associated 
with higher CCIMT in Blacks. However, SBP and PP were positively correlated with both 
mean and maximum CCIMT on univariate analysis. SBP did not remain an independent 
predictor of CCIMT after adjusting for traditional cardiovascular risk factors. This finding 
may either be due to the relatively small sample in the black cohort or may be due to the 
presence of co-existent cardiovascular risk factors of diabetes and smoking which would 
make it harder to find any independent effect of SBP after these were adjusted for.  
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Patients with diabetes have previously been found to have increased CCIMT when compared 
to non-diabetic populations [Poredos et al. 1997]. The presence of diabetes was associated 
with statistically significantly higher mean and maximum CCIMT in both South Asian and 
Black subjects on univariate analysis. However, when traditional risk factors were adjusted 
for it was no longer an independent predictor. As mentioned above, the presence of co-
existent risk factors may have contributed to this finding. HbA1c was positively correlated 
with mean and maximum CCIMT in both ethnic groups on univariate analysis. Because of 
the low level of blood sampling in this study, particularly in the South Asian subjects, 
HbA1c was not brought forward into multivariate analyses. However one would expect it not 
to retain independence given that diabetes would have been adjusted for and this marker is 
inherently related to that risk factor. 
 
Lifetime smoking has previously been found to be strongly related to CCIMT [Poredos et al. 
2004]. Amongst the South Asian subjects, smoking resulted in higher mean and maximum 
CCIMT on univariate analysis and even after adjusting for traditional cardiovascular risk 
factors remained a significant independent predictor of mean CCIMT on multivariate 
analysis. Given that smoking leads to an atherogenic microenvironment, one would expect it 
to have a greater impact on mean CCIMT, which reflects an overall picture of atherogenesis 
rather than maximum or focal thickening. No relationship between smoking and CCIMT was 
found in the Black subjects on wither univariate or multivariate analysis, which suggests that 
smoking may have a greater impact on the development of vascular disease in South Asians, 
in spite of the prevalence of smoking being very low in this ethnic group. The findings may 
also reflect that other risk factors are more important in the progression of CCIMT in Blacks 
other than smoking. 
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With regards to dyslipidaemias, LDL-Cholesterol has previously been found to be strongly 
related to CCIMT [Poredos et al. 2004]. Amongst South Asians, total cholesterol and LDL-C 
were significantly correlated with mean and maximum CCIMT on univariate analysis. 
However due to the low levels of blood sampling these were not taken forward into the 
multivariate analysis due to the low level of statistical power. 
 
This study supports previous associations between both asymptomatic and symptomatic 
PAD and CCIMT in other populations [Allan et al. 1997; McDermott et al. 2005]. On 
univariate analysis in both South Asian and Black subjects PAD was associated with higher 
mean and maximum CCIMT. This finding remained apparent on multivariate analysis even 
after adjusting for traditional cardiovascular risk factors, ethnicity and age. Given that PAD 
is in another vascular territory, i.e. the lower limbs, the finding of raised CCIMT in these 
subjects suggests that people with vascular disease in any vascular territory will have a 
greater atherogenic burden overall, which might explain the overlap found between PAD, 
CAD and CBVD [CAPRIE steering committee 1996; Pasternak et al. 2004]. 
 
Patients are usually started on antiplatelet and cholesterol lowering medication when they 
either have overt cardiovascular disease (e.g. CAD, PAD or CBVD) or are at high 
cardiovascular risk (e.g. Diabetics). One would expect that subjects taking these medications 
would therefore have greater mean and maximum CCIMT, If CCIMT is considered to be a 
marker of atherosclerosis and of cardiovascular risk [Baldessarre et al. 2007]. The finding of 
subjects on antiplatelets and cholesterol lowering medication having higher mean and 
maximum CCIMT on univariate analysis in both ethnic groups supports this. 
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Limitations 
A number of different methods have been used to measure CCIMT.  A semi-automated 
analysis system was used in this study to determine the mean and maximum CCIMT over a 
1cm segment of the common carotid artery, whose central point is 2cm from the carotid 
bifurcation. This site was chosen as the intima-medial boundaries are better defined than in 
other segments [Folger et al. 1987; Zierler et al. 1987]. There is currently no standardisation 
in equipment and protocol for the measurement and recording of CCIMT. As such, caution 
must be taken when attempting to draw comparisons between results of different studies  
 
Due to the cross-sectional design of this study, causal associations between socio-
demographic variables and CCIMT could not be reported.   Another limitation of this study 
is that of responder bias. Whilst all eligible South Asian and Black subjects were invited to 
participate in the E-ECHOES study, patients could respond via a free-phone telephone 
number or return a stamped addressed envelope. To minimise responder bias, especially 
from non-English speakers, subjects were telephoned and a verbal explanation was provided. 
Another possible bias was that consent for blood was low, especially amongst South Asian 
participants, which may have affected the strength of associations we found with CCIMT. 
However, the rate of blood sampling in this study was comparable to other national surveys 
[HSE 1999]. 
 
Another limitation of this community based study was that South Asian and Black 
participants were not matched on gender or on whether they were 1
st
 or 2
nd
 generation 
migrants. Whilst CCIMT comparisons were made by gender, differences in prevalence of 
risk factors and their associations with CCIMT may have been affected by differences in 
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gender proportions in each ethnic group. Subjects were invited to participate in this study 
based on their ethnicity. The significant difference in 1
st
 generation migrants between the 
South Asian and Black groups may have had effects on the prevalence of cardiovascular risk 
factors and their associations with CCIMT. 
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3.3.7 Conclusion 
 
In this study, Black ethnicity is related to greater mean and maximum CCIMT compared to 
south Asians, even after adjusting for traditional cardiovascular risk factors.  There appear to 
be ethnic differences in the associations between CCIMT and traditional cardiovascular risk 
factors. The presence of PAD independently predicts mean and maximum CCIMT after 
adjusting for ethnicity, age and traditional cardiovascular risk factors. 
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3.4 Haemostatic Cardiovascular Risk Factors, Common Carotid Intima-Medial 
Thickness and Peripheral Arterial Disease in South Asians and Blacks 
 
3.4.1 Abstract 
 
Objectives: To determine whether ethnic differences exist in inflammatory (interleukin-6 
and C-reactive protein) and hemostatic biomarkers (platelets, soluble P-selectin [sP-sel], von 
Willebrand factor [VWF], and fibrin D-dimer) between South Asian (people originating 
from India, Pakistan, and Bangladesh) and Black (Black Caribbean and Black African) 
groups, the two largest minority ethnic groups in the UK. To determine associations between 
these biomarkers and common carotid intima–media thickness (CCIMT) and peripheral 
arterial disease (PAD).  
Methods: 572 subjects (356 South Asian and 216 Black) aged ≥ 45 years were recruited as a 
sub-study to a community screening project, the Ethnic-Echocardiographic Heart of England 
Screening (E-ECHOES) study. All subjects completed an interviewer-led questionnaire, 
anthropometric measurements were taken, and blood sampling was performed if consent was 
granted. ABPI was calculated, and the CCIMT was measured. PAD was defined as ABPI < 
0.9. ELISA was used to quantify inflammatory and hemostatic biomarkers.  
Results: The incidence of hypertension (>70%) and diabetes (>27%) was high, but non-
significantly different between the two ethnic groups. South Asians had higher platelet count 
and sP-sel levels than Blacks (p<0.0001 for both) on univariate analysis, despite there being 
no significant difference in antiplatelet medication. Blacks had higher D-dimer levels 
(p=0.0052) on univariate analysis. Among South Asians, VWF correlated with ABPI 
(p=0.047) and mean (p=0.002) and maximum CCIMT (p=0.011) on univariate analysis, and 
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remained an independent predictor of mean and maximum CCIMT on multivariate analysis 
with traditional cardiovascular risk factors (p=0.034 and p=0.046, respectively). In Blacks, 
D-dimer levels were higher in PAD than in normal ABPI participants (p=0.04), and was 
associated with ABPI in both univariate analysis (p=0.014) and multivariate analysis 
(p<0.0001) with traditional cardiovascular risk factors.  
Conclusion: Ethnic differences are evident in inflammatory and hemostatic factors, as well 
as in their associations with CCIMT and PAD. These may reflect differences in 
cardiovascular risk factors or pathophysiologic processes that characterize each ethnic group. 
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3.4.2 Introduction 
 
Peripheral arterial disease (PAD) is an important global healthcare problem associated with 
considerable morbidity and mortality [Norgren et al. 2007]. This disease is an important 
manifestation of atherosclerosis and the pathophysiological processes involved in its 
development, progression and complications are endothelial dysfunction/damage leading to 
atherothrombosis and thromboembolism.  
 
Given improvements in biochemical techniques, there has been an increased interest in the 
prognostic value of biomarkers in the development of PAD and its symptomatic 
complications. For example Von Willebrand Factor (VWF), an established index of 
endothelial dysfunction/ damage has been shown to be elevated in PAD [Seigneur et al. 
1995; Lee et al. 1995; Cassar et al. 2003; Cassar et al 2005]. Platelet activation is a crucial 
component of thrombogenesis and may be quantified by measurement of soluble P-selectin 
(sP-sel). sP-sel has been associated with prevalent PAD [Ridker et al. 2001] and platelet 
concentration and sP-sel have been reported to independently predict severity of PAD [Tan 
et al. 2005].  
 
Another biomarker, fibrin D-dimer, is a fibrin degradation product that marks on-going 
fibrin turnover and reflects a hypercoagulable state [Matsuo et al. 2000]. D-dimer correlates 
with both symptomatic and asymptomatic PAD and also with disease severity [Lee et al. 
1995, Tzoulaki et al. 2007] and functional impairment [McDermott et al. 2003]. 
Inflammation also plays a major role in all stages of atherosclerotic vascular disease, and 
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Interleukin-6 (IL-6) and CRP are associated with PAD development, progression and its 
severity [Ridker et al. 2001; Tzoulaki et al. 2007; Aboyans et al. 2006; Tzoulaki et al. 2005]. 
 
Abnormalities in markers of thrombogenesis (novel risk factors) appear to be related to, or 
even additive to, traditional cardiovascular risk factors [Ridker et al. 1997; Khalegi et al. 
2009] in the initiation and acceleration of atherogenesis. There is also evidence of the 
prognostic value for these biomarkers of thrombogenesis, which suggests that they are not 
merely consequences of atherothrombotic diseases, such as PAD, but may actively 
contribute to the pathogenesis of vascular disease and its complications [Lip & Blann 2004].  
Even after adjusting for traditional risk factors some biomarkers still remain significantly 
associated with PAD [Khawaja et al. 2007; Allison et al. 2006]. However, despite ethnic 
differences having been documented in PAD prevalence groups [Table 1.1] [Premalatha et 
al. 2000, Criqui et al.2005; UK Prospective Diabetes Study Group 1994; Mohan et al. 1995; 
Chaturvedi et al.2007; Collins et al. 2005; McDermott et al.2005], much of the research on 
PAD pathophysiology has been carried out on predominantly White European populations, 
and limited research has been directed on these biomarkers in relation to the ethnic 
susceptibility to PAD [Allison et al. 2006].  
 
The aim of this study was to investigate whether markers of endothelium damage/ 
dysfunction (VWF), thrombogenesis (Platelets, sP-sel, D-dimer) and inflammation (IL-6, 
CRP) are associated with common carotid intima media thickness (CCIMT) and PAD in 
South Asians (that are, people originating from India, Pakistan and Bangladesh) and Blacks 
(Black Caribbean and Black African) as these are the most prevalent minority ethnic groups 
in the UK.  
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3.4.3 Hypothesis to be tested 
 
There will be ethnic differences in associations between circulating markers of 
inflammation, haemostasis and thrombosis (CRP, IL-6, D-dimer, sP-sel, VWF) and CCIMT 
and PAD in South Asians and Blacks. 
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3.4.4 Patients & Methods 
 
Study Design &Recruitment 
Details of the study design and recruitment into the E-ECHOES study and into this sub-
study are described in detail in Chapter 2.4.1.2 on page 82. 
 
Clinical Assessment 
The clinical assessment performed in described in detail in chapter 2.4.1.3 on page 86. 
 
Common Carotid Artery Intima Medial Thickness (CCIMT) Assessment 
CCIMT assessment is described in chapter 2.4.1.4 on page 88.  
 
PAD Assessment 
A description of how PAD was assessed is found in chapter 2.4.1.6 on page 92.  
 
Laboratory 
Venous blood was taken atraumatically from the antecubital fossa by the student for routine 
laboratory tests, including full blood count, Urea & electrolytes and D-dimer, as well as for 
research indices. Blood was stored on ice for a maximum of 2 hours before being spun down 
at 1500 x g; the supernatant was then frozen at -70ºC for future batch analysis. Samples were 
tested for novel risk factors using commercially available ELISA kits: VWF (Dako, Ely, 
UK), IL-6 (R&D systems reagents, Abingdon, UK), CRP (Biokit, SA, Barcelona, Spain), sP-
sel (R&D systems, Abingdon, UK). D-dimer was measured with a Cobas Integra 400 plus 
auto-analyser (Roche Diagnostics, UK). Intra-assay and inter-assay variances of all assays 
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were <5% and <10% respectively. Lower limits of detection were IL-6: 9.375 pg/ml, sP-sel: 
0.125 ng/ml, VWF: 25 iu/dl, CRP: 0.71 mg/l. Consent for blood sampling was obtained in 
269 out of 572 (47%) of this sub-study to E-ECHOES (143 out of 356 (40.2%) South Asians 
and 126 out of 216 (58.3%) Blacks).  
 
 
Power calculation 
For correlations between haemostatic risk factors and CCIMT and ABPI a power calculation 
was set to detect a correlation coefficient of r>0.25, for alpha p<0.05 and 1-ß >0.8. This 
required 123 subjects to minimise the risks of type 1 and type 2 errors. In the analysis of 
ethnic differences on haemostatic risk factor expression [Table 3.25] a sample size of 250 
brings the alpha p<0.05 and 1-ß p >0.8 to determine a real difference of 0.22 of a standard 
deviation. In the analysis of impact of gender on expression of haemostatic risk factors 
[Tables 3.26.1 & 3.26.2] a sample size of 100 for each gender brings the alpha p<0.05 and 1-
ß p>0.8 to determine a real difference of 0.35 of a standard deviation.  
 
Statistical Analysis 
Statistical analysis was undertaken using Minitab version 15 (State Coll, PA, USA). Data 
were summarised using mean, median, standard deviation and inter-quartile range for 
continuous parameters. Student’s t-test and Mann-Whitney U test were used for differences 
in continuous variables and Chi-squared test for categorical data. Spearman rank correlation 
coefficient was calculated to test the association between the ABPI and a number of risk 
factors. Based on previous reports on the dangers of multiple significance testing in cross-
sectional studies (described in chapter 2.4.1.10 on page 98), a Bonferroni correction was not 
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performed and a p-value <0.05 was deemed significant. In an attempt to see is any of the 
research indices in this study were independently predictive of CCIMT and ABPI, they were 
all entered into multivariate analyses adjusting for traditional cardiovascular risk factors. 
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3.4.5 Results 
 
Between March 2008 and February 2009, 574 subjects (358 South Asians and 216 Blacks) 
were recruited, aged between 45 and 100 years; 2 subjects with ABPI >1.39 were excluded, 
bringing the total analysed to 356 South Asians and 216 Black subjects [Table 3.24]. In both 
groups the incidence of diabetes and hypertension was high but equivalent [Table 3.24]. 
Mean SBP was also high in both South Asians (142 (20) mmHg) and Blacks (145 (18) 
mmHg). South Asians had a greater proportion of men, (p=0.005), 1
st
 generation migrants 
(p<0.0001), higher illiteracy (p<0.0001), higher triglycerides (p<0.0001) and HbA1c 
(p=0.0007) [Table 3.24] and lower BMI (p=0.001) than Blacks. South Asians also had a 
greater proportion of never smokers than Blacks (p<0.0001). 
 
The ethnic breakdown of the South Asian group was: 40.4% Pakistani, 38.9% Indian, 16.9% 
Bangladeshi and 2.8% East African Asian, broadly representative of the distribution of these 
ethnic groups within Birmingham [National Statistics Online]. The South Asian group was 
analysed as one heterogeneous group in order to improve the statistical power of any 
findings. 
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Table 3.24: Clinical and Demographic characteristics of South Asian and Black 
subjects 
 
Variable 
South Asian 
 (n=356) (SD) [IQR]   
Black 
(n=216) (SD) [IQR] p-value 
    
Demographic Details    
Age (years) 61 (11) 63 (11) 0.108 
Male (%) 58.7  46.8 0.005 
1st generation migrants (%) 98.6 86.1 <0.0001 
Illiteracy (%) 30.1 0 <0.0001 
BMI 28 (4.9) 29.5 (5.8) 0.001 
Waist circumference (cm) 98.4 (13.1) 97.6 (12.8) 0.452 
SBP (mmHg) 142 (20) 145 (18) 0.085 
DBP (mmHg) 82 (11) 83 (10) 0.43 
PP (mmHg) 60 (16) 62 (17) 0.137 
Resting Pulse rate (bpm) 80 (13) 78 (13) 0.042 
    
Cardiovascular Risk Factors    
Diabetes (%) 30.6 27.3 0.4 
Hypertension (%) 70.8 75.5 0.224 
Never Smoker (%) 71.3 51.8 <0.0001 
Ex-smoker (%) 16.7 26.1 0.011 
Current Smoker (%) 12 22.1 0.003 
    
Vascular disease states    
CAD (%) 12.9 6.5 0.01 
CBVD (%) 3.7 4.8 0.5 
PAD (%) 13.2 10.2  0.283 
    
    
Vascular measurements    
Lowest side ABPI 1.02 (0.1) 1.04 (0.1) 0.11 
Mean CCIMT (mm) 0.61 (0.13)
€
 0.64 (0.14)
Ý
 0.022 
Maximum CCIMT (mm) 0.73 (0.16)
€
 0.75 (0.16) 
Ý
 0.113 
    
Vascular disease treatment    
Antiplatelet usage (%) 34.8 33.8 0.8 
Cholesterol lowering medication 
(%) 48 42.6 0.2 
    
    
Laboratory measurements    
Triglycerides (mmol/l) 2.0 [1.3-2.7] 
¥ 
 1.36 [0.7-2.2] 
ҝ
  <0.0001 
LDL-C (mmol/l)  2.3 [1.8-2.9] 
¥
  2.52 [1.8-3.1] 
ҝ
 0.297 
HDL-C (mmol/l)   1.1 [0.8-1.2] 
¥
  1.32 [1.1-1.6] 
ҝ
  <0.0001 
Total Cholesterol (mmol/l)  4.4 [3.8-5.2] 
¥
 4.63 [3.7-5.3]
 ҝ
  0.295 
HbA1c (%) 6.7 (1.3) 
¥
  6.1 [5.7-6.6]
ҝ
  0.0007 
217 
 
Research Indices    
sP-sel (ng/ml) 32.9 [26.2 - 41.6]
β 
25.6 [20.4 - 32.9]
α 
<0.0001 
Platelets (x10
3
cell/µl) 282.5 (74)
β
 251.7 (74)
α 
<0.0001 
D-dimer (µg/ml) 0.26 [0.15 - 0.49]
β 
0.36 [0.19 - 0.69]
α 
<0.0052 
VWF (iu/dl) 75.3 (13.7)
β 
78.2 (17)
α 
0.132 
CRP (mg/l) 1.95 [0.76 - 5.03]
β 
1.71 [0.55 - 3.92]
α 
0.179 
IL-6 (pg/ml) 42.5 [16.3-230.4]
β 
47.4 [19.4-207.4]
α 
0.635 
    
 
Data are mean (SD) or median [IQR]. IQR: Inter-quartile range; SD: standard deviation.  
¥
: 
n=143; 
ҝ
: n=126; 
€
: n= 293; 
Ý
: n= 199; 
β
: n=134; 
α
: n=129.  SBP: systolic blood pressure; 
DBP: diastolic blood pressure, PP: pulse pressure; LDL-C: low density lipoprotein 
cholesterol; HDL-C: high density lipoprotein cholesterol; HbA1c: glycosylated 
haemoglobin, ABPI: ankle brachial pressure index; CAD: coronary artery disease; CBVD: 
cerebrovascular disease; PAD: peripheral arterial disease; IC: intermittent claudication; sP-
sel: soluble P-selectin; VWF: Von Willebrand factor; CRP: C-reactive protein; IL-6: 
interleukin-6. 
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Ethnic differences in indices of haemostasis and inflammation 
Overall South Asians had statistically significantly higher platelets (p<0.0001) and sP-sel 
(p<0.0001) despite no differences in antiplatelet usage and Blacks appeared to have 
statistically significantly higher levels of D-dimer (p=0.0052) [Table 3.24]. Amongst 
women, South Asians had statistically significantly higher sP-sel (p=0.0015) and platelets 
(p=0.03) and a lower D-dimer (p=0.0172) and VWF (p=0.017) than Blacks [Table 3.25]. 
The findings in men supported those found in the female subjects in that South Asians had 
statistically significantly higher sP-sel (p=0.0001) and platelets (p=0.046) than Black 
subjects. South Asian men also had statistically significantly higher CRP (p=0.0382) than 
Blacks [Table 3.25].  No differences were found in IL-6 between the ethnic groups overall or 
by sex. 
 
When comparing the markers of haemostasis and inflammation between subjects with and 
without PAD this study found no statistically significant differences and so associations 
were investigated using ABPI as a continuous variable. 
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Table 3.25: Ethnic differences in expression of indices of Haemostasis and 
Inflammation by sex 
 
 
 
3.25.1: Male subjects: 
 
Variable 
South Asian (n=84) 
(SD) [IQR] 
Black (n=54) (SD) 
[IQR] p-value 
sP-sel (ng/ml) 33.8 [28.4- 42.1] 26.9 [21.2- 35.2] 0.0001 
Platelets (x10
3
cell/µl) 272.4 (68.8) 251.7 (74.1) 0.046 
D-dimer (µg/ml) 0.26 [0.15- 0.49] 0.33 [0.19-0.56] 0.229 
VWF (iu/dl) 76.7 (14.9) 76.3 (13.8) 0.874 
CRP (mg/l) 1.7 [0.71- 5.3] 1.15 [0.5- 2.8] 0.0382 
IL-6 (pg/ml) 28.7 [13.3-206.6] 74.4 [22-236] 0.124 
 
3.25.2: Female subjects: 
 
sP-sel: soluble P-selectin; IL-6: Interleukin-6; VWF: Von Willebrand Factor; CRP: C-
reactive protein; SD: standard deviation; IQR: inter-quartile range.
Variable 
South Asian (n= 50) 
(SD) [IQR] 
Black (n= 75) (SD) 
[IQR] p-value 
sP-sel (ng/ml) 31.4 [23.5- 40.5] 24.9 [19.3- 31.8] 0.0015 
Platelets (x10
3
cell/µl) 299.7 (81.3) 267.2 (73.8) 0.031 
D-dimer (µg/ml) 0.24 [0.15- 0.46] 0.37 [0.24- 0.82] 0.0172 
VWF (iu/dl) 73.1 (11.4) 79.5 (18.9) 0.017 
CRP (mg/l) 2.69 [0.82-4.5] 2.05 [0.72-5.35] 0.754 
IL-6 (pg/ml) 65.2 [23.7-260.3] 41.9 [16.7-153.9] 0.250 
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Associations between indices of haemostasis and inflammation with ABPI, mean and 
maximum CCIMT  
 
South Asians: 
Based on my power calculation to minimise the risks of types 1 and 2 errors, the only 
significantly powered association in South Asians on univariate analysis was between VWF 
and mean CCIMT (r=0.283; p=0.002) [Table 3.22]. There was a weak, but not significantly 
powered association between VWF and maximum CCIMT (p=0.011) and ABPI (p=0.047) 
on univariate analysis. Another weak association was found between D-dimer and mean 
CCIMT (p=0.043) on univariate analysis. 
 
I looked for univariate associations between indices of haemostasis and inflammation and 
traditional cardiovascular risk factors and in South Asians found VWF and D-dimer both 
correlated with age (r=0.347; p<0.0001 and r=0.458; p<0.0001 respectively). There was also 
a weak correlation between platelets and LDL-C (r=0.251; p=0.008). However these results 
were not significantly powered. 
 
I wanted to see if any of the indices of haemostasis and inflammation was an independent 
predictor of mean CCIMT (Model 1), maximum CCIMT (Model 2) and ABPI (Model 3) 
when adjusting for traditional cardiovascular risk factors on multivariate analysis. Of the 
research indices investigated, VWF was an independent predictor of mean (p=0.034; R
2
 for 
model=19.3%) and maximum (p=0.046; R
2
=18.4%) CCIMT and D-dimer was an 
independent predictor of mean CCIMT (p=0.036; R
2
=18.5%). None of the research indices 
was an independent predictor of ABPI in the South Asian subjects. 
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Table 3.26.1:  Univariate correlations between novel cardiovascular risk factors, ABPI, 
mean and maximum CCIMT 
 
3.26.1: South Asians 
Variable  
 
ABPI  
r-value 
ABPI  
p-value 
Mean 
CCIMT 
r-value 
Mean 
CCIMT  
p-value 
Maximum 
CCIMT  
r-value 
Maximum 
CCIMT  
p-value 
sP-sel 
(ng/ml) 0.036 0.664 0.038 0.678 0.098 0.283 
Platelets 
(x10
3
cell/µl) 0.015 0.872 0.020 0.837 0.047 0.629 
D-dimer 
(µg/ml) -0.005 0.95 0.186 0.043 0.108 0.36 
VWF (iu/dl) -0.168 0.047 0.283* 0.002 0.232 0.011 
CRP (mg/l) 0.063 0.461 0.122 0.192 0.086 0.36 
IL-6 (pg/ml) -0.106 0.323 0.021 0.861 -0.013 0.910 
 
      3.26.2: Blacks 
Variable 
ABPI  
r-value 
ABPI  
p-value 
Mean 
CCIMT 
r-value 
Mean 
CCIMT  
p-value 
Maximum 
CCIMT  
r-value 
Maximum 
CCIMT  
p-value 
sP-sel 
(ng/ml) -0.033 0.709 0.148 0.104 0.21 0.02 
Platelets 
(x10
3
cell/µl) 0.102 0.254 -0.201 0.03 -0.201 0.03 
D-dimer 
(µg/ml) -0.214 0.014 -0.067 0.464 -0.032 0.727 
VWF (iu/dl) -0.140 0.109 0.027 0.767 0.01 0.909 
CRP (mg/l) -0.0003 0.974 0.156 0.095 0.159 0.09 
IL-6 (pg/ml) -0.07 0.537 0.025 0.838 0.09 0.454 
 
 
sP-sel: soluble P-selectin; IL-6: interleukin-6; VWF: Von Willebrand factor; CRP: C-
reactive protein; SD: standard deviation; IQR: inter-quartile range; ABPI: ankle brachial 
pressure index; CCIMT: common carotid intima media thickness; *: sufficiently powered 
result 
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Blacks: 
Amongst Black subjects this study observed no sufficiently powered significant associations 
between research indices, ABPI and mean and maximum CCIMT.   D-dimer was weakly 
associated with ABPI (p=0.014) [Table 3.22] and platelet count was weakly associated with 
both mean and maximum CCIMT (p=0.03 for both) and sP-sel was weakly associated with 
maximum CCIMT (p=0.02) [Table 3.22].  
 
Univariate associations between traditional cardiovascular risk factors and research indices 
this study observed were between platelet count and age (r=-0.259; p=0.003) and D-dimer 
and mean SBP and age (r=0.25; p=0.004 and r=0.404; p<0.0001 respectively).   
 
On multivariate analysis, adjusting for traditional cardiovascular risk factors, of the research 
indices studied, only D-dimer remained an independent predictor of ABPI (p<0.0001; R
2
 for 
model=21.8%). None of the research indices was an independent predictor of either mean or 
maximum CCIMT on multivariate analysis after adjusting for traditional cardiovascular risk 
factors.  
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3.4.6 Discussion 
 
This is the first community based study of ethnic associations between circulating 
inflammatory and haemostatic biomarkers, CCIMT and ABPI in the UK. This study reports 
ethnic differences in biomarker profile and report different associations between biomarkers, 
CCIMT and ABPI in South Asians and Blacks. Notably Blacks had significantly higher D-
dimer than South Asians overall and in women, whilst South Asians had higher sP-sel and 
platelet concentrations overall and in each sex, despite equivalent antiplatelet medication use 
between the two ethnic groups. Of the haemostatic biomarkers, D-dimer was the only one 
which significantly differed between the PAD and normal ABPI cohorts in Blacks, 
supporting findings reported in predominantly White European populations [Lee et al. 1995; 
Tzoulaki et al. 2007]. 
 
Differences in prevalence of cardiovascular diseases are known to exist between ethnic 
groups. In particular, South Asians and Blacks have a higher cardiovascular disease burden 
when compared to the general population [Gill et al. 2007]. This increased susceptibility is 
not completely explained by prevalence if traditional cardiovascular risk factors. Indeed, 
novel risk factors may play some role at least in the development of vascular diseases, such 
as PAD, possibly in the ethnic susceptibility to cardiovascular disease [Allison et al. 2006; 
Khalegi et al. 2009]. 
 
D-dimer is a sensitive marker of thrombosis formation and subsequent fibrinolysis and 
higher D-dimer maybe indicative of a pro-coagulant state favouring progression of 
atherosclerosis and its thrombotic complications. This study’s findings of higher D-dimer 
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support those in the US comparing African Americans to other ethnic groups [Lutsey et al. 
2006]. Even though African Americans and UK Blacks differ with regards to their 
cardiovascular risk and healthcare access [Forouhi et al. 2006], this study suggests Black 
ethnicity may be associated with a greater predisposition to a hypercoagulable and 
prothrombotic state than other ethnic groups, which may in part explain the increased 
prevalence of PAD and thrombotic complications in this ethnic group [Norgren et al. 2007].  
 
Whilst equivalent levels of VWF were found in South Asians and Blacks overall; women in 
the latter group had higher levels than the former. This supports findings of a  recent US 
study investigating markers of cardiovascular disease also reported VWF to be 
independently associated with being an African American female [Kim et al. 2010].  Of the 
haemostatic biomarkers, VWF was also independently associated with mean and maximum 
CCIMT on linear regression in South Asians. VWF is considered a well-validated plasma 
marker for the measurement of endothelial dysfunction/ damage in atherosclerosis [Zanetta 
et al. 2000]. This study’s findings may reflect greater endothelial damage/dysfunction and 
possibly higher atherosclerotic load, but not overt disease, in South Asians.  
 
There is evidence to suggest that there are regional differences in atherosclerotic risk 
susceptibility to specific haemostatic biomarkers [Chaturvedi et al. 2007]. It is also possible 
that different pathophysiological processes are more predominant in different ethnic groups, 
which may contribute to the susceptibility of disease in different vascular territories. If this is 
the case, VWF may play a role in the susceptibility of South Asians to atherosclerotic 
disease of carotid and coronary arteries. D-dimer on the other hand, reflecting the 
hypercoagulable and pro-thrombotic state found in PAD [Makin et al. 2002; Chung et al. 
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2003/2004; Lowe et al. 2003/2004], and its thrombotic complications, may in part explain 
the apparent higher susceptibility to PAD with Black ethnicity [Norgren et al. 2007]. 
 
VWF has previously been associated with traditional cardiovascular risk factors [Blann et al. 
1993a; Blann et al. 1993b, Spencer et al. 2002] and PAD [Seigneur et al. 1995; Lee et al. 
1995; Cassar et al. 2003; Cassar et al. 2005].  This study found VWF to be associated with 
age but not with LDL-C, diabetes, hypertension or smoking in South Asians.  D-dimer was 
associated with age only in South Asians and SBP and age in Blacks, supporting literature in 
other populations [Lee et al. 1995; Khalegi et al. 2009]. Other associations did not reach 
sufficient statistical power. 
 
It was surprising to find no associations between inflammatory markers and PAD in this 
study. Likewise the lack of an association between CRP and IL-6 with ABPI and mean and 
maximum CCIMT contrasts with published findings of their associations in White 
populations [Ridker et al. 2001; Tzoulaki et al. 2007; Aboyans et al. 2006; Tzoulaki et al. 
2005]. This may reflect different pathophysiological processes predominating in different 
ethnic groups, as discussed above or could be a result of small numbers of subjects in this 
study. 
 
Limitations 
This study is limited by its cross-sectional design and the low numbers of participants in 
some of the subgroups studied. Participant numbers were small, especially those with PAD, 
which may have affected some associations between haemostatic factors, CCIMT and ABPI. 
Consent for blood was low, especially amongst South Asians, but comparable to those found 
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in national surveys [Health Survey for England 1999].  The low numbers of participants and 
low blood sampling may have contributed to the lack of sufficient power in some of the 
results, which may be subject to types 1 and 2 errors. This study population consisted of 
predominantly 1
st
 generation UK migrants. These are less likely to have adopted a Western 
lifestyle than subsequent generations, which in itself may enhance cardiovascular risk and 
influence the results in this chapter. However differences in the proportion of 1
st
 generation 
migrants between South Asians and African Caribbeans may have contributed to differences 
in haemostatic risk factors in these populations.  
 
Another possible limitation of this study is that of responder bias. Whilst all eligible subjects 
were invited to take part in the E-ECHOES study, patients responded via a free-phone 
telephone number or return a stamped addressed envelope.  To minimise response bias 
especially from non-English speakers, subjects were also telephoned and a verbal 
explanation was provided. It is also possible that eligible subjects with existing 
cardiovascular disease were more likely to participate in a cardiovascular screening study 
than those without, which may have affected our results.  This study population had higher 
incident diabetes and hypertension than previous studies [Chaturvedi et al. 1994; Diabetes in 
the UK 2004], which may have contributed to the associations with haemostatic risk factors 
which we found. However the incidence of these risk factors was equivalent in South Asian 
and Black subjects. Likewise significant differences in other cardiovascular risk factors, 
notably dyslipidaemias, BMI, smoking and incident CAD may have played a role in 
contributing to the differences in haemostatic risk factors between the South Asian and 
Black groups. It is difficult to know whether ethnicity per se or differences in cardiovascular 
risk factors between the 2 ethnic groups played the greater role in this study’s findings. 
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Nonetheless, this study still represents the first epidemiological-based study of 
pathophysiological biomarkers in ethnic minority groups in the UK community setting. 
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 3.4.7 Conclusion 
 
Ethnic differences are evident in inflammatory and haemostatic factors, and their 
associations with CCIMT and PAD.  Whilst this may reflect differences in cardiovascular 
risk factors, this may reflect different pathophysiological processes predominating in 
different ethnic groups. 
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CHAPTER 4 
 
HOSPITAL BASED STUDY 
 
4.1 Ethnic Differences in Circulating Markers of Angiogenesis and their Association 
with Cardiovascular Risk Factors and Cardiovascular Disease 
 
4.1.1 Abstract 
 
Objectives: To determine (a) whether ethnic/racial differences exist in circulating markers 
of angiogenesis (Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), soluble Tie-2 receptor 
(sTie2) and Angiogenin) between South Asian (from India, Pakistan and Bangladesh); Black 
African-Caribbean and White ethnic groups, and (b) associations between these markers in 
stable cardiovascular disease (CVD) and cardiovascular risk factors. 
Methods: 243 (82 South Asian, 84 Black and 77 White) subjects were recruited into this 
study; Symptomatic and clinically confirmed CVD (n=108), risk factor controls (with ≥1 
cardiovascular risk factor, e.g. smoking, diabetes mellitus, dyslipidaemia, hypertension) and 
with ankle brachial pressure index >1) (n=64) and healthy controls free of CVD and risk 
factors (n=56). Angiogenic markers were measured by enzyme linked immunoassay. 
Results: There were no statistically significant differences in any of the research indices 
when comparing all subjects in the 3 ethnic groups. In healthy controls, angiogenin was 
higher in South Asian and Black subjects, compared to Whites (p=0.05). sTie2 correlated 
inversely with angiogenin (p=0.001), was higher in women (p=0.029) and was lower in 
smokers (p=0.007). Overall, age (p=0.001) was the only independent factor associated with 
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angiopoietin-1. Angiogenin (p=0.01) and SBP (p=0.014) were both independently higher in 
the Black group compared to the White group.  
Conclusions: Ethnic, racial, and demographic differences are evident in certain circulating 
markers of angiogenesis. With the exception of an effect of smoking on sTie2, these 
differences are not influenced by the presence of other risk factors, nor the presence of stable 
cardiovascular disease. 
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4.1.2 Introduction 
 
Cardiovascular disease, manifesting as peripheral arterial disease, coronary artery disease or 
cerebrovascular disease, is an important consequence of atherosclerosis. Angiogenesis, the 
formation of new blood vessels, is evident in these conditions and is closely related to 
atherogenesis, thrombogenesis and the development of intra-plaque vasa vasorum [Sluimer 
& Daemen 2009; Post et al. 2004]. Furthermore, angiogenesis is a feature of disease 
development and progression [Moreno et al. 2004; Kolodgie et al. 2003], and is especially 
frequent in advanced cardiovascular disease and may characterise atherosclerotic lesions at 
high risk of haemorrhage or rupture [Kolodgie et al. 2003; McCarthy et al. 1999; Mofidi et 
al. 2001]. Vascular endothelial growth factor (VEGF), acting on the endothelium, is one of 
the major growth factors driving angiogenesis, and raised plasma levels in diabetes, 
peripheral artery disease and coronary artery disease is evidence of this increased angiogenic 
activity [Blann et al. 2002].   
 
In addition to VEGF, the angiopoietins (Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) 
are additional angiogenic growth factors that are specific for endothelium. Ang-1 and Ang-2 
play modulatory roles by binding a common receptor, the endothelial cell-specific tyrosine 
kinase receptor Tie-2 [Chong et al. 2004; Van der Heijen et al. 2010], a soluble form of 
which (i.e. sTie2) can be detected in plasma. Together, the angiopoietins regulate endothelial 
cell differentiation: Ang-1 accelerates the maturation of the blood vessel, while Ang-2, an 
antagonist of Ang-1, destabilises the vessel and degrades the basal lamina [Felmelden et al. 
2003; Stetler-Stevonson et al. 1999]. Plasma levels of Ang-1 and Ang-2 levels are abnormal 
in, and are associated with, cardiovascular risk in patients with cardiovascular disease 
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[Findley et al. 2008] and also in other manifestations of atherosclerosis, including heart 
failure, acute coronary syndromes and hypertension [Chong et al. 2004; Felmelden et al. 
2003a; Felmdelen et al. 2003b; Nadar et al. 2005; Lim et al. 2004; Lee et al. 2004]. 
 
Angiogenin is a small polypeptide implicated in angiogenesis normally found in the 
vasculature, but also in some physiological and pathological conditions, including peripheral 
and coronary atherosclerosis [Bond & Valee 1990; Burgmann et al. 1996; Tello-Montoliu et 
al. 2006]. Angiogenin levels have been found to be higher in those with severe peripheral 
atherosclerosis, compared to mild and moderate disease [Burgmann et al. 1996], and raised 
levels in acute coronary syndromes predict a poor outcome at six months [Tello-Montoliu et 
al. 2006]. Thus, angiogenin could potentially be an indicator of endothelial activity related to 
progression of vascular disease. 
 
Given improvements in biochemical techniques there has been an increasing interest in value 
of biomarkers related to the development of atherosclerosis and its symptomatic 
complications. Despite ethnic and racial differences having been documented in the 
prevalence of atherosclerosis, much of the research on pathophysiology has been carried out 
on predominantly White populations [Burgmann et al. 1996; Tello-Montoliu et al. 2006] and 
limited research has been directed on these biomarkers in relation to ethnic and/or racial 
susceptibility to this disease [Allison et al. 2006]. 
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4.1.3 Hypotheses to be tested 
 
Ethnic differences will exist in plasma expression of angiogenic markers (Ang-1, Ang-2, 
Angiogenin, sTie2). Ethnic differences will also exist in the association of angiogenic 
markers with traditional cardiovascular risk factors and cardiovascular disease.   Furthermore 
this study also tested the hypothesis that Ang-1, Ang-2, sTie2 and angiogenin levels would 
be higher in those with at least one cardiovascular risk factor compared to healthy controls, 
with a further increase in those with clear cardiovascular disease.  
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4.1.4 Patients & Methods   
 
Study Design & Recruitment 
Participants were recruited from among those attending cardiovascular disease outpatient 
clinics (cardiology and peripheral artery disease) and from hypertension clinics. Recruitment 
to this study is described in detail in chapter 4.2.2.2 on page 100.  
 
Exclusion criteria for all subjects were infectious diseases, rheumatoid arthritis and other 
chronic inflammatory disorders, sepsis, malignancy, haemodynamically significant valvular 
heart disease, atrial fibrillation, renal failure, immunity-modulating drugs and hormone 
replacement therapy, recurrent venous thromboembolism, congestive cardiac failure, 
multiple sclerosis and anaemia. The study was approved by Birmingham East, North & 
Solihull Local Research Ethnics Committee and written informed consent was obtained from 
all study participants. 
 
Clinical Assessment 
The clinical assessments undertaken for this study are described in detail in chapter 4.2.2.3 
on page 103. 
 
Laboratory 
Venous blood was taken from the antecubital fossa into sodium citrate. Blood was stored on 
ice for a maximum of 2 hours before being centrifuged at 1500 x g; the plasma supernatant 
was then frozen at -70ºC for future batch analysis. Samples were tested for angiogenic 
markers using commercially available ELISA kits (R&D systems, Abingdon. UK). Intra-
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assay and inter-assay variances of all assays were <5% and <10% respectively.   Lower 
limits of detection were 3.8ng/ml for Ang-1, 0.1 ng/ml Ang-2, 0.1 ng/ml angiogenin and 1.0 
ng/mL for sTie2. All patients consented for blood to be collected for use in this study. 
 
Sample size justification and statistical analysis 
Data are presented as mean with standard deviation (SD) or median with inter-quartile range 
(IQR) for continuous parameters, as distribution defined. Chi-squared test was used for 
categorical data. One way ANOVA or the Kruskal-Wallis test was used to assess differences 
between three groups (South Asian, Black, White, and Healthy controls, cardiovascular risk 
factor, cardiovascular disease) for continuous variables, with Tukey’s post-hoc analysis 
performed for inter-group differences. Determinants of the four research indices on 
multivariate analysis were sought using a general linear model, inputting ethnic group and 
sex as nominal categories, disease progression state as an ordinal category. When necessary, 
data was logged for normality. A p-value <0.02 was deemed significant. Two-sided 
Spearman correlations were sought with a 1-beta power of 0.85: a correlation coefficient of 
>0.4 was considered large enough to minimise false positives [Machin & Campbell 1987]. 
This study hypothesised a 25% - 50% difference in one of the research indices in one of the 
three nominal groups of SA, AC and White, and of a similar increase across the spectrum of 
health (modelling 100 [90-140] units/mL), to risk factors (125 [115-165] units/mL) to 
cardiovascular disease (150 [149-190] units/mL). To achieve this at p<0.001, a sample size 
of 50 per group was required. However, with four research indices, and expecting greater 
heterogeneity in the CVD group, this study recruited in excess in each group for extra 
statistical confidence. Statistical analyses were carried out using Minitab version 15 (State 
Coll, PA, USA). 
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4.1.5 Results 
 
243 subjects with a mean age of 64.3 (SD 11.9) years were recruited. Diabetes was present 
in 25.9% and 55.1% were male. Breakdown by age, sex, blood pressure, body mass index, 
clinical grouping, risk factors, cardiovascular territory and use of aspirin according to 
racial/ethnic group is presented in table 4.1. 
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Table 4.1: Clinical and demographic details of Hospital Study Participants 
 
 
 
Data are % or mean (standard deviation); SBP: systolic blood pressure; DBP: diastolic blood 
pressure; BMI: body mass index; PAD: peripheral arterial disease; CAD: coronary artery 
disease; CBVD: cerebrovascular disease. Age, SBP, DBP, BMI analysed by ANOVA, all 
others by chi-squared 
Variable South Asian 
(n=82) (SD) 
Black (n=84) 
(SD) 
White 
(n=77) 
(SD) 
P-value 
Demographic details     
Age (years) 62 (10) 66 (13) 63 (11) 0.146 
Male sex (%) 60.7 48.3 54.4 0.254 
SBP (mmHg) 142 (27) 144 (21) 134 (18) 0.024 
DBP (mmHg) 81 (13) 80 (12) 76 (9) 0.020 
BMI (kg/m2) 26.7 (4.4) 28.9 (5.5) 27.8 (5.2) 0.018 
 
Clinical grouping 
    
Healthy Controls (%) 21.9 22.6 26.0  
Risk factor controls 
(%) 
18.3 33.3 32.5 0.102 
Cardiovascular 
disease (%) 
 
Cardiovascular risk 
factors 
59.7 44.0 41.4  
 
Current smoking (%) 12.2 21.4 24.7 0.115 
Diabetes (%) 31.7 30.9 14.3 0.019 
Hypertension (%) 63.4 66.7 57.1 0.450 
Dyslipidaemia (%) 55.1 46.1 49.4 0.879 
 
Cardiovascular disease 
territory 
    
PAD (%) 30.5 34.5 36.4  
CAD (%) 35.4 14.3 20.8 0.154 
CBVD (%) 
 
Use of antiplatelets 
(%) 
 
11.0 
 
50.0 
7.1 
 
46.6 
6.5 
 
49.3 
 
 
0.887 
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Subjects in the three ethnic groups (South Asian, Black, White) were matched for age and  
sex and were also matched for the proportion of healthy volunteers, subjects with actual 
cardiovascular risk factors (smoking, hypertension, dyslipidaemia, & diabetes) (Risk factor 
controls) and those who had CVD. The three ethnic groups were also matched for the 
proportion of subjects with disease in each cardiovascular disease territory and matched for 
use of aspirin. SBP and DBP were lower in Whites compared to the other two groups, whilst 
BMI was lower in South Asian compared to the Black group. There were fewer diabetics in 
the White group compared to the other two groups. The risk factor group consisted of 42 
people with a single risk factor, 25 with two risk factors and one person with all four risk 
factors. Of those with cardiovascular disease, 80 had disease in one territory, 33 had disease 
in two and 4 patients had disease in all three. 
 
Univariate analysis of the angiogenic markers are shown in table 4.2. Angiogenin was lower 
in White compared to South Asian and to Black groups. Compared to healthy controls, 
angiopoietin-2 was higher in the risk factor and the cardiovascular disease group. In the 56 
healthy controls, only angiogenin varied between the ethnic groups: 6.35 (3.2-8.6) ng/mL in 
18 South Asians, 5.3 (3.7-7.5) ng/mL in 18 Blacks, and 3.3 (1.7 – 6.0) in the 20 White 
(p=0.043 overall, p<0.05 South Asian vs. White). However, this finding was no longer 
apparent in subjects with at least one cardiovascular risk factor or subjects with 
cardiovascular disease. In fact, in subjects with one or more cardiovascular risk factors, none 
of the research indices were associated with ethnic/racial group.   
 
Investigating possible associations between the research indices on univariate analysis, sTie2 
correlated inversely with angiogenin (r = -0.44, p=0.001, Figure 4.1). No other univariate 
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associations were found between the research indices.  sTie2 was lower in 16 smokers (87 
(61-130) ng/mL) compared to 48 non-smokers (136 (100-166) ng/mL, p=0.007). sTie2 
appeared to be higher in the women (124 (83-170) ng/mL) compared to the men (86 (75-
133) ng/mL (p=0.029) although this was not significant and the possible effect of sex on 
sTie2 seen in healthy volunteers also became non-significant. There were no correlations 
where the coefficient exceeded 0.4.  
 
In the 108 cases with stable cardiovascular disease, there was no effect of ethnicity, or of the 
number of symptomatic cardiovascular territories on the research indices, and no effect of 
smoking or sex on levels of sTie2. There were no correlations where the coefficient 
exceeded 0.4. 
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Table 4.2: Univariate Comparisons of Angiogenic Markers 
 
4.2.1 Analysis by racial/ethnic group 
4.2.2 Analysis by disease process 
4.2.1 
Angiogenic 
Marker 
 
South Asian 
(n=82) [IQR] 
Black 
 (n=84) [IQR] 
White 
European 
(n=77) [IQR] 
p-value 
 
Angiopoitein-1 
 
16.8 [4.9-33.2] 
 
12.4 [6.0-32.5] 
 
9.4 [5.1-21.0] 
 
0.246 
 
Angiopoietin-2 
 
1.3 [0.85-1.78] 
 
1.2 [0.69-2.65] 
 
1.35 [0.87-3.3] 
 
0.301 
 
sTie2 
 
103 [79-146] 
 
119 [80-168] 
 
127 [83-166] 
 
0.191 
 
Angiogenin  
 
240 [135-386] 
 
261 [187-367] 
 
169 [95-319] 
 
0.01* 
 
 
4.2.2     
Angiogenic 
Marker 
 
 
Healthy  
Controls 
(n=56) [IQR] 
 
Risk  
Factors 
(n=64) [IQR] 
 
Cardiovascular 
disease 
(n=108) [IQR] 
 p-value 
Angiopoitein-1 
 
14.8 [5.2-33.0] 
 
12.4 [5.2-35.8] 
 
12.3 [5.3-26.8] 
 
0.950 
 
Angiopoietin-2 
 
0.88 [0.69-1.71] 
 
1.32 [0.81-3.1] 
 
1.52 [0.9-2.4] 
 
0.006** 
 
sTie2 
 
117 [79-158] 
 
126 [87-153] 
 
114 [82-162] 
 
0.851 
 
Angiogenin  
 
260 [137-372] 
 
221 [114-314] 
 
238 [135-371] 
 
0.347 
 
 
 
 
sTie2: soluble Tie-2 receptor; IQR: interquartile range; Units for all growth factors, ng/mL. 
Data analysed by the Kruskal-Wallis Test for non-parametric testing between 3 groups. 
*Lower in Whites compared to South Asians and to Blacks (p<0.05). Multivariate analysis 
showed this relationship to be present only in those free of risk factors or cardiovascular 
disease. **Higher in risk factors and cardiovascular disease (p<0.05). However, the effect of 
the disease spectrum on angiopoietin-2 disappeared in multivariate analysis. 
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Figure 4.1: Correlation between sTie2 and angiogenin in the healthy controls 
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In multivariate analysis, general linear models identified age (p=0.001) to be the only 
independent factor associated with angiopoietin-1, whilst ethnic group (p=0.018) and SBP 
(p=0.01) were the only factors associated with angiogenin. In nominal regression analysis, 
SBP (p=0.014) and levels of angiogenin (p=0.01) both remained higher in the Black group 
compared to the White group. 
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4.1.6 Discussion 
 
This study reports for the first time an analysis of circulating markers of angiogenesis in 
three different ethnic groups and the effect of risk factors and in stable atherosclerotic 
disease. It also investigated the inter-relationships between Ang-1, Ang-2, sTie2 and 
angiogenin.  
 
This study found angiogenin levels to be significantly lower in healthy White than in both 
South Asian and Black groups. However, this effect disappeared in the presence of risk 
factors, and in stable cardiovascular disease, indicating some effect of the latter two 
processes. Others have reported raised angiogenin in acute coronary syndromes [Burgmann 
et al. 1996; Tello-Montoliu et al. 2006; Idriss et al. 2010], but not in stable coronary artery 
disease [Idriss et al. 2010] in predominantly White populations. This study now extends this 
by reporting no change in angiogenin in South Asians and Blacks with stable cardiovascular 
disease. Angiogenin has been thought to be an indicator of endothelial damage related to 
progression of vascular disease, it binds actin on the surface of endothelial cells, and its 
plasma levels are dependent on the presence of an angiogenic stimulus [Tello-Montoliu et al. 
2006]. Its levels may therefore be expected to be associated with related molecules, and the 
correlation with sTie2 as found in this study may reflects this.  
 
Several studies have suggested that angiogenin, and other angiogenic factors, could promote 
atherosclerosis and potentially de-stabilise plaques by promoting intra-lesional angiogenesis 
[Kolodgie et al. 2003; Khurana et al. 2005]. If so, this study’s data suggest that plasma levels 
do not reflect this process. The higher levels in healthy asymptomatic middle aged (mean 
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age 56 years) South Asians and Blacks may in part explain the apparently higher 
cardiovascular disease burden in these ethnic groups when compared to the general 
population [Allison et al. 2006; Gill et al. 2007]. It is also possible that the higher angiogenin 
levels could in part be attributable to higher blood pressure and/or the higher prevalence of 
diabetes amongst the South Asians and Blacks with respect to the White groups.  
 
The relationship between angiogenin and race/ethnicity present in health was only just lost in 
the presence of risk factors (p=0.087), but markedly so in stable cardiovascular disease 
(p=0.595), imply an effect to the latter two aspects on the growth factor. Such an effect may 
be effect of pathophysiology and/or drug therapy on the endothelium. 
 
sTie2 was higher in the middle aged healthy women than in health men, precisely the reverse 
of a much larger community-based study, although the latter subjects were younger (and the 
women more likely to be pre-menopausal [mean age 40 years]) and had more disease [Lieb 
et al. 2010], although in this study this effect disappeared in risk factors and in frank disease. 
Some of this may be due to the effect of smoking. Notably, this finding parallels that of 
reduced plasma levels of the receptor for VEGF, feline McDonough Sarcoma-like tyrosine 
receptor-1 (Flt-1) in smokers [Belgore et al. 2000]. Curiously, this may have a real 
cardiovascular effect as smoking, and so lower Flt-1, protects against pre-eclampsia 
[Jeyabalan et al. 2008]. Failure to find altered sTie2 in stable cardiovascular disease 
contrasts with others who reported raised levels in acute coronary syndromes [Wang et al. 
2005], suggesting that alterations in angiogenic markers are the result of the acute changes. 
Cleavage of the extra-cellular domain of Tie2 on endothelial cells occurs in response to 
inflammation and results in circulating sTie2, a process which is reduced by hypoxia [Van 
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der Heijen et al. 2010]. In acute inflammatory states, sTie2 in the plasma is bound by Ang-1 
preferentially over Ang-2 due to its higher affinity for the receptor, leading to greater 
binding of Ang-2 to endothelial Tie2 and increasing endothelial permeability [Van der 
Heijen et al. 2010; Jones et al. 2001]. In hypoxic states, the relatively lower endothelial 
release of sTie2, leads to less Ang-1 binding within the plasma and greater endothelial 
binding, which accelerates vessel maturation [Post et al. 2008]. This preferential binding of 
Ang-1 over Ang-2 may explain the rise in plasma Ang-2 found in the presence of 
cardiovascular risk factors and cardiovascular disease seen in this study. However, whether 
or not these effects, prominent in cell biology, have any role in the pathophysiology of 
cardiovascular disease cannot be inferred from this study. 
 
The only significant correlation was inversely between sTie2 and angiogenin. However, 
there seems to be no clear physiological or pathological relationship between the two. 
Further research into the possible relationship between these two angiogenic markers is 
required before firm conclusions can be made as to whether they have any physiological 
effect on each other. 
 
Limitations 
This study is limited by its cross-sectional design, but it still represents the first study to 
investigate ethnic differences in circulating markers of angiogenesis and their association 
with cardiovascular risk factors and frank, but stable, cardiovascular disease. Although this 
study has adjusted for various know risk factors, as well as age and gender, in the 
multivariate analysis, clearly residual confounding may still be present. 
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4.1.7 Conclusion 
 
Ethnic differences are evident in circulating markers of angiogenesis, which may reflect 
susceptibility of particular groups to a greater predilection to cardiovascular disease. 
However, once cardiovascular disease or its risk factors are present, the value of these 
plasma markers diminishes. 
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CHAPTER 5 
 
 SUMMARY AND CONCLUSIONS 
 
5.1 Summary of Results 
 
In this thesis it has been demonstrated that ethnic differences exist in the prevalence of 
traditional cardiovascular risk factors, in pre-clinical atherosclerosis (CCIMT) and in 
peripheral arterial disease (PAD). It has also been shown that ethnic differences are apparent 
in markers of haemostasis and thrombosis and that different pathophysiological processes 
predominate in different ethnic groups. 
 
Chapter 3.1 attempted to validate the Edinburgh Claudication Questionnaire in languages of 
the Indian sub-continent and also amongst 1
st
 generation UK Black Caribbean migrants. It 
found the sensitivity and specificity and overall diagnostic accuracy of the ECQ was lower in 
Punjabi and Urdu translations and amongst Black Caribbeans than in the Edinburgh Artery 
Study but reflected the findings of other studies. It is unclear from this study whether the 
apparent lower sensitivities and specificities found are due to linguistic and cultural 
differences in describing the location and duration of pain or due to insufficient physical 
activity to bring on symptoms of intermittent claudication in the ethnic minority groups 
studied. It is also possible that the findings are the result of measuring ABPI, a more 
objective measure of claudication than was used in the Edinburgh Artery Study. 
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Chapter 3.2 investigated the prevalence of PAD in South Asians and Blacks. When 
comparing the two groups as a whole it found no significant differences in PAD prevalence. 
However, among female subjects, South Asians had a statistically significantly higher 
prevalence of this disease than Blacks. While both ethnic groups had equivalent levels of 
hypertension and diabetes, South Asian women had significantly lower levels of smoking. In 
previous research in predominantly White European populations it has been thought that 
abnormalities in the components of the lipid profile do not appear to carry the same 
importance as smoking and diabetes in the development of PAD [Faxon et al. 2004]. The 
most frequent dyslipidaemia associated with PAD is elevated triglycerides and low HDL-C 
[Smith et al. 2004]. In this study South Asian women had significantly higher triglycerides 
and lower HDL-C than their black counterparts. It might be possible that in South Asian 
women where the prevalence of smoking is low [Bhopal et al. 1999], dyslipidaemias are 
more important in the development of PAD. However causal associations cannot be made as 
a result of this cross-sectional study. 
 
It’s also possible that the South Asian women have less access to healthcare due to language 
barriers and high levels of illiteracy, even in their first language. The communication 
difficulties could mean they are less likely to be targeted by primary prevention strategies set 
out to reduce their cardiovascular risk. It’s also possible that their increased prevalence of 
PAD is due to having more sedentary lifestyles than other ethnic groups [Hayes et al. 2006, 
Fischbacher et al. 2004]. 
 
Chapter 3.2 found the prevalence of diabetes and hypertension in both South Asian and 
Black participants was high overall and higher than in previous UK population based studies 
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[Chaturvedi et al. 1994; Diabetes in the UK 2004], with no significant differences between 
the two groups. However South Asians overall had a less favourable glycosylated 
haemoglobin level, which has been shown to be related to an elevated risk of incident PAD 
[UKPDS 1998]. 
 
With regards to the hypothesis that ethnic differences will exist in the associations between 
traditional cardiovascular risk factors and PAD, this thesis showed that male sex, SBP, 
diabetes and smoking were all independent predictors for PAD in South Asians after 
adjusting for traditional cardiovascular risk factors. In Blacks, only age was an independent 
predictor of this disease. This could suggest that cardiovascular risk factors are more closely 
related to each other in their effect on the pathophysiology of PAD in Blacks; although 
causal associations cannot be inferred from this cross-sectional study. 
 
Chapter 3.3 investigated the hypotheses that ethnic differences will exist in mean and 
maximum CCIMT, a marker of pre-clinical atherosclerosis, and its relationship to 
cardiovascular risk factors and PAD. This chapter found that on univariate analysis Blacks, 
as a whole group, had higher mean CCIMT. This was also apparent in male and female 
subjects when analysed separately. On multivariate analysis, adjusting for traditional 
cardiovascular risk factors, Black ethnicity was a significant independent predictor of both 
mean and maximum CCIMT. This supports the possibility of a genetic/ ethnic predisposition 
to vascular disease in different vascular territories and supports previous research 
[D’Agostino et al. 1996; Kuller et al. 1998]. 
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Chapter 3.3 also found ethnic differences in associations between CCIMT and traditional 
cardiovascular risk factors. In South Asians, the presence of hypertension was associated 
with greater mean and maximum CCIMT on univariate analysis as were SBP and PP. SBP 
remained an independent predictor of both mean and maximum CCIMT after adjusting for 
traditional cardiovascular risk factors. This finding was not found in the Black subjects in 
spite of equivalent levels of hypertension prevalence in both ethnic groups. Diabetes had 
univariate associations with mean and maximum CCIMT in both ethnic groups, as did 
HbA1c, but no longer remained an independent predictor of CCIMT on multivariate 
analysis. Maybe this is because subjects with diabetes are more likely to have co-existent 
risk factors, such as higher systolic blood pressure or are more likely to be older, which are 
more important risk factors than diabetes as predictors of raised CCIMT. 
 
Interestingly no associations were found between smoking and CCIMT in Black subjects in 
this study even though Blacks had a higher prevalence of ever and current smoking than 
South Asians. Amongst the South Asians smoking had univariate associations with both 
mean and maximum CCIMT but on multivariate analysis was only an independent predictor 
of mean CCIMT. This finding could reflect the role smoking has on initiating and 
accelerating atherogenesis by altering components of Virchow’s triad.  
 
Finally, chapter 3.3 found univariate associations between PAD and mean and maximum 
CCIMT in both South Asian and Black subjects. Even after adjusting for traditional 
cardiovascular risk factors, ethnicity and age, PAD remained an independent predictor of 
both raised mean and maximum CCIMT on multivariate analysis, reflecting the greater 
cardiovascular burden in subjects with this disease.  
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Chapter 3.4 investigated the hypothesis that ethnic differences would be apparent in 
associations between markers of inflammation (CRP, IL-6) and haemostasis (sP-sel, VWF 
and fibrin D-dimer) and CCIMT and PAD. This chapter found differences in biomarker 
profile between South Asians and Blacks and reported different associations between 
biomarkers, CCIMT and ABPI. Notably, it found Blacks to have greater D-dimer levels than 
South Asians overall and in women. This study’s findings support a previous study of raised 
D-dimer when compared to other ethnic groups in African Americans [Lutsey et al. 2006]. 
This finding suggests Black ethnicity may be associated with a greater predisposition to a 
hypercoagulable and prothrombotic state than South Asians. 
 
Chapter 3.4 found South Asians had higher sP-sel and platelets than Blacks overall and when 
analysed by sex. It found Black women had higher VWF than South Asian women, 
supporting previous research [Kim et al. 2010]. In the South Asian subjects, VWF was 
associated with both mean and maximum CCIMT on multivariate analysis, after adjusting 
for traditional cardiovascular risk factors. This may reflect greater endothelial dysfunction/ 
damage and possibly a higher atherosclerotic load but not overt disease in South Asians. 
 
Rather surprisingly no associations were reported between markers of inflammation and 
CCIMT and PAD in this chapter as IL-6 and CRP have previously been associated with 
PAD development, progression and severity of disease [Ridker et al. 2001; Devaraj et al. 
2003; Tzoulaki et al. 2005] in predominantly White European populations. This study’s 
findings could be a result of low levels of blood sampling or may reflect different 
pathophysiological processes predominating in different ethnic groups. 
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Chapter 4.1 investigated the hypothesis that ethnic differences will exist in the plasma 
expression of markers of angiogenesis (Angiopoietin-1, Angiopoietin-2, soluble Tie-2 
receptor and Angiogenin) and their association with traditional cardiovascular risk factors 
and cardiovascular disease. This chapter also tested the hypothesis that the plasma levels of 
these biomarkers will be higher in subjects with traditional cardiovascular risk factors and 
higher still stable cardiovascular disease. This chapter found angiogenin levels were lower in 
healthy White subjects when compared to Blacks and South Asians but this finding 
disappeared in the presence of cardiovascular risk factors and stable cardiovascular disease, 
indicating some effect of the latter two processes on this biomarker. While it is possible that 
the increased angiogenin in Black and South Asian subjects could be partly attributed to the 
higher prevalence of hypertension and/ or diabetes, the fact that the apparent ethnic 
difference disappears in the presence of these conditions suggests these conditions are not 
the only reason for this difference. 
 
Angiogenin is thought to be an indicator of endothelial damage related to the progression of 
vascular disease. Its levels may therefore be expected to be associated with related 
angiogenic molecules. This chapters finding of a negative correlation between angiogenin 
and sTie-2 may reflect this. In hypoxic states there is a reduction in the release of sTie-2 
leading to less Ang-1 binding in the plasma and greater endothelial binding. As vascular 
disease progresses there is an increase in relative tissue hypoxia and an increase in plasma 
angiogenin. Chapter 4.1 failed to find any other ethnic differences in the plasma levels of the 
angiogenic markers investigated in the presence of traditional cardiovascular risk factors and 
stable cardiovascular disease. 
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5.2 Recommendations for Future Study 
 
This thesis did not adjust for multiple significance testing in either the sub-study to E-
ECHOES or the hospital based study. Reasons for this are that both studies were cross-
sectional in their design, had small numbers of subjects in each cohort and the aims were to 
investigate possible associations between research parameters in areas where there is 
currently very little evidence due to limited research. Michels and Robins have previously 
stated that, “Cross-sectional studies should be used to find undiscovered associations so that 
further hypotheses can be generated for further investigation” [Michels & Robins 1996]. On 
speaking about epidemiological studies, Bland and Altman have previously suggested that 
the Bonferroni correction is highly conservative and may miss real differences [Bland & 
Altman 1995]. Taking these thoughts into account and realising that little is known about 
PAD in South Asians and Blacks and its associations with traditional cardiovascular risk 
factors and markers of haemostasis, inflammation and angiogenesis it was thought adjusting 
the level of significance could potentially miss real associations and limit further 
investigation into associations found in this thesis. Hypotheses generated as a result of 
findings from each chapter for future investigation will be discussed in turn below. 
 
The findings of low sensitivity and specificity of the ECQ for diagnosing IC in South Asians 
and Blacks found in Chapter 3.1 has thrown up several questions. Notably could the 
difference in sensitivity and specificity simply be due to methodological differences in IC 
diagnosis between the Edinburgh Artery study and this thesis? A hypothesis to be tested 
would be: There will be a difference in the sensitivity and specificity of the ECQ at 
diagnosing intermittent claudication between a doctor made diagnosis of PAD and using 
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ABPI. A straightforward study could be designed using vascular surgeons assessing subjects 
with leg pain for possible IC using the ECQ, blinded to the ABPI of the study subjects. The 
sensitivity and specificity of the ECQ could then be calculated to see if differences in 
methodology result in differences in the ECQ’s sensitivity and specificity.  
 
The next question that has arisen is whether the difference in sensitivity and specificity is 
due to linguistic differences in describing pain. To test this difference amongst South Asian 
subjects, one could investigate bilingual subjects who could complete the ECQ in English 
and in their chosen South Asian language separated by a time interval, perhaps a week, 
randomised to whether they completed the ECQ in English or in a South Asian language 
first. Comparing the responses the subjects gave in the different language ECQ might allow 
assessment of any linguistic differences in completing the questionnaire. 
 
It is also possible subjects completing the ECQ did not exercise sufficiently to experience 
symptoms of claudication in this thesis. Treadmill testing of subjects over a specified 
distance or time, with ABPI measurement before and after the session in conjunction with 
subjects completing the ECQ in their chosen language could investigate the apparent 
findings of low sensitivity and specificity found in this study. Finally, it’s possible this 
thesis’ findings are due to low statistical power from low recruitment of subjects with leg 
pain on exertion. Any future studies aiming to validate the ECQ may be better focused to 
include subjects referred to the vascular surgical department with leg pain rather than 
opportunistically asking everyone involved in a community based screening survey, such as 
the E-ECHOES study as focussed recruitment might yield a greater number of subjects with 
IC. 
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The original purpose of this thesis was to be a pilot study investigating PAD and its 
associations with traditional cardiovascular risk factors and CCIMT, a marker of pre-clinical 
atherosclerosis in the two largest minority ethnic groups in the UK as it had not been 
investigated before. A p-value <0.05 was deemed significant for the purposes of this thesis. 
It would be possible to investigate all possible associations found in this thesis with greater 
numbers of participants and a greater level of blood sampling to improve the power of the 
results and make more firm conclusions based on associations with PAD. 
 
This thesis has reported differences in PAD prevalence between South Asian and Black 
women, while no difference was found when comparing the two ethnic groups as a whole or 
in men. It also found ethnic differences in CCIMT, with significantly higher CCIMT in 
Blacks. Based on power calculations made following the results of this study’s estimate of 
PAD prevalence in South Asians and Blacks, a large prospective epidemiological study 
investigating the prevalence of PAD in these ethnic groups could be performed. Subjects 
would be included only if they consent for blood sampling. At baseline they would have all 
demographic details, lifestyle questionnaire, anthropometric measurements and blood 
sampling undertaken. Subjects could then be followed up at 5 yearly intervals and reassessed 
with further blood sampling and measurement of markers of inflammation, haemostasis and 
thrombosis. Over time, differences in these markers and their associations with the 
development of PAD could be assessed and further hypotheses generated from the research 
could be investigated further. This thesis found ethnic differences in markers of haemostasis 
and thrombosis. A prospective follow up study would determine with more accuracy if such 
differences are apparent and if so, give more insight into how these differences play a role 
257 
 
the development and progression of PAD South Asians and Blacks over time. A longitudinal 
study might also show that risk factor modification has an impact on these novel markers. 
Likewise, structured exercise programmes have previously shown improvements in ABPI 
and symptomatology. Assessing the effect of structured exercise programmes on the plasma 
levels of novel markers and their associations with ABPI and symptomatology may shed 
further light on the pathophysiology of PAD. 
 
Another finding of this thesis which needs to be investigated further is the lack of an 
association between inflammatory markers and PAD in South Asians and Blacks, which 
goes against previous research [Ridker et al. 2001; Devararj et al. 2003; Tzoulaki et al. 
2005]. Are the results of this thesis due to low levels of blood sampling or is inflammation a 
greater determinant of the development and progression of PAD in White populations?  
Could it be that there are ethnic differences in the pathophysiological processes involved the 
development and progression of PAD and that elevated markers of thrombosis are more 
important in Black subjects than in White populations? Only future, greater powered 
research might answer this question. 
 
A longitudinal study could also look at whether maximum or mean CCIMT is more 
important in the progression of atherosclerosis and its symptomatic complications. If one is 
found to have greater prognostic significance over the other, it may lead to the incorporation 
of this measurement as a screening tool or indeed either mean or maximum CCIMT 
measurement may be used to monitor the effect of risk factor modification on this parameter 
over time. 
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Other future developments investigating possible ethnic differences in atherosclerotic 
vascular diseases could be focussed on a radiological diagnosis of disease. Rather than using 
a surrogate marker for PAD, such as ABPI, magnetic resonance angiography (MRA) or CT 
angiography (CTA) could be used to accurately measure the degree and distribution of 
atherosclerotic disease throughout the body in subjects from different ethnic groups and its 
progression over time. MRA although more costly, would not subject study participants to 
radiation or intravenous contrast that CT angiography would. Subjects could be screened for 
lower limb disease, abdominal aortic aneurysm, coronary artery disease and cerebrovascular 
disease. MRA or CTA could also be used to see whether there are differences in the ‘normal’ 
range of vessel calibre between ethnic groups, as this could be a factor in the predilection of 
atherosclerosis to different vascular territories in different ethnic groups. Indeed it may also 
be possible to investigate if there are ethnic differences in the burden of vascular disease in 
different vascular territories. 
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5.3  Conclusion 
 
Peripheral arterial disease is an important healthcare problem accounting for significant 
morbidity and mortality. Previous PAD research has been performed in predominantly White 
European populations with relatively little research performed in non-White populations. 
While ethnic differences are apparent in cerebrovascular and cardiovascular disease, the 
answer as to whether ethnic differences exist in the prevalence of PAD is unknown. In an 
attempt to address the current dearth of literature on the subject, this thesis set out to 
investigate possible differences in the epidemiology and pathophysiology of PAD in the 2 
largest minority ethnic groups living in the UK. The results reported in this thesis suggest 
differences in the prevalence of traditional cardiovascular risk factors and their associations 
with PAD and mean and maximum CCIMT.  
 
This thesis also suggests there may be ethnic differences in the prevalence of PAD, 
especially amongst women, which cannot be explained by existing risk factor profile alone. 
Furthermore, this thesis also demonstrated for the first time ethnic differences in markers of 
haemostasis, thrombosis and angiogenesis and their relationship with PAD and CCIMT. 
Interestingly it found no associations between markers of inflammation and PAD, which 
goes against previous reports in predominantly White European populations. 
 
In an attempt to assess the validity and applicability of using the ECQ in non-White 
populations (A healthcare questionnaire designed to diagnose IC in predominantly White 
European populations) this thesis investigated the ECQ in South Asian and Black subjects. 
This thesis reported differences in sensitivity and specificity to results found in the original 
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Edinburgh Artery Study. It is possible that methodological differences, linguistic and 
cultural differences in the description of pain or lack of sufficient exertion to bring about the 
onset of symptomatic PAD in the form of IC, could explain this thesis’ findings.  
 
In summary, this thesis has already furthered our understanding of possible ethnic 
differences in the epidemiology and pathophysiology of PAD in South Asians and Blacks 
living in the UK, in this relatively under-investigated field; however clearly further 
investigation is needed. This thesis’ contribution to the existing medical literature is 
evidenced by the fact that every data chapter has been published in peer reviewed journals.  
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Consent form for Hospital Based Study 
 
Comparison of plasma versus histological indices of angiogenic markers in atherosclerosis 
(Comparison between the blood and blood vessel wall levels of special proteins in patients with 
hardening of the arteries) 
CONSENT FORM 
Name of Researcher: _____________________Patient Identifier_____________________ 
 
Please initial box  
I confirm that I have read and understand the information sheet dated 01/05/08 (Version 
2.0) for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.  
 
I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected.  
 
I understand that relevant sections of my medical notes and data collected during this 
study may be looked at by individuals from Sandwell and West Birmingham Hospitals 
NHS Trust, where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records.  
 
I understand that my personal details will be held by the Department on computers that are   
Subject to the Data Protection Act, and that such details are confidential to the members of 
the research team. 
 
I understand that the blood and tissue samples I give will be kept until the end of the  
study year and then destroyed 
 
I agree to my GP being informed of my participation in the study  
 
A copy of the information sheet and signed consent form will be given to you to keep. 
By signing hereunder I accept the contents of this consent form and agree to participate in this study 
voluntarily. 
 
________________   ________________   _________________  
Name of Patient    Date     Signature  
 
_________________   ________________   ___________________  
Name of Person    Date     Signature  
taking consent 
SECTION BELOW TO BE COMPLETED IF NECESSARY 
 
____________________ ___________________     ______________ ___________ 
Impartial Witness Name Relationship to patient     Signature  Date 
One copy for researcher (original), one for patient, one for patient notes. 
 
APPENDIX II. 
Participant Information Sheet 
This information sheet is in two parts. Part 1 provides brief and clear information on the 
essential elements of the specific study: what the research is about, the condition or 
treatment under study, voluntary nature of involvement, what will happen during and after 
the trial, what treatment may be withheld, the participant’s responsibilities, the potential 
risks, inconvenience or restrictions balanced against any possible benefits.  
 
Part 2  contains additional information on factors such as confidentiality and data protection, 
communication with the GP, indemnity and compensation, etc., which should, of course, be 
read and understood before the participant decides whether they want to participate.  
 
 
Part 1 of the information sheet 
 
 
1. Study title 
Comparison of plasma versus histological indices of angiogenic markers in atherosclerosis 
(Comparison between the blood and blood vessel wall levels of special proteins in patients 
with hardening of the arteries) 
 
2. Invitation paragraph  
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
Thank you for reading this. 
 
3. What is the purpose of the study? 
Peripheral artery disease (narrowing of the blood vessels) is an important healthcare problem 
in developed nations and is the commonest cause of stroke, non-cardiac sudden death and 
amputation. Peripheral artery disease is important because it is an indicator of widespread 
atherosclerosis (hardening of the blood vessels) in other places in the body such as the brain 
and heart. Atherosclerosis is associated with angiogenesis (The formation of new blood 
vessels).  Angiogenesis is controlled by a number of different special proteins in the blood 
and in the blood vessel wall. We aim to investigate the levels of some of these special 
proteins contributing to angiogenesis both in the blood and in the blood vessel wall (From 
the specimen we collect) to see if their levels are related to each other. 
 
 
4. Why have I been chosen? 
You have been chosen because you are due to have surgery for peripheral artery disease and 
there are likely to be left-over blood vessel specimens that would normally have been thrown 
away. 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive. 
 
6. What will happen to me if I take part? 
If you take part, on the day of your operation before your surgery we will take a small 
sample of your blood. Any left over blood vessels, that would normally be removed during 
your operation and thrown away, will be collected and stored as part of our study. We will 
perform tests on the blood and blood vessel wall at a later date. We will not take any blood 
vessel specimens from you that have not already been removed as part of your surgery.  
If you are having carotid end-arterectomy (surgery on the neck blood vessels) you will be 
invited to City Hospital to have a special scan of your heart. This scan involves putting jelly 
on your chest allowing us to see the heart. There is a very small chance of detecting a 
problem if you have no previous history of heart disease. If we detect a problem we will 
organise any follow up that you might require with the heart specialists at Sandwell and 
West Birmingham hospitals NHS Trust. 
 
7. What do I have to do? 
You will be asked to donate a small sample of your blood before your operation. You will 
have the surgery that you have agreed to previously. The left over blood vessel will be 
collected during your operation. 
If you are booked for a carotid end-arterectomy you will be invited to attend Birmingham 
City Hospital at another date before your surgery to have a special scan of your heart, the 
results of which will be sent to your GP. 
All samples we obtain from you will be kept until the end of the study year and then 
destroyed. 
  
9. Are there any side effects/ risks or disadvantages of taking part?   
Apart from the risk of a small bruise you may get from having blood taken there will be no 
added risks from being in this study. The usual risks and complications of your operation 
will apply to you.   
 
11. What are the possible benefits of taking part? 
There will be no direct benefit to you for taking part but the information we get from this 
study will help to improve our understanding of the causes of atherosclerosis, the main cause 
of PAD. This may benefit people in the future. 
 
12. What will happen to the results of the research study? 
The results will be published in medical journals and you will not be identified in any report 
or publication. 
 
13. What happens when the research study stops? 
Your routine care will continue regardless of the duration of this study. 
 
 
 
 
 
 
 
 
 
 
 
Part 2 of the information Sheet 
 
14. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available. If 
new potential markers for angiogenesis (New blood vessel formation) are identified we may 
test the blood and blood vessel specimens we receive from you for these.  This will not alter 
your treatment in any way. 
 
15. What if something goes wrong? 
Taking blood is a routine procedure with very little risk. You will have had blood taken 
before and therefore will be aware that very little can go wrong. With regards to your blood 
vessel specimen, we will only be collecting a sample from you that would otherwise be 
thrown away during your procedure.  
If you are invited to have a scan, this involves having gel put on your chest in order for the 
scanner to see your heart. This will not cause you any harm. 
If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action but you may have to pay for it. Regardless of this, if you wish to complain, or have 
any concerns about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints mechanisms should be 
available to you. 
 
16. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital/surgery will have 
your name and address removed so that you cannot be recognized from it. 
 
All data will be stored on a password protected database in the University Department of 
Medicine at Birmingham City Hospital. Data will only be accessible to members of the study 
team. 
 
17. Who has reviewed the study? 
Birmingham East North and Solihull Ethics Committee 
 
18. Will my General Practitioner be informed? 
Your General practitioner will be informed of your decision to participate in the study. If you 
are having a heart scan your GP will be informed of the result. 
 
19. Contact for Further Information 
If you wish to discuss this study further then you may contact the following: 
Philip Bennett  Research Fellow    
Stanley Silverman  Consultant Vascular Surgeon   
 
If you want independent advice about whether or not to participate in this study you may 
contact the following through the hospital switchboard (0121 5543801): 
 
The Patient Advice and Liaison Service (PALS) 
The Research and Development Office at Sandwell or City Hospitals 
Dr Siddique Cardiology Research Fellow   
 
You are under no obligation whatsoever to participate, and your decision would in no 
way influence your care and medical treatment in hospital. 
APPENDIX III. 
Letter to GP 
 
Patient Identifier Label: 
 
 
 
Dear Doctor, 
 
The above patient has consented to participate in a study investigating angiogenesis in 
peripheral arterial disease at Sandwell and West Birmingham Hospitals NHS Trust. 
The study will involve taking a blood sample from the patient and discarded arterial 
tissue obtained during their procedure. Patients having carotid end-arterectomy will be 
invited to attend City Hospital on another occasion to have echocardiography. The 
patient will not be followed up as part of this study but will be followed up routinely 
by the vascular team. The study will not alter the management of this patient but may 
help in the future management of patients with peripheral arterial disease. 
 
If you have any concerns do not hesitate to contact me on the above number. 
 
Yours sincerely, 
 
 
 
 
 
 
Philip Bennett MBChB MRCS 
Vascular Surgery Research Fellow 
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